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Abstract 
Prostate cancer is a significant health problem worldwide. Although localised 
disease is curable, current treatments for advanced, metastatic disease are simply 
palliative, or at best achieve short-term benefits. Thus, there is an urgent need for 
more effective therapeutic strategies to be developed. This requires a better 
understanding of the mechanisms that drive prostate cancer growth and progression 
to a castrate-resistant state. Oxidative stress may potentially increase prostate cancer 
risk and disease progression. While excessively high levels of reactive oxygen 
species (ROS) can cause damage to DNA proteins and lipids, low to moderate levels 
of ROS may participate in cellular processes important in malignant transformation 
and the maintenance of an aggressive phenotype in prostate cancer cells through the 
activation of redox-sensitive transcription factors. Antioxidants may thus be 
beneficial in preventing or slowing the progression of prostate cancer. However, the 
limited efficacy of dietary antioxidants in clinical trials does not support their use in 
cancer patients. 
Nitroxides are a class of low molecular weight, membrane permeable stable 
free radicals that have well established roles as antioxidants. Paradoxically, these 
compounds may function as pro-oxidants or cytotoxic agents by inducing apoptosis 
in cancer cells through free radical mediated processes and the disruption of 
mitochondrial events. Alternatively, nitroxides could induce an antiproliferative 
effect by relieving the oxidative stress present in these cells. In either case, these 
compounds clearly demonstrate the ability to modulate the cellular redox state and 
may thus be useful as therapeutic agents in the management of prostate cancer.  The 
isoindoline nitroxides have a number of advantages over the more commonly used 
pyrrolidine and piperidine species due to their fused aromatic structure. Notably, 
CTMIO (5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl) has been shown to 
alleviate the deleterious effects of oxidative stress and to delay the onset of thymic 
lymphomas in Atm-mutant mice with the disease A-T. Yet little is known regarding 
the effects of this, and other nitroxides on prostate cancer cells. Neither has their 
mechanism of action been well characterised.    
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Therefore, the aim of the current study was to investigate the pro- or 
antioxidant effect of nitroxides on prostate cancer cells and to identify the 
mechanisms through which they elicit their effects. Cell survival was assessed in a 
panel of prostate cell lines following treatment with these compounds over a 96 hr 
period. Exposure to the piperidine nitroxide Tempo (2,2,6,6-tetramethylpiperidine-1-
oxyl) resulted in cell death in a dose and time-dependent manner, confirming 
previously reported cell survival data for PC-3, DU-145 and LNCaP cells. Likewise, 
its derivative Tempol (4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) induced 
significant cell death after 48 and 96 hrs of treatment. In contrast, the isoindoline 
nitroxide CTMIO displayed minimal cytotoxicity. C-Tempo (4-Carboxy-2,2,6,6-
tetramethylpiperidine-1-oxyl) was also investigated in cell survival studies because it 
bears structural similarity both to Tempo and CTMIO. C-Tempo demonstrated 
greater cell killing than that for CTMIO yet less than that for the other piperidine 
nitroxides, suggesting that nitroxide potency is influenced by their ring structure and 
the type of substituent present at position-4 of the nitroxide ring. Because of the lack 
of toxicity observed with CTMIO, electron paramagnetic resonance (EPR) studies 
were performed to evaluate the stability of CTMIO both in the conditioned media 
and intracellularly over the time course used in the cell survival assay experiments. 
After 96 hrs, the CTMIO EPR signal was still detectable in the conditioned media, 
indicating that this compound retains its free radical activity for the duration of our 
experiments and is thus likely to be taken up by the cells. Nitroxide signal however 
could not be detected intracellularly. To determine whether factors secreted by 
prostate cancer cells were instead responsible for the reduction in CTMIO signal 
intensity seen in the conditioned media, culture media in which PC-3 and LNCaP 
cells were grown were incubated with CTMIO. The signal intensity of CTMIO 
treated PC-3 culture media remained relatively stable over 96 hrs, confirming that 
this nitroxide is not degraded by cellular factors. The loss in CTMIO signal intensity 
in the conditioned media can therefore be attributed to cellular uptake of the 
compound from the media.   
Given the dual nature of nitroxide compounds, the antioxidant capacity of 
CTMIO was assessed in several models of stress or oxidative stress. Prostate cancer 
cell lines were treated with increasing concentrations of docetaxel in combination 
with CTMIO, and exposed to the glycolytic inhibitor 2-deoxy-D-glucose, in the 
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presence and absence of this nitroxide. However, CTMIO did not protect against the 
cytotoxic effects of these agents. Inconclusive results and potential flaws in the 
experimental design of some of these studies also meant that these model systems 
were not suitable for further evaluation. Therefore, as a third model of oxidative 
stress, LNCaP cells were exposed to H2O2 in combination with CTMIO, after which 
the cells were recovered in media containing nitroxide alone. Significantly reduced 
levels of glutathione were observed within the cells after the recovery period, 
suggesting that CTMIO treatment could not reverse the H2O2-induced oxidative 
stress. Nevertheless, brief exposures to sublethal doses of H2O2 have been shown to 
activate various signalling pathways. In addition, changes in gene expression have 
been reported in breast cancer cells under similar treatment conditions as that used in 
our study. Hence, it could not be ruled out that as an antioxidant, CTMIO elicits 
subtle changes at the gene level to protect LNCaP cells from the damaging effect of 
H2O2 that is not evident from the glutathione assay.  
To delineate the signalling pathways involved in the oxidative stress response, 
we examined the expression of 84 oxidative stress and antioxidant defence related 
genes in the H2O2 oxidative stress model using PCR arrays. These experiments were 
repeated in LNCaP cells exposed to DCTEIO (1,1,3,3-tetraethyl-5,6-
dicarboxylisoindoline-2-yloxyl), a derivative of CTMIO which is not as readily 
reduced intracellularly due to its hindered structure. Forty-four genes were identified 
as differentially expressed in response to H2O2, the nitroxides CTMIO or DCTEIO, 
and the combined treatments. Of these, the haem peroxidases (PTGS1, PTGS2, LPO 
and MPO), NOX or their components (DUOX2 and CYBA) and the collectins (MBL2 
and SFTPD) were the most significantly regulated. Many of these genes participate 
in free radical scavenging and biosynthesis processes, and the inflammatory 
response. Furthermore, similar gene expression patterns were observed between the 
two nitroxides and the H2O2 treatment, suggesting that these compounds may have a 
pro-oxidant rather than antioxidant role within prostate cancer cells. DUOX2, MPO 
and CYBA were upregulated across both datasets, whereas PTGS2 was upregulated 
only in the CTMIO dataset. In contrast, downregulation in SFTPD and MBL2 was 
seen only in the DCTEIO dataset. Network analyses revealed that MKL1, MKL2, 
SP3, CEBPB, CEBPD and TP53 were the major transcription factors regulating 
many of the genes of interest; either directly or indirectly, via interactions with other 
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transcription factors and downstream molecules such as the enzymes LTF, RAC2 
and UBC.  
In summary, this study demonstrated that nitroxides exert varying degrees of 
cytotoxicity in prostate cancer cells, which is dependent on their ring structure and 4-
position functional group. Although neither a cytotoxic or protective role for CTMIO 
could be determined, we observed changes in gene expression in response to 
treatments in the H2O2 oxidative stress model. Moreover, CTMIO and DCTEIO 
exhibited a similar pattern of gene regulation to H2O2, indicating that they may have 
a pro-oxidant role in prostate cancer cells. Overall, this study has provided for the 
first time mechanistic insights into the action of isoindoline nitroxides intracellularly.  
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Chapter 1: Introduction and Literature 
Review  
1.1 PROSTATE CANCER 
1.1.1 Introduction 
Prostate cancer is the most commonly diagnosed cancer in Australian men and 
the second leading cause of cancer deaths after lung cancer (AIHW & AACR, 2012). 
In 2009, there were 21,808 new prostate cancer diagnoses, accounting for almost a 
third of all cancer cases in males (AIHW, 2013). With prostate cancer incidence 
continuing to rise at a rate of 164 new cases per 100,000 males per year, it is 
expected that there will be more than 25,300 new cases diagnosed in 2020 (AIHW, 
2012). Hence, prostate cancer remains a major public health concern. Worldwide, 
prostate cancer incidence varies by more than 25-fold, and is generally higher in 
more developed regions than in developing nations due to increased awareness of 
prostate cancer, and to the widespread use of prostate specific antigen testing to 
screen for this disease in asymptomatic men (AIHW, 2010; GLOBOCAN, 2012). 
Incidence rates are highest in Australia/New Zealand, Northern America, and in 
Western and Northern Europe, and lowest in Northern African and Asian 
populations. Prostate cancer is primarily a disease of older men, with 90% of new 
cases reported among males aged 55 and over (AIHW, 2013). Compared with other 
cancers, it has one of the highest 5-year survival rates (92%) for men diagnosed with 
localised disease. However, advanced castrate-resistant prostate cancer remains a 
significant health issue, with no effective long-term therapeutic options currently 
available for end-stage metastatic disease.   
1.1.2 Underlying Basis of Prostate Cancer 
At the cellular and molecular level, genetic aberrations including both 
inherited, and acquired genetic changes drive the formation and aggressiveness of 
prostate cancer (Bookstein, 2001; Chung et al., 2001; Gao & Isaacs, 2002; DeMarzo 
et al., 2003). Every carcinoma focus is presumed to arise from a single cell that 
progressively accumulates genetic changes affecting regulatory genes (e.g. 
oncogenes and tumour suppressor genes), resulting in a growth or survival advantage 
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(Djakiew, 2000; Hanahan & Weinberg, 2000). High-grade prostatic intraepithelial 
neoplasia (PIN) has been proposed to be a precursor lesion to many peripheral and 
intermediate to high-grade adenocarcinomas of the prostate (McNeal et al., 1991; 
Haggman et al., 1997; Woenckhaus & Fenic, 2008). These lesions may be initiated 
by inflammation, following exposure to different infectious agents and/or ingestion 
of carcinogens (De Marzo et al., 2007; Dong et al., 2007; Nakai et al., 2007). As pre-
malignant lesions progress to primary cancer, metastatic cancer and eventually 
androgen-independent prostate cancer, genetic alterations continue to accumulate 
within tumour cells (DeMarzo et al., 2003; Mazzucchelli et al., 2004; Rennert et al., 
2005; Alcaide & Martínez-Piñeiro, 2006; Dong, 2006). In addition, androgens, which 
are responsible for both normal and hyperplastic growth of the prostate gland 
(Peterson et al., 1977; Hsing & Comstock, 1993; Brawley, 2003), can act as 
promoters for further growth and proliferation of tumour cells.  
Yet, genetic alterations in tumour cells alone are not enough to confer 
metastatic status without a supporting tumour microenvironment. In recent years, 
there has been a shift in our perception of prostate cancer; no longer is it viewed 
simply as a disease of abnormally proliferating epithelial cells but rather as a disease 
of complex interactions between these cells and the surrounding tissues (stromal 
compartment) in which they reside (Taichman et al., 2007; Dayyani et al., 2011). 
Moreover, there is a growing appreciation for the role of the tumour 
microenvironment in controlling local cancer growth and invasion, and in promoting 
prostate cancer progression to androgen independence and distant metastases (Chung 
et al., 2005). The success of future therapy therefore resides in the combining of 
classic chemotherapy with the ability of new agents to target specific signal 
transduction pathways and to exploit tumour cell-microenvironment interactions 
(Edlund et al., 2004; Tantivejkul et al., 2004; Chung et al., 2005). 
1.1.3 Risk Factors 
Prostate cancer is an age-related condition. Men younger than 50 years of age 
represent less than 0.1% of all affected patients, while it is estimated that by age 85, 
1 in 5 men will be diagnosed with this disease (Grönberg, 2003; Alam et al., 2009). 
Epidemiological studies, particularly those in twin populations have consistently 
revealed a hereditary component in the risk of prostate cancer (Grönberg et al., 1994; 
Ahlbom et al., 1997; Page et al., 1997; Lichtenstein et al., 2000). Men with a father 
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or brother affected by prostate cancer are twice as likely to develop this disease as 
those with no family history (Steinberg et al., 1990; Spitz et al., 1991; Whittemore et 
al., 1995; Bratt, 2002; Johns & Houlston, 2003; Alam et al., 2009). In addition, there 
is a trend of increasing risk with increasing number of affected family members, or if 
family members were diagnosed with the cancer at an early age (i.e. <55 years of 
age) (Steinberg et al., 1990; Lesko et al., 1996; Rodríguez et al., 1997; Bratt, 2002; 
Heidenreich et al., 2011). Complex segregation analyses have suggested that 
dominantly inherited susceptibility genes with high penetrance such as HPC1, MSR1, 
RNASEL, PCAP and BRAC2 may account for a substantial proportion of early onset 
disease (Carter et al., 1992; Grönberg et al., 1997; Schaid et al., 1998; Verhage et al., 
2001; Edwards et al., 2003). However, difficulties in confirming these findings in 
other families with hereditary prostate cancer, or in different ethnic groups suggest 
that mutations in many of these loci are present at low frequencies in the population 
(reviewed in Bratt, 2002; Nelson et al., 2003). In view of this, it has been proposed 
that environmental factors and comparatively more common genetic polymorphisms 
may influence prostate cancer risk in families with or without multiple cases of the 
disease(Bratt, 2002). Candidate genes for such genetic variations include the AR, 
SRD5α2, CYP17 and CYP19(reviewed in Ross et al., 1998; Wadelius et al., 1999; 
Nelson et al., 2003), all of which are known to be involved in androgen biosynthesis 
and metabolism. X-linked (Monroe et al., 1995; Xu et al., 1998; Schleutker et al., 
2000), or recessive inheritance may also be important in some families (Cui et al., 
2001; Dong & Hemminki, 2001).    
Prostate cancer incidence and mortality vary greatly between different 
countries (Quinn & Babb, 2002), with lowest rates reported in Asian populations and 
highest rates among African Americans (Whittemore et al., 1995; Hsing et al., 2000). 
Yet the prevalence of latent cancer at autopsy is remarkably similar (Gittes, 1991; 
Muir et al., 1991; Nomura & Kolonel, 1991). An increasing incidence of prostate 
cancer with migration from low- to high-risk areas, as seen among Japanese and 
Chinese immigrants to the United States (Haenszel & Kurihara, 1968; Shimizu et al., 
1991; Cook et al., 1999; Parkin, 2001; Gann, 2002), suggests that environmental 
factors such as diet (Adlercreutz, 1990; Chan et al., 2005; Denis et al., 2012) are 
important in the transformation of latent tumours into more aggressive clinical 
cancer. Diets rich in fat and red meat exert a promotional effect (Giovannucci et al., 
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1993; Gann et al., 1994; Le Marchand et al., 1994; Hayes et al., 1999; Kolonel, 2001; 
Bostwick et al., 2004), whereas a soy-supplemented diet (Pollard & Luckert, 1997; 
Landström et al., 1998; Mentor-Marcel et al., 2001) or one containing potent 
antioxidants such as vitamin E (Heinonen et al., 1998), carotenoids (Kirsh et al., 
2006) and selenium (Clark et al., 1996; Clark et al., 1998) protect, suggesting that 
oxidative stress may contribute to the development of prostate cancer. A high intake 
of tomatoes (Giovannucci et al., 1995; Gann et al., 1999) and cruciferous vegetables 
(Cohen et al., 2000) have also been correlated with a diminished risk of prostate 
cancer. Furthermore, research has identified other lifestyle-related factors including 
smoking, obesity, alcohol consumption and sexual activity to be associated with 
prostate cancer risk (Cerhan et al., 1997; Sesso et al., 2001; Dennis & Dawson, 2002; 
Bostwick et al., 2004; Leitzmann et al., 2004; Schoonen et al., 2005; Gong et al., 
2006; MacInnis & English, 2006; Rodriguez et al., 2007). However at present, 
evidence related to these factors are still inconclusive.   
1.2 OXIDATIVE STRESS AND ANTIOXIDANT SYSTEMS 
Oxidative stress is defined as “a disturbance in the pro-oxidant-antioxidant 
balance in favour of the former, leading to potential damage” (Seis, 1991). This may 
result from an overproduction of reactive species or a decrease in antioxidant 
defences.  
Reactive oxygen species (ROS) encompass a heterogeneous group of oxygen-
centred radical and non-radical molecules including superoxide, hydroxyl and 
peroxyl radicals, as well as hydrogen peroxide (H2O2) and peroxynitrite (Halliwell & 
Gutteridge, 2007). ROS can be produced endogenously through metal-catalysed 
reactions, the inflammatory process, as by-products of normal oxidative 
phosphorylation, or as second messengers in signalling pathways (Han et al., 2001a; 
Klaunig & Kamendulis, 2004). Other endogenous sources of ROS include 
cytochrome P450, NADPH oxidase (NOX), peroxisomes and xanthine oxidase. In 
addition, ROS can be taken up directly from the extracellular milieu or generated 
intracellularly in response to environmental insults such as xenobiotics, chlorinated 
compounds and radiation (Klaunig & Kamendulis, 2004). Under normal 
physiological conditions, cells are capable of counterbalancing the generation of 
ROS with their elimination by antioxidants, in turn preventing the accumulation of 
ROS and subsequent oxidative stress. The cellular antioxidant defence system is 
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composed mainly of enzymatic scavengers of ROS and includes catalase (CAT), 
superoxide dismutase (SOD), glutathione peroxidase (GPX), peroxiredoxin and 
thioredoxin reductase (Betteridge, 2000; Abuja & Albertini, 2001; Klaunig & 
Kamendulis, 2004). While non-ezymatic dietary antioxidants such as β-carotene, 
vitamin C, vitamin E and selenium aid the cellular defence mechanisms by 
quenching singlet oxygen and free radicals (Das, 1994; McEligot et al., 2005). 
ROS can affect cell behaviour in many ways. Yet the responses which are 
elicited following exposure to ROS may vary considerably depending on several 
factors, such as the relative balance between pro- and anti-apoptotic signals within 
the cell, the type of ROS initiating the effect, the dosage and duration of exposure 
and the cell-type (Irani et al., 1997; Teshima et al., 2000; Klaunig & Kamendulis, 
2004). At low/moderate levels, ROS regulate many important physiological or 
pathophysiological functions within the cell, including proliferation, cell cycle 
progression, migration, angiogenesis, metastasis and inhibition of apoptosis 
(Shibanuma et al., 1990; Irani et al., 1997; Engel & Evens, 2005; Menon & 
Goswami, 2006; Halliwell, 2007b), through the activation of signal transduction 
pathways (Monteiro & Stern, 1996) and modulation of redox-sensitive transcription 
factor activities (Xia et al., 1995; Sun & Oberley, 1996; Müller et al., 1997; Schulze-
Osthoff et al., 1998; Chang & Karin, 2001; Chen et al., 2001; Shaulian & Karin, 
2001). In contrast, excessive levels of ROS can lead to cellular dysfunction and loss 
of cell viability due to the severe damage they cause to DNA, proteins and lipids 
(Halliwell & Gutteridge, 2007). 
1.3 THE ROLE OF OXIDATIVE STRESS IN CANCER 
There is substantial evidence linking oxidative stress and damage to the 
pathogenesis of a wide range of degenerative and chronic diseases (Coyle & 
Puttfarcken, 1993; Baynes & Thorpe, 1999; Tak et al., 2000; Barnham et al., 2004; 
Madamanchi et al., 2005; Valko et al., 2007) including cancer (reviewed in Klaunig 
& Kamendulis, 2004; Schumacker, 2006; Halliwell, 2007b; Gupta et al., 2012). 
Cancer cells produce higher levels of free radicals than normal cells due to their 
active metabolism associated with the dysregulation of various cellular events and 
are thus under constant oxidative stress (Szatrowski & Nathan, 1991; Toyokuni et al., 
1995; Behrend et al., 2003). An overproduction of ROS can result in detrimental cell 
damage and ultimately cell death (Halliwell, 2007b), while moderate levels can 
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facilitate cancer cell survival and promote tumour growth (Cerutti, 1985; D'Souza et 
al., 1993; Burdon, 1995; Slater et al., 1995; Pervaiz & Clement, 2004; Vaquero et al., 
2004). Therefore, cancer cells rely heavily on antioxidant enzymes and other 
adaptive antioxidant defences to maintain intracellular levels of ROS within a 
tolerable threshold and thus protect cells from damage (Huang et al., 2000; Hileman 
et al., 2004). However, low levels of SOD, CAT and GPX1 are often reported in 
primary cancers and transformed cell lines (Oberley et al., 1994; Coursin et al., 1996; 
Oberley & Oberley, 1997; Bostwick et al., 2000; Oberley et al., 2000; Oberley, 
2005), further implicating elevated levels of reactive species in the development of 
malignancy. Indeed, knock-out of various antioxidant enzymes have been shown to 
increase oxidative damage levels and to promote age-related cancer development in 
animals (Ishii et al., 1996; Neumann et al., 2003; Chu et al., 2004; Egler et al., 2005; 
Elchuri et al., 2005). In explaining these findings, much attention has focused on 
direct oxidative damage to DNA by reactive species such as hydroxyl radicals, which 
generates multiple mutagenic purine, pyrimidine and deoxyribose oxidation products 
(Wiseman & Halliwell, 1996; Sentürker & Dizdaroglu, 1999; Evans et al., 2004; von 
Sonntag, 2006; Halliwell & Gutteridge, 2007). Many of these DNA lesions cause 
structural damage to the DNA molecule(Shibutani et al., 1991; Moriya, 1993; 
Hussain & Harris, 1998)and if unrepaired, could lead to replication errors (Cheng et 
al., 1992; Demple & Harrison, 1994) and genomic instability, and in turn appreciably 
increase the likelihood of tumour formation and contribute to tumour heterogeneity. 
Nevertheless, it is important to point out that direct oxidative damage to DNA alone 
is insufficient to cause cancer, as evidenced by cases where levels of oxidative DNA 
damage products are elevated but cancer rates do not increase (Halliwell, 2002; 
Nakabeppu et al., 2004; Arai et al., 2006), as well as the presence of high levels of 
oxidative modifications to proteins and lipids in various primary cancers in addition 
to oxidative DNA damage. Furthermore, other ROS-mediated mechanisms, such as 
their ability to suppress apoptosis and promote proliferation, invasiveness, 
metastasis, angiogenesis and chronic inflammation, must also be important for 
cancer development (reviewed in Storz, 2005; Halliwell, 2007b). 
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1.4 OXIDATIVE STRESS IN PROSTATE CANCER 
1.4.1 Prostate Cancer Risk Factors and Oxidative Stress 
Many of the risk factors associated with prostate cancer such as ageing, 
androgens, dietary fat and inflammation have been linked to oxidative stress. Ageing 
causes a shift in the pro-oxidant-antioxidant balance of many tissues toward a more 
oxidative state (Warner, 1994; Benzi & Moretti, 1995; Mo et al., 1995; Finkel & 
Holbrook, 2000), resulting in the progressive accumulation of damage to DNA, 
proteins and lipids that may eventually appear in age-related health issues or diseases 
such as prostate cancer.  
The prostate is particularly vulnerable to oxidative stress, because androgen 
activity may alter the intracellular pro-oxidant-antioxidant balance. In the androgen-
responsive LNCaP prostate cancer cell line, physiological levels of androgens were 
found to promote the production of ROS and decrease glutathione levels and the 
activity of certain detoxification enzymes that are important for the maintenance of 
the cellular redox state, suggesting a potential mechanism by which androgen 
exposure may play a role in prostate carcinogenesis (Ripple et al., 1997).  
Both observational data and epidemiological studies have demonstrated a 
strong correlation between high fat intake and increased risk of prostate cancer 
mortality (reviewed Giovannucci et al., 1993; Gann et al., 1994; Ross & Henderson, 
1994; Fleshner & Klotz, 1998a). Diets high in fat can lead to higher concentrations 
of plasma androgen in healthy men by affecting androgen secretion and metabolism 
(Hämäläinen et al., 1984; Gromadzka-Ostrowska, 2006), thereby providing a 
biologically plausible reason for the association between fat and prostate cancer 
(Ross & Henderson, 1994). Moreover, consumption of large amounts of dietary fat 
may contribute to prostate cancer via oxidative lipid peroxidation (Burcham, 1998; 
Kolonel et al., 1999; Fleshner & Kucuk, 2001; Almushatat et al., 2006; Barrera, 
2012) and by enhancing the growth of tumour cells (Wang et al., 1995). Oxidative 
stress may also be exacerbated by prostatitis because this leads to the activation of 
acute and chronic inflammatory cells that are capable of generating superoxide, H2O2 
and other ROS (Babior, 1984; Espey et al., 2002). The continual exposure of prostate 
tissues to the source of inflammation can cause further damage, resulting in enhanced 
epithelial cell proliferation that ultimately leads to the induction of PIN, a potential 
precursor lesion of prostate cancer (Naber & Weidner, 2000). 
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1.4.2 Evidence for Increased ROS Production within the Prostate 
Given that the mitochondrion is a major site of ROS production (Esposito et 
al., 1999; Melov et al., 1999), altered mitochondria bioenergetics and mitochondrial 
DNA mutations are likely to be important in the development of prostate cancer 
(Petros et al., 2005; Dakubo et al., 2006). Malignant transformation of the prostate is 
associated with an early metabolic switch, leading to decreased zinc accumulation 
and increased citrate oxidation (Costello & Franklin, 1998; Costello et al., 2005). 
Consequently, prostate cancer cells are capable of higher rates of respiration, and in 
turn are more energetically efficient and generate more ROS than normal prostate 
epithelial cells. This increase in ROS production may account for the accelerated 
mitochondrial DNA (mtDNA) mutations observed in prostate cancer. With 
advancing age, an increase in the occurrence of mtDNA mutations in the malignant 
prostate has also been demonstrated (Jessie et al., 2001). Regardless of the cause, 
accelerated mutations in the mitochondrial genome may further increase ROS 
production by compromising oxidative phosphorylation, thus setting in motion a 
vicious cycle of oxidative stress in prostate cancer cells that may enhance tumour 
progression (Petros et al., 2005; Storz, 2005; Dakubo et al., 2006; Ishikawa et al., 
2008).  Indeed, the degree of ROS generation in prostate cancer cells has been shown 
to be directly proportional to their aggressive phenotype (Kumar et al., 2008). In 
another study which characterised the effects of cellular redox state on prostate 
cancer cell growth in vitro, LNCaP cells were found to have higher levels of 
ROS/RNS and lipid peroxidation, but a lower reduced glutathione to oxidised 
glutathione (GSH/GSSG) ratio compared to PC-3 cells during cell growth 
(Chaiswing et al., 2007). These findings suggest that LNCaP cells may require a pro-
oxidant state for cell proliferation, whereas PC-3 cells may proliferate with a low 
level or absence of such a pro-oxidant state. Interestingly higher levels of NOX1 
protein were also observed in LNCaP cells compared to PC-3 cells.  
NOX enzymes are not only an important source of ROS production in prostate 
cancer cells but have also been demonstrated to be critical for the growth and 
maintenance of the malignant phenotype in these cells (Arbiser et al., 2002; Brar et 
al., 2003; Lim et al., 2005). Both NOX1 and NOX5 are present in prostate cancer 
cells or tissues, while other isoforms (NOX2, NOX4 and NOX5) have been found in 
prostate cancer cell lines which are absent in normal cells (Kumar et al., 2008; 
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Khandrika et al., 2009). Given that various NOX isoforms are expressed in prostate 
cancer and the apparent connection between ROS generation by these enzymes and 
tumourigenic potential, this pathway may be an important target for therapeutic 
intervention 
Interestingly, hypoxia may also lead to an increase in intracellular ROS 
production, mainly originating from the mitochondria (Mansfield et al., 2005; Guzy 
& Schumacker, 2006). Hypoxia-induced ROS generation contributes to the 
stabilisation of H1F-1α through the activation of PI3K and p38 MAPK (Greijer & 
Van der Wall, 2004; Emerling et al., 2005). Consistent with these findings, studies 
have shown that under hypoxic conditions, human prostate cancer cells have elevated 
levels of ROS and HIF-1α (Bourdeau-Heller & Oberley, 2007). This protein is a key 
mediator of the hypoxic response, controlling numerous genes that play a pivotal role 
in regulating cellular metabolism, survival, cell cycle progression, angiogenesis, and 
inhibition of apoptosis (Carmeliet et al., 1998; Ke & Costa, 2006; Galanis et al., 
2008).        
One of the most compelling pieces of evidence for redox regulation or 
dysregulation in cancer is the altered expression of redox-sensitive transcription 
factors such as p53, Nrf2, AP-1 and NF-κB (Sen & Packer, 1996; Sun & Oberley, 
1996; Shan et al., 2012). These transcription factors in turn are capable of regulating 
downstream genes affecting the cellular redox state. The importance of p53 as a 
tumour suppressor gene is underscored by the fact that it is mutated in many human 
cancers. Furthermore, p53 is known to have both pro-survival and pro-apoptotic 
effects related to its pro-oxidant and antioxidant functions (Macip et al., 2003; 
Sablina et al., 2005; Zhao et al., 2005b; Dhar et al., 2006). Although p53 mutations 
are uncommon in primary prostate cancers, a mutation or loss of expression has been 
associated with prostate cancer progression (Bookstein et al., 1993; Navone et al., 
1993; Abate-Shen & Shen, 2000). Nrf2 mediates the expression of a number of 
antioxidant and detoxification enzymes through the antioxidant response element. 
Downregulation of Nrf2 in prostate cancer has been shown to reduce the expression 
and activity of several glutathione-S-transferase family members, leading to an 
increase in oxidative stress and DNA damage associated with the progression to 
metastatic disease (Frohlich et al., 2008). AP-1 and NF-κB regulate the expression of 
genes involved in cellular processes such as proliferation, apoptosis and angiogenesis 
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(Suh et al., 2002; Eferl & Wagner, 2003; Sweeney et al., 2004). Constitutive 
activation of AP-1 and NF-κB in prostate cancer is believed to contribute to 
malignant transformation and progression toward a hormone-refractory phenotype 
(Suh et al., 2002; Zerbini et al., 2003; Edwards et al., 2004). Together these studies 
demonstrate that disrupting the sensitive balance between the oxidant and antioxidant 
components of prostate cells and their regulatory mechanisms may contribute to the 
development of a malignant state in prostate tissue.  
1.4.3 Altered Antioxidant Defences in Prostate Cancer 
The expression of antioxidant enzymes such as CAT, SOD and GPX is 
frequently downregulated in PIN and prostate cancer tissues compared to benign 
epithelium (Baker et al., 1997a; Bostwick et al., 2000; Oberley et al., 2000; Aydin et 
al., 2006), indicating a shift in the cellular redox state with progression to prostate 
cancer. On the other hand, antioxidant enzyme activities have variably been reported 
to be decreased or unchanged in malignant tissues compared to benign prostatic 
epithelium (Jung et al., 1997; Bostwick et al., 2000; Aydin et al., 2006). Protein 
levels are not always equivalent to enzyme activity because antioxidant enzymes are 
frequently inactivated by reactive species. Thus, it is important to evaluate enzyme 
activities in the context of oxidative damage to biomolecules to help clarify the 
mechanisms responsible for changes in antioxidant enzyme levels (Shan et al., 2012). 
Several studies have reported elevated lipid peroxidation with a concomitant 
decrease in SOD and GPX activities in prostate cancer patients compared to BPH 
patients and healthy controls (Yilmaz et al., 2004; Aydin et al., 2006). Levels of 
oxidative damage products were also elevated in metastatic prostate cancer compared 
to primary prostate cancer, although this correlated with an increase in MnSOD 
expression (Oberley et al., 2000). Overexpression of MnSOD has been shown to alter 
gene regulation, including the expression of matrix metalloproteinases which can 
enhance tumour invasion (Oberley et al., 2000). More importantly, high levels of this 
enzyme can protect against ROS, thus contributing to radiation therapy and 
chemotherapy resistance in metastatic cancer cells (Hirose et al., 1993; Satomi et al., 
1995; Nakano et al., 1996; Janssen et al., 1998). 
Another common feature found during the early stages of prostate 
carcinogenesis is hypermethylation of the GSTP1 gene (Brooks et al., 1998; 
Jerónimo et al., 2002; Nelson et al., 2004; Schulz & Hatina, 2006), which may 
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facilitate cancer progression due to impairment of cellular processing of mutagens, 
allowing ROS to damage DNA.  
Interestingly, prostate cancer cells lines display higher SOD, catalase and 
glutathione reductase activities, but lower glutathione-S-transferase and GPX 
activities compared to primary cell cultures, potentially to cope with oxidative stress 
imposed by the cell culture process (Halliwell, 2003). Together, these studies point to 
altered antioxidant defences in human prostate cancer compared to normal tissues. 
Nonetheless, it remains unclear whether these alterations in enzyme activities are the 
cause or consequence of carcinogenesis (Jung et al., 1997; Bostwick et al., 2000; 
Aydin et al., 2006). Regardless, lower antioxidant enzyme expression would 
undoubtedly suggest a decreased ability of prostate cancer cells to respond to ROS, 
and to prevent or reverse malignant transformation since ROS plays a crucial role in 
carcinogenesis. 
1.5 ANTIOXIDANTS AS POTENTIAL THERAPY FOR PROSTATE 
CANCER 
Promising results from a number of epidemiological and laboratory 
investigations suggesting that dietary antioxidants such as Vitamin E, selenium and 
lycopene may be beneficial in preventing prostate cancer (reviewed in Fleshner & 
Klotz, 1998a)have prompted large scale clinical trials like the alpha-tocopherol, beta-
carotene prevention (ATBC) study, heart outcome prevention evaluation – the 
ongoing outcomes (HOPE-TOO) study, prostate, lung, colorectal and ovarian 
(PLCO) cancer screening trial, and the selenium and vitamin E cancer prevention 
trial (SELECT) to be undertaken in recent years(Heinonen et al., 1998; Gohagan et 
al., 2000; Lonn et al., 2005; Kirsh et al., 2006; Lippman et al., 2009). Surprisingly, 
collective data from these clinical studies demonstrate that the overall risk for 
prostate cancer is unaffected by dietary antioxidant supplements (Hennekens et al., 
1996; Omenn et al., 1996a; Lippman et al., 2009). Despite striking evidence from 
some studies such as the ATBC trial and a double blinded randomised clinical trial 
that have demonstrated a reduction in prostate cancer incidence and mortality among 
men who received supplementary vitamin E (Albanes et al., 1995) or selenium 
(Clark et al., 1996; Clark et al., 1998), these results were not definitive because the 
reduction in prostate cancer incidence was not an a priori hypothesis of these studies. 
In 2011, updated data from the SELECT trial showed a significantly increased risk of 
 12 Chapter 1: Introduction and Literature Review 
prostate cancer among healthy men taking Vitamin E (400 IU/day) (Klein et al., 
2011; National Cancer Institute, 2014). Furthermore, men with higher levels of 
selenium at the start of the trial had doubled the risk of developing high-grade 
prostate cancer by taking selenium supplements (National Cancer Institute, 2014). 
The findings from epidemiological studies are themselves conflicting, with some 
reporting an inverse association between dietary antioxidant intake (e.g. vitamin A, 
β-carotene, lycopene, selenium) and prostate cancer risk (Graham et al., 1983; 
Heshmat et al., 1985; Kolonel et al., 1988; West et al., 1991; Talamini et al., 1992) 
while others have found no association or protection  (Ohno et al., 1988; Mettlin et 
al., 1989; Rohan et al., 1995).  This inconsistency has also been observed in follow-
up findings (Paganini-Hill et al., 1987; Hsing et al., 1990; Daviglus et al., 
1996).Thus, at the present time, population-wide implementation of high dose 
antioxidant supplementation for the prevention of prostate cancer is not justified. 
Nevertheless, the data obtained from these studies were beneficial to some 
subgroups. For example a 50 mg intake of vitamin E daily significantly reduced 
prostate cancer incidence and mortality in smokers compared to those assigned to 
receive placebo (Heinonen et al., 1998).  
The lack of efficacy observed with antioxidant-combinations in improving 
patient outcomes could perhaps be due to the fact that these agents can only 
neutralize ROS accumulated within the cells but are not capable of inhibiting ROS 
generation. Supporting this hypothesis is the finding that ROS production rather than 
its accumulation plays an  important role in the aggressive phenotypic behaviour of 
prostate cancer cells (Khandrika et al., 2009). Because malignant cells are under 
intrinsic oxidative stress, another approach could be to stress these cells further by 
exposing them to agents that generate reactive species. These agents should have 
limited effect on normal cells, but might, when added to cancer cells push them ‘over 
the edge’, increasing ROS levels to a point that overwhelms the antioxidant capacity 
(Kong et al., 2000; Zhou et al., 2003; Pelicano et al., 2004), resulting in irreversible 
damage and apoptosis. Indeed increased formation of ROS has been shown to 
contribute to the anti-tumour effects of radiotherapy (von Sonntag, 2006), and is in 
part responsible for the cytotoxicity of many chemotherapeutic agents (Halliwell, 
2007b). The metabolic differences between cancer cells and normal cells can thus be 
exploited for the development of new therapeutic strategies to selectively kill cancer 
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cells.  
Whether the overall antioxidant defence capacity is related to the dose-
dependent effects of antioxidants needs to be addressed since low concentrations 
under physiological conditions are protective whereas higher concentrations are 
cytotoxic and can cause damage to biomolecules (Carr & Frei, 1999; Oberley, 2005). 
Another possibility for paradoxical effects may be failure of the antioxidants to reach 
sufficient concentrations in target tissues at the doses administered due to uneven 
distribution in specific cellular compartments, or perhaps lower doses of antioxidants 
are also protective for cancer cells by relieving oxidative stress. Taking these factors 
into consideration, the development of a redox signature score for each patient by 
combining parameters of oxidative damage with those of redox state, DNA repair 
activity and antioxidant defence, similar to individualised drug therapy, may 
potentially be a useful therapeutic tool, as it would eliminate the need for an 
antioxidant dosage that is expected to work on all subjects (Halliwell, 2007b). 
1.6 NITROXIDES 
1.6.1 Introduction 
Nitroxides are a class of low molecular weight, membrane permeable, stable 
free radicals that possess an unpaired electron, which gives rise to their paramagnetic 
nature and enables their detection using electron paramagnetic resonance (EPR) 
spectroscopy (Kocherginsky et al., 1995).  
Nitroxides persist as stable free radicals (Berliner, 1976; Mitchell et al., 1991; 
Hahn et al., 1992a; Gallez et al., 1996a) mainly due to the high delocalisation energy 
of the unpaired electron over the nitrogen-oxygen bond (Figure 3.1), which makes 
dimerisation to form a peroxy-type bond energetically unfavourable (Fossey et al., 
1995). 
 
Figure 1.1. Delocalisation of the unpaired electron over the nitrogen-oxygen bond 
(Morrow, 2010) 
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In addition, their stability is influenced by the type of substituents directly 
attached to the radical centre. Bis(tert-alkyl) substituents rather than hydrogen atoms, 
heteroatoms or aromatic rings confer the greatest stability, as they provide steric 
hindrance to the radical centre and prevent the disproportionisation of the nitroxide 
to hydroxylamines and nitrones (Volodarsky et al., 1994).  
Because of their unique properties, nitroxides have been employed in a wide 
variety of applications, including as stabilisers in plastics, radical traps in radical-
mediated polymerisation processes (Ballesteros et al., 2001; Coenjarts et al., 2003), 
contrast agents for magnetic resonance imaging (Brasch et al., 1983; Swartz, 1986) 
and spin labels and probes in EPR spectroscopy to study biophysical and 
biochemical parameters, such as oxygen concentration (Morse & Swartz, 1985; Hu et 
al., 1992; Glockner et al., 1993; Baker et al., 1997b; Kuppusamy et al., 1998; Gallez 
et al., 2004), membrane fluidity (Lai et al., 1980; Edgcomb et al., 2000), pH (Gallez 
et al., 1996b), temperature (Eckburg et al., 1996), and the structural properties of 
membrane transport proteins(Spooner et al., 1999; Yordanov et al., 2002). 
Furthermore, as spin probes and contrast agents, nitroxides are useful tools for 
monitoring the cellular or tissue redox status in living animals, non-
invasively(Berliner & Wan, 1989; Ilangovan et al., 2002; Kuppusamy et al., 2002; 
Yamada et al., 2002; Kasazaki et al., 2003; Hyodo et al., 2006; Swartz et al., 2007). 
1.6.2 Bioreduction and Regeneration of Nitroxides 
In cells and tissues, nitroxides are readily reduced to their corresponding 
hydroxylamines through enzymatic and non-enzymatic pathways (Schallreuter & 
Wood, 1986; Gascoyne et al., 1987; Keana et al., 1987; Chen & Morse, 1988a; Chen 
& Swartz, 1989b). The primary site of these one-electron reductions occurs at the 
level of ubiquinone in the mitochondrial respiratory chain (Iannone et al., 1989; 
Chen et al., 1989a; Swartz, 1990; Iannone et al., 1990a, 1990b). But in cells rich in 
ascorbate such as erythrocytes, hepatocytes and kidney cells, ascorbate is the 
principal reducing agent (Rauckman et al., 1984; Eriksson et al., 1987; Keana et al., 
1987; Sentjurc et al., 1995; Saphier et al., 2003). Glutathione on the other hand 
contributes significantly to the reduction of nitroxides indirectly by acting as a 
secondary source of reducing equivalents (Kuppusamy et al., 2002; Glebska et al., 
2003).  
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The bioreduction of nitroxides depends on their physicochemical properties, in 
particular, the nature of the ring in which the nitroxide moiety is located (Keana & 
Van Nice, 1984; Belkin et al., 1987; Swartz, 1990; Morris et al., 1991; Lin et al., 
1999), the lipophilicity or hydrophilicity of the nitroxide (Sentjurc et al., 1986; Chen 
& Morse, 1988a) and the charge on the molecule (Ross & McConnell, 1975; Bartosz 
et al., 1981; Gwoździński et al., 1981; Eriksson et al., 1986; Kocherginsky et al., 
1995). In addition, cells under different oxygen concentrations (Chen et al., 1989a), 
pH (Swartz & Timmins, 2000), or having different cellular redox metabolic state 
(Zhang et al., 1999) may have different rates of nitroxide metabolism.  
Initially, the short half-life of nitroxides (Komarov et al., 1994) was seen as a 
limitation, as it reduces their effectiveness in biological systems. Consequently, long-
term exposure to these compounds or higher concentrations of nitroxides is required 
to effectively inhibit tumour growth (Gariboldi et al., 2003) and to achieve a 
therapeutic dose in vivo (Mitchell et al., 1991; Suy et al., 2005). Nevertheless 
because reduction of nitroxides to their hydroxylamines results in a loss of magnetic 
resonance intensity, monitoring the rate of nitroxide reduction using EPR has 
enabled the evaluation of tissue redox status (Kuppusamy et al., 2002; Matsumoto et 
al., 2004; Yamada et al., 2004; Hyodo et al., 2006) and ROS generation in 
vivo(Kasazaki et al., 2003; Yamada et al., 2004). Likewise, oxidation of the 
hydroxylamine back to the nitroxide radical has been used for measuring intracellular 
ROS levels and oxygen concentration (Dikalov et al., 1999; Yokoyama et al., 2000; 
Liu et al., 2004). In this we see the reversible nature of nitroxide reduction – in the 
presence of oxygen or oxidising agents, cells can oxidise hydroxylamines back to the 
nitroxides (Chen & Swartz, 1988b; Kocherginsky et al., 1995). Under reducing 
conditions however, such as in hypoxic tumours, reoxidation of the hydroxylamine to 
the nitroxide is less efficient, resulting in increased nitroxide decay rates(Berliner & 
Wan, 1989; Ishida et al., 1989; Minetti & Scorza, 1991; Ilangovan et al., 2002; 
Kuppusamy et al., 2002). This may explain why treatment with nitroxides selectively 
protects normal tissues and not the tumour against radiation damage (Hahn et al., 
1997; Cotrim et al., 2007), and lends further support to the notion that nitroxide 
radicals provide greater radioprotection than hydroxylamines (Mitchell et al., 1991; 
Krishna et al., 1998; Sasaki et al., 1998; Xavier et al., 2002).Interestingly however, 
when Tempol hydroxylamine (Tempol-H) was administered to C3H mice, significant 
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protection was observed against whole-body irradiation, indicating that Tempol-H 
had been rapidly oxidised to the active radioprotective form in vivo(Hahn et al., 
2000). Therefore, it may be concluded that regardless in which form the nitroxide is 
administered, a distribution of nitroxide radical or hydroxylamine will be achieved in 
vivo, depending on the oxygen status and the reducing equivalents available (Belkin 
et al., 1987; Krishna et al., 1992; Krishna et al., 1998). 
1.6.3 Dual Nature of Nitroxides – as Antioxidants and Pro-oxidants 
During the past decade, the protective effects of nitroxides against diverse 
oxidative damage induced at the cellular, isolated organ or systemic level, for 
example by reperfusion injury (Gelvan et al., 1991; Samuni et al., 1991b), 
mechanical trauma to the brain (Beit-Yannai et al., 1996), chemically induced gastric 
mucosal damage (Rachmilewitz et al., 1994), ROS (Samuni et al., 1991a; Samuni et 
al., 1991b; Degraff et al., 1992; Reddan et al., 1992; Reddan et al., 1993), ionising 
radiation (Mitchell et al., 1991; Hahn et al., 1992a; Xavier et al., 2002; Metz et al., 
2004; Cotrim et al., 2007) and chemotherapeutic drugs (Krishna et al., 1991; DeGraff 
et al., 1994; Monti et al., 1996), have been thoroughly investigated. Furthermore, 
treatment with Tempol has been shown to extend the life-span of Atm mutant mice 
by increasing latency to tumourigenesis, which was associated with a reduction in 
oxidative stress and damage (Schubert et al., 2004). Likewise, the chemopreventative 
effects of Tempol have been observed in mice with Faconi Anaemia (Zhang et al., 
2008) and in C3H mice prone to age-related spontaneous tumour incidence (Mitchell 
et al., 2003). 
Several mechanisms have been proposed to account for the antioxidant activity 
of nitroxides. Firstly, nitroxides can detoxify oxygen  metabolites (Dikalov et al., 
1997a; Dikalov et al., 1997b; Soule et al., 2007) and carbon-centred 
radicals(Beckwith et al., 1992; Bowry & Ingold, 1992; Brede et al., 1998) 
catalytically through their action as SOD mimics(Samuni et al., 1988, 1989; Krishna 
et al., 1998; Hahn et al., 2000; Offer et al., 2000; Shankar et al., 2000). By 
undergoing one-electron transfer reactions, nitroxides are readily reduced to 
hydroxylamines or oxidised to oxoammonium cations (Swartz, 1990; Krishna et al., 
1992)(Figure 3.2). Consequently, nitroxides can afford protection either as reducing 
agents or as oxidants, while continuously being recycled. Another example of their 
SOD mimetic activity is their ability to maintain transition metals in highly oxidised 
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states, thereby pre-empting Fenton or metal-catalysed Haber-Weiss reactions that 
lead to the generation of free radicals and in turn damage to DNA and proteins 
(Mitchell et al., 1990; Samuni et al., 1991a). Moreover, nitroxides can stimulate 
catalase-like activity in haem proteins (Krishna et al., 1996b), as well as participate 
in radical-radical recombination and chain breaking reactions. 
 
 Figure 1.2. Redox cycling ability of nitroxides (Adapted from Morrow, 2010). 
The antioxidant activity of nitroxides strongly depends on their concentration, 
which results in bell-shaped dose-response curves (Offer et al., 2000). At 
concentrations lower than 20 mM, Tempol protected the proteolytic enzyme papain 
from oxidative inactivation induced by xanthine/xanthine oxidase but this protection 
was lost at higher concentrations (Offer et al., 2000). Similarly, Tempol at the 
relatively low concentrations of 5–50 µM protected against metal-induced cyto- and 
genotoxicity in human lymphocytes (Lewinska et al., 2008). Although at higher 
concentrations (100 and 1000 µM), Tempol itself had adverse effects on the cells. 
This may be attributed to the fact that when present in excess, nitroxides are 
converted by superoxide to highly oxidising oxoammonium cations that readily 
attack cellular components essential to various biological processes, rather than being 
reduced back to nitroxides in subsequent reactions with superoxide radicals (Offer et 
al., 2000).  
Alternatively, nitroxides may indirectly cause damage to biomolecules by 
generating ROS via its SOD mimetic (Krishna et al., 1996) and complex 1 inhibiting 
activities (Voest et al., 1992; Monti et al., 2001). Monti and colleagues further 
demonstrated that this increase in intracellular oxidative stress and impairment of 
oxidative phosphorylation, which was accompanied by glutathione depletion and a 
decrease in mitochondrial membrane potential, resulted in the induction of apoptosis 
in the HL60 human leukemia cell line (Monti et al., 2001). Such a mechanism of 
action is particularly appealing given that mitochondrial events play a crucial role in 
Hydroxylamine Nitroxide Oxoammonium Ion 
     (Reduced State) (Oxidised State) (Free Radical)
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the apoptotic process; furthermore the requirement for activation of the p53 pathway, 
a major pathway in DNA damage-induced apoptosis, would be bypassed if Tempol 
were to act primarily on the mitochondria. This could potentially explain the dose-
dependent increase in p21WAF1/CIP1 levels in C6 glioma cells even in the absence of 
detectable p53 protein, following exposure to Tempol (Gariboldi et al., 2003). 
Furthermore, Tempo and its derivative 4-ferrocenecarboxyl-Tempo have been shown 
to inhibit cancer cell viability through activation of caspase 3, a key player in the 
mitochondrial-related intrinsic apoptotic pathway, providing substantial evidence 
that nitroxide-induced cell death can occur through mitochondrial mediated events 
(Suy et al., 2005; Wu et al., 2006). Besides activation of potent cell death effectors, 
Tempo treatment is also known to induce cell cycle arrest, decrease cell proliferation, 
and increase ceramide levels, which in turn enhances oxidative damage (Suy et al., 
1998; Gariboldi et al., 2003; Suy et al., 2005). Thus, it appears that Tempo may 
induce a multifactorial cell death response involving oxidative stress. More 
importantly, the anti-tumour activity of Tempo has also been observed in vivo, 
against both hormone responsive and hormone refractory prostate cancer xenografts 
grown in athymic mice (Suy et al., 2005).  
Likewise, upon exposure times longer than 24 hrs, Tempol was found to exert 
a significant inhibitory action on cell growth in a panel of human and rodent cell 
lines derived from various solid and haematological malignancies, possibly by 
triggering a free radical-mediated apoptotic mechanism (Gariboldi et al., 1998). 
Interestingly, this effect was more potent in neoplastic cells compared to non-
neoplastic cells, suggesting that Tempol may exhibit some degree of selectivity as a 
cytotoxic agent. This could be due to the fact that unlike normal cells, cancer cells 
constitutively express elevated levels of ROS, which would create a highly oxidising 
environment promoting increased formation of toxic Tempol intermediates, such as 
the oxoammonium cation (Krishna et al., 1992; Samuni et al., 2004). Other factors 
that could have accounted for the effects of this nitroxide in the individual cell lines, 
include uptake and metabolism of the compound, DNA repair capability of the cell 
line tested, as well as their ability to set up a program of apoptotic cell death, based 
on the expression of such genes as BCL2, BAX and p53. In contrast, Tempol did not 
discriminate between tumour cells displaying a multidrug resistant (MDR) phenotype 
and the corresponding parental cell line; neither was there a significant difference in 
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cytotoxicity between estrogen receptor-positive and -negative breast cancer cells 
(Gariboldi et al., 1998). These results have significant implications given that MDR 
and loss of hormone receptors are often related to an unfavourable prognosis. 
Therefore, the efficacy demonstrated by Tempol against cell lines with these 
characteristics points to a further potential benefit for the therapeutic use of this class 
of compounds.  
The cytotoxic effects of nitroxides in tumour cells may also be influenced by 
the presence or type of substituent(s) at position-4 of the piperidine ring (Metodiewa 
et al., 1999a; Koceva-Chyla et al., 2000; Metodiewa et al., 2000a; Wu et al., 2006). 
However, others have also demonstrated differences in radioprotection and in vivo 
distribution among 3-substituted pyrrolidine-N-oxyls (Anzai et al., 2006), suggesting 
that the effect of substituent structure on nitroxide potency is not only limited to 
piperidine nitroxides. In addition, nitroxides can act as chemosensitisers to enhance 
the cytotoxic effects of chemotherapeutic agents, such as mitoxantrone and 
doxorubicin, in cancer cells (Suy et al., 2005; Gariboldi et al., 2006).  
Despite similarities between Tempol and Tempo, these nitroxides may have 
different mechanism of action at the molecular level, as evidenced by the induction 
of divergent signal transduction pathways in MDA-MB 231 breast cancer cells (Suy 
et al., 1998). Tempol stimulated extracellular signal-regulated kinase 1 activity, 
whereas an equimolar concentration of Tempo (10 mM) induced ceramide 
generation, stress-activated protein kinase activation and apoptotic cell death. The 
ability of these nitroxides to elicit distinct signalling pathways in the absence of 
environmental oxidative stress was perhaps triggered by secondary radicals 
associated with cellular metabolism, and differentially regulated by early events, 
such as the control of protein tyrosine phosphorylation and generation of ceramide. 
The localisation of Tempol and Tempo within different subcellular compartments 
could also have been a contributing factor. Although both nitroxides readily cross the 
cell membrane, the more lipophilic nature of Tempo compared to Tempol 
(Kocherginsky et al., 1995) leads to its greater accumulation in the cell membrane. In 
contrast, Tempol being more water soluble is more evenly distributed throughout the 
cell. Furthermore, this nitroxide has been shown to stimulate the expression of the 
urokinase receptor protein UPAR, which has both physiological and 
pathophysiological roles, and to reduce superoxide levels in human prostate cancer 
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cells (Lejeune et al., 2006).  
While many of the studies cited above have found nitroxides to elicit apoptosis 
in cancer cells by means of oxidative stress, others have postulated apoptosis to arise 
as a consequence of a reductive stress induced by nitroxide antioxidant activity 
(Clement et al., 1998). In support of this, the antioxidants pyrrolidine 
dithiocarbamate and Vitamin E have been shown to promote cell death in colorectal 
cancer cells while causing a concomitant decrease in the generation of intracellular 
peroxides (Chinery et al., 1997).   
Together these findings indicate that nitroxides not only exert antioxidant 
activity in protecting biological systems against diverse oxidative insults but are also 
capable of inducing cytotoxicity depending on their specific microenvironment, 
treatment dose and exposure time. Clearly, identification of nitroxide compounds 
which activate apoptotic pathways by modulating the intracellular redox state makes 
them ideal for use as chemotherapeutic agents, particularly if cell death occurs via 
p53-independent mechanisms, since many tumours lack functional p53.  
Furthermore, their efficacy in late stage cancer e.g. in breast cancer cells exhibiting 
MDR and loss of hormone receptors, together with their ability to selectively kill 
tumour cells versus normal cells and sensitise cancer cells to chemotherapeutic 
drugs, confer greater advantages for their clinical use. However, these studies have 
mainly involved piperidine and pyrrolidine (5-membered ring) nitroxides, with little 
known regarding the isoindoline nitroxides which are of interest to our study.  
1.6.4 Isoindoline Nitroxides 
The general structure of isoindoline nitroxides is 1,1,3,3-tetraalkylisoindolin-2-
yloxyl. Within this class of compounds both alkyl and aromatic substituted 
derivatives exist. The isoindoline-based systems have many advantages over the 
more commonly used pyrrolidine and piperidine species because of their fused 
aromatic moiety which imparts rigidity to the ring structure. They display resistance 
to ring-opening reactions that lead to the decomposition of the other nitroxides 
(Keana et al., 1971; Harrison et al., 1984), excellent thermal and chemical stability in 
a variety of environments (Moad et al., 1982a; Griffiths et al., 1982b), narrower 
intrinsic EPR line-widths (Bolton et al., 1993; Fairhurst et al., 1996; Bottle et al., 
1999), and an internal UV chromophore and symmetrical nature that facilitate their 
 Chapter 1: Introduction and Literature Review 21 
separation, purification and characterisation (Micallef et al., 1999; Bottle et al., 
2000). 
Since this class of compounds were first synthesised (Giroud & Rassat, 1979; 
Griffiths et al., 1983), their primary uses were as radical traps in the investigation of 
radical-mediated polymerisation processes due to their enhanced free radical 
scavenging properties (Rizzardo et al., 1982; Griffiths et al., 1982a; Moad et al., 
1982a; Griffiths et al., 1982b; Adam et al., 1992). Later, they were successfully 
applied as EPR spin probes in a variety of systems. For instance, to study molecular 
motion in a low traction lubricant fluid (Britton et al., 1997), and to determine the 
effects of heating on the starch and lipid components of dough (Belton et al., 1999). 
However, their use in biological systems was hindered until the synthesis of 5-
carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl (CTMIO)(Reid & Bottle, 1998), the 
water soluble derivative of TMIO (Figure 1.3). 
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Figure 1.3. 5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl (CTMIO) 
 
1.6.5 Use of CTMIO in Biological Systems 
In a biological setting, CTMIO has largely been investigated in the context of 
Ataxia Telangiectasia (A-T), an autosomal recessive disorder characterised by a 
pleiotropic phenotype. Features of this disease include progressive 
neurodegeneration, immunodeficiency, a strong predisposition to cancer, 
radiosensitivity and genome instability (Boder, 1974; Swift et al., 1987; Peterson et 
al., 1991; Sedgwick & Boder, 1991; Spring et al., 2002). Ataxia Telangiectasia 
Mutated (ATM), the gene defective in A-T, encodes a key protein involved in 
regulating cellular responses to DNA damage and cell cycle checkpoint activation 
(Savitsky et al., 1995; Lavin & Shiloh, 1997; Shiloh & Kastan, 2001). 
The neurodegenerative phenotype in this disease has been proposed to arise as 
a consequence of oxidative stress due to observations of significantly reduced total 
antioxidant capacity in A-T patients (Reichenbach et al., 1999), and increased levels 
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of oxidative stress both in A-T cells (Rotman & Shiloh, 1997a; Gatei et al., 2001)and 
in the cerebellum of Atm-deficient mice (Barlow et al., 1999; Kamsler et al., 2001; 
Stern et al., 2002; reviewed in Watters, 2003; Browne et al., 2004). Furthermore, 
Purkinje cells from these mice demonstrate poor survival and markedly reduced 
dendritic branching and elongation in culture compare to cells from their wild-type 
littermates (Chen et al., 2003)(Figure 3.4A and C). Remarkably, treatment with 
CTMIO protected against Purkinje cell death in vitro and enhanced dendritogenesis 
to wild-type levels (Figure 1.4B). 
 
 
 
 
 
Figure 1.4. Cultured Purkinje neurons of a) Atm-deficient mice b) Atm-deficient 
mice in the presence of 100 µM CTMIO and c) wild-type mice (from Chen et al., 
2003). 
Likewise, administration of this antioxidant throughout pregnancy improved 
the survival of Purkinje cells from Atm-mutant offsprings, and reduced oxidative 
stress and damage in the cerebellum of older animals, as evidenced by an increase in 
catalase activity and reduced levels of nitrotyrosine (Chen et al., 2003). CTMIO also 
corrected for the neurobehavioural abnormalities observed in Atm-deficient mice 
(Gueven et al., 2006). 
The predisposition of A-T patients to lymphoid tumours is recapitulated in 
Atm-disrupted mice, with almost all animals succumbing to thymic lymphomas 
within five months of birth (Barlow et al., 1996; Elson et al., 1996; Xu et al., 1996). 
CTMIO dramatically increased the longevity of Atm-deficient mice by delaying the 
onset of thymic lymphomas, although this did not appear to be by a mechanism 
involving the induction of apoptosis (Gueven et al., 2006). Notably, the extent of 
tumour protection exhibited by CTMIO was much greater than that previously 
observed with Tempol (Schubert et al., 2004) and the salen-manganese antioxidant 
EUK-189 (Browne et al., 2004). The effectiveness of CTMIO in protecting against 
 
 
(a)  (b) (c) 
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tumour development is further substantiated by its lack of toxicity and efficacy at 
micromolar doses.  
Promising results were reported in another study where A-T cells pre-incubated 
with CTMIO and other carboxy nitroxides had greater survival rates post-irradiation 
and fewer chromosomal aberrations compared to untreated cells (Hosokawa et al., 
2004). In contrast, the well known antioxidant vitamin E and its water soluble 
analogue Trolox, had little impact on the survival of irradiated A-T cells. This could 
possibly be due to differences in the mechanism of action of nitroxides (Goldstein et 
al., 2003) compared to vitamin E (Wang & Quinn, 1999; Herrera & Barbas, 2001).  
1.7 SUMMARY AND RELEVANCE TO THE PROJECT 
Prostate cancer is the most common cancer and the second leading cause of 
cancer death among men in developed countries. Although localised disease carries a 
favourable prognosis, there is presently no cure for castrate-resistant prostate cancer. 
Over the last decade, there has been increasing evidence that oxidative stress 
contributes to the development and progression of this disease. Prostate cancer cells 
produce high levels of ROS due to alterations in mitochondrial metabolism, mtDNA 
mutations, and upregulation of NOX enzymes. Increased ROS production coupled 
with a decrease in antioxidant defences results in a shift in the redox balance towards 
oxidative stress. While excessively high levels of ROS are capable of causing 
irreversible cell damage and death, low to moderately high levels of ROS may 
participate in cellular processes that are important in malignant transformation and 
the development of an aggressive phenotype in prostate cancer cells through the 
activation of redox-sensitive transcription factors. However, clinical trials to date 
have largely shown dietary antioxidant supplements to be ineffective in reducing 
prostate cancer risk. Therefore, identification of novel agents that can either decrease 
the inherent oxidative stress present in prostate cancer cells, or serve to further stress 
the cells by generating ROS may enable the development of better therapeutic 
interventions for advanced-stage prostate cancer that can improve patient outcome 
and survival. 
Nitroxides are a class of low molecular weight, membrane permeable, stable 
free radicals that have been shown to function as antioxidants in protecting many 
biological systems against diverse oxidative insults. Paradoxically, these compounds 
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may exhibit pro-oxidant properties depending on factors such as concentration, 
exposure time and the specific microenvironment. The piperidine nitroxides Tempol 
and Tempo have been found to elicit apoptosis in cancer cells by means of free 
radical mediated processes and disruption of mitochondrial events. Tempol exhibits 
some degree of selectivity as a cytotoxic agent, being more potent in cancer cells 
compared to normal cells. On the other hand, the antiproliferative effect of nitroxides 
may arise as a consequence of a reduction in oxidative stress and damage due to their 
antioxidant properties. Of interest to this study was the isoindoline family of 
nitroxides due to the advantages conferred by their fused aromatic structure over the 
more commonly used pyrrolidine and piperidine nitroxides. Notably, CTMIO has 
been shown to alleviate the deleterious effects of oxidative stress and to delay the 
onset of thymic lymphomas in Atm-mutant mice with the disease A-T. Yet little is 
known regarding the effects of this, and other nitroxides on prostate cancer cells. In 
addition, the mechanisms by which these compounds elicit their effects have not 
been well characterised. 
1.7.1 Hypothesis 
Therefore, the hypotheses of this study were: 
1. The piperidine and isoindoline nitroxides exert varying degrees of 
cytotoxicity in prostate cells due to their structural differences. 
2. CTMIO may exhibit antioxidant or pro-oxidant properties in prostate 
cancer cells.  
3. Functional and network analyses will identify the signalling pathways and 
cellular processes regulated by the genes of interest and their 
interconnection with one another 
1.7.2 Project Aims 
To investigate these hypotheses, the specific aims of this project were: 
1. To assess cell survival in both normal and prostate cancer cell lines 
following treatment with CTMIO, compared to treatment with Tempo and 
its derivatives, Tempol and C-Tempo  
2. To examine the protective effects of CTMIO in prostate cancer cells under 
different oxidative stress conditions. 
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3. To identify the oxidative stress and antioxidant-related genes mediating the 
effects of CTMIO in prostate cancer cells.   
4. To determine the biological functions of these genes of interest, and their 
interactions with each another and with upstream and downstream 
signalling molecules, functional and network analyses were undertaken 
using the Ingenuity Pathway web-based application.  
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Chapter 2: Materials and Methods 
2.1 INTRODUCTION 
This chapter describes all the cell and molecular biology procedures employed 
in this project. Any deviations from these standard protocols are highlighted in the 
individual results chapters where they appear. 
2.2 GENERAL REAGENTS AND CHEMICALS 
All reagents and chemicals of analytical grade were purchased from Ajax 
Finechem (Crown Scientific, NSW, Australia), BDH Chemicals (Lomb Scientific, 
Thermo Fisher Scientific, Coopers Plains, QLD, Australia) or Sigma-Aldrich (Castle 
Hill, NSW, Australia) unless otherwise noted. Both CTMIO (Reid & Bottle, 1998) 
and 5,6-dicarboxy-1,13,3-tetraethylisoindolin-2-yloxyl (DCTEIO;(Fairfull-Smith et 
al., 2009)were synthesized by and obtained from Dr Kathryn Fairfull-Smith 
(Molecular Synthesis and Recognition Group, QUT). 
2.3 CELL LINES 
The RWPE-1, RWPE-2, LNCaP, DU-145 and PC-3 prostate cell lines were 
obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). 
RWPE-1 cells were derived from non-neoplastic adult human prostatic epithelium 
and immortalized with the human papillomavirus 18(Rhim et al., 1994). Subsequent 
transformation of these cells with the v-Ki-ras oncogene produced the RWPE-2 cell 
line. While both cell lines demonstrate androgen responsiveness (Rhim et al., 1994; 
Bello et al., 1997), only RWPE-2 is invasive, displays anchorage independent growth 
in soft agar and forms tumours in nude mice. LNCaP cells were established from a 
supraclavicular lymph node of a patient with metastatic prostate cancer and exhibit 
androgen dependent growth characteristics in vitro and in vivo (Horoszewicz et al., 
1980). This androgen responsiveness arises due to the presence of androgen 
receptors (AR), as detected in the cytosolic and nuclear extracts from cultured cells 
and nude mice tumours (Horoszewicz et al., 1983). Both PC-3 cells, isolated from a 
lumbar vetebral metastasis (Kaighn et al., 1979) and DU-145 cells derived from a 
brain metastasis (Stone et al., 1978) lack AR, and in turn are androgen independent   
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and androgen insensitive (Chlenski et al., 2001). 
2.4 CELL CULTURE 
All cells were maintained in a humidified IR Sensor Incubator (Sanyo, 
Quantum Scientific, Brisbane, Australia) at 37oC, with 95% air and 5% CO2. The 
DU-145, LNCaP and PC-3 cell lines were cultured in Roswell Park Memorial 
Institute (RPMI) 1640 medium (Invitrogen, Mt Waverly, VIC, Australia) containing 
L-glutamine, 10% foetal calf serum (FCS, Invitrogen), 50 U/mL Penicillin G and 50 
µg/mL Streptomycin (Invitrogen). The RWPE-1 and RWPE-2 cell lines were grown 
in Keratinocyte serum-free media (KSFM, Invitrogen) supplemented with 50 µg/mL 
bovine pituitary extract (BPE) and 5 ng/mL recombinant human epidermal growth 
factor (EGF) (Invitrogen). Culture media for these cells were replaced every 3 to 4 
days. All cell lines were subcultured once they reached 80-85% confluency, using 
either1X trypsin (Invitrogen) for DU-145, PC-3 and LNCaP cells, or the stable 
trypsin-like enzyme TrypLETM Express (Invitrogen) for RWPE-1 and RWPE-2 cells. 
Cell morphology and viability was monitored by microscopic examination and 
regular testing for Mycoplasma infection was performed using the Takara Bio PCR 
detection kit (Scientifix, Cheltenham, VIC, Australia). For all experiments, low 
passage cells (up to passage 40) were seeded and treated in their respective culture 
media, unless otherwise indicated.  
2.4.1 Cryopreservation and Storage of Cells 
For cryopreservation, cells were grown to 80–85% confluency, trypsinised, 
resuspended in culture media and centrifuged at 1000 rpm for 5 min. Cell pellets 
were then resuspended in their respective culture media containing 10% dimethyl 
sulphoxide (DMSO) and an additional 20% FCS (with the exception of RWPE-1 and 
RWPE-2 cells). The resulting cell suspension was aliquoted into cryovials, placed in 
a freezing container filled with 100% isopropanol and frozen to -80oC, at a cooling 
rate of -1oC/min. Once frozen, cells were transferred to liquid nitrogen for long term 
storage. To resuscitate stocks, cells were rapidly thawed at 37oC in a waterbath, 
resuspended in 4 mL culture media and centrifuged at 1000 rpm for 5 min. Cell 
pellets were then resuspended in 5 mL culture media and transferred into T25 cm2 
flasks (Nunc, Thermo Fisher, Scoresby, VIC, Australia). 
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2.4.2 Cell Counting 
To determine cell numbers, cells were firstly detached using 1X trypsin or 
TrypLETM Express and resuspended in growth medium. Cell suspensions were then 
mixed with equal volumes of lysis and stabilising buffers, drawn up into 
NucleoCassettes (Chemometec) containing propidium iodide to stain cell nuclei, and 
placed into the automated NC-100 NucleoCounter (ChemoMetec, Allerød, 
Denmark). Alternatively, cell suspensions were mixed with 0.4% Trypan Blue 
solution (Invitrogen) and the cells manually counted using a haemocytometer 
(ProSciTech, Thuringowa, QLD, Australia).  
2.5 CELL SURVIVAL ASSAYS 
Cells were seeded at the following densities: DU-145 1.5x103, PC-3 2.5x103, 
LNCaP 2.5x103, RWPE-1 4x103 and RWPE-2 4x103 cells per well, unless stated 
differently, onto clear 96-well plates (Nunc) or black 96-well ViewPlates 
(PerkinElmer, Rowville, VIC, Australia ), with each well containing 100 µL culture 
medium. Cells were seeded at different densities to account for differences in growth 
rate and to achieve 85–90% confluency by the end of the treatment period. Stock 
solutions of each treatment were prepared in DMSO or 100% AR-grade ethanol 
unless otherwise indicated. After cultivating the cells for 24 hrs, the medium in each 
well was replaced with 100 µL fresh medium supplemented with the appropriate 
concentration of treatment. Cells were exposed to the various treatments or vehicle 
alone for designated time intervals. The final vehicle concentration in all treatments 
was 0.1% or less. At the end of each treatment period, cell morphology was observed 
with an Olympus CK40 light microscope (Olympus).Following this, cell survival 
was assessed using both the WST-1(Roche, Castle Hill, NSW, Australia)and the 
CyQUANT® NF (Invitrogen) cell proliferation assay kit according to manufacturer’s 
instructions. The colourimetric WST-1 assay, which is dependent on cellular 
metabolic activity, is an indirect measure of cellproliferation or viability. After the 
removal of treatment media from the wells, 100 µL of a 1:10 concentration of WST-
1 solution (1 mL in 10 mL phenol red-free media containing 10% FCS) was added to 
each well. Cells were incubated with WST-1 for 2 hrs at 37oC under a 5% 
CO2atmosphere to allow for any colour development. Plates were cooled to room 
temperature before measuring the absorbance using the Benchmark Plus microplate 
reader (Bio-Rad, Hercules, CA, USA) at 450 nm, with a reference wavelength of 650 
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nm. When using the DNA based CyQUANT® NF assay, which is a direct measure of 
cell proliferation or viability, the treatment media was removed from the wells and 
the bottoms of the black ViewPlates were sealed with a black film, prior to 
dispensing 100 µL of the 1X DNA dye binding solution into each well. The plates 
were protected from light and incubated for 1 hr at 37oC, under a 5% CO2 
atmosphere to allow for the equilibration of dye-DNA binding. Fluorescence was 
measured using a POLARstar plate reader (BMG Labtech, Mornington, VIC, 
Australia), with excitation at 485 nm and emission detection at 520 nm. Cell survival 
was expressed as a percentage of the vehicle control for all experiments. 
2.6 CELL CYCLE ANALYSIS USING FLOW CYTOMETRY 
DU-145, LNCaP, PC-3 and RWPE-1 cells were seeded in 6-well plates at 
densities chosen so that they would be 85–90% confluent by the end of each 
treatment interval, and allowed to attach overnight before being treated with 1.5 mL 
of media containing 10, 100 and 500 µM CTMIO for 24 and 48 hrs or 10, 250 and 
1000 µM Tempol for 48 and 96 hrs. At each time point, conditioned media was 
collected from duplicate wells per treatment. Cells were washed twice with cold PBS 
and harvested from duplicate wells per treatment using 1X trypsin or TrypLETM 
Express. Trypsin was inactivated by the addition of culture media. Harvested cells 
were pooled with the conditioned media and centrifuged at 1000 rpm for 5 min. Cell 
pellets were resuspended thoroughly in 300 µL cold PBS, fixed in 700 µL ice-cold 
100% ethanol for 30 min at 4oC or -20oC and stored at -20oC if they were not stained 
immediately. Fixed cells were centrifuged at 1000 rpm for 5 min, washed with 
nuclease-free PBS and re-centrifuged at 1000 rpm for 5 min. Cell pellets were 
resuspended in 500 µL nuclease-free PBS containing 2 µg/mL propidium iodide 
(Invitrogen) and 1 mg/mL DNase-free RNase (Roche) and incubated in the dark for 
30 minutes at room temperature then kept on ice. Cells were filtered through a 38 µm 
nylon filter mesh (Sefar, Huntingwood, NSW, Australia) prior to analysis on a Cell 
Lab QuantaTM SC flow cytometer (Beckman Coulter, Mount Waverly, VIC, 
Australia), using 488 nm laser excitation. The mean fluorescent intensity of 10 000 
cells was analysed per sample. The percentage of cells in different phases of the cell 
cycle was then determined by applying the Dean-Jett-Fox mathematical model to the 
cell cycle data without any constraints, using the FlowJo software v7.6.3 (Tree Star, 
Inc, Oregon, USA). 
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2.7 ELECTRON PARAMAGNETIC RESONANCE (EPR) STUDIES 
2.7.1 Collecting Conditioned Media and Whole Cells from 6-well Plates 
Following CTMIO Treatment 
PC-3 and LNCaP cells were seeded in 6-well plates the day before treatment at 
different densities to achieve 85–90% confluence by the end of the treatment period. 
The cells were treated by replacing the medium with 2 mL fresh media containing 
10, 100 and 500 µM CTMIO. Control treatments received DMSO or ethanol vehicle 
alone. The final vehicle concentration in all treatments was 0.1%. Cells were exposed 
to the various treatments for 24, 48 and 96 hrs. At the end of each treatment interval, 
conditioned media was firstly collected and pooled from duplicate wells and 
centrifuged at 1000 rpm for 5 min to remove any cellular debris. The supernatant was 
then transferred to a fresh tube and placed on ice. The cells were washed twice with 
PBS and harvested from duplicate wells by trypsinisation, pooled and centrifuged at 
1000 rpm for 5 min. Cell pellets were washed once with ice-cold EPR buffer (50 mM 
Tris-HCl, pH 7.5, 140 mM NaCl and 50 mM KCl), centrifuged at 1000 rpm for 5 
min, resuspended in 1–3 mL ice-cold EPR buffer and kept on ice.  
2.7.2 Collecting CTMIO & DCTEIO Conditioned Media from T75 cm2 Flasks 
PC-3 cells were seeded in T75 cm2 flasks 24 hrs before treatment at a density 
to achieve 85-90% confluence by 96 hrs. Cells were treated by replacing the medium 
with 12 mL of fresh media containing 10 and 100 µM CTMIO or DCTEIO. For the 
vehicle controls, cells were treated with DMSO or media alone. The final vehicle 
concentration in all treatments was 0.1%. 5 mL of conditioned media was removed 
from the same T75 cm2 flask at each time point (24 and 96 hrs) and centrifuged at 
1000 rpm for 5 min to remove any cellular debris. The supernatant was then 
transferred to a fresh tube, which was sealed with parafilm and stored at -20oC until 
the completion of all the time points (7 days), before EPR analysis was undertaken. 
For these experiments, EPR spectra measurements for all the samples were 
performed on the same day.  
2.7.3 Re-oxidising CTMIO in Lysed Cells 
Seeding of PC-3 cells in 6-well plates, treatment with 500 µM CTMIO for 24 
hrs and cell harvesting were performed as described in Section 2.7.1. Following 
centrifugation at 1000 rpm for 5 min, cell pellets were resuspended in 1 mL EPR 
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buffer and kept on ice. Prior to EPR analysis, 200 µL cell lysis buffer (10 mM Tris 
pH 8.0, 150  mM NaCl, 5 mM EDTA, 1% Triton X-100, 1X complete EDTA-free 
protease inhibitor cocktail (Roche) and 1X phosphatase inhibitor cocktail 2) was 
added to each sample. Samples were incubated for 10 min on ice. The cells were 
further lysed mechanically by pipetting up and down 10–15 times and vortexing the 
samples. Lysed cells were incubated with 10, 100, 500 and 2000 µM (final 
concentration) potassium ferricyanide (K3Fe(CN)6 or 50 µM hydrogen peroxide 
(H2O2) (final concentration) for 15 min at room temperature to allow any reduced 
CTMIO to re-oxidise. Samples were then adjusted with EPR buffer to 3 mL so that 
there was an equal volume across all samples before EPR measurements were 
undertaken. 
2.7.4 Re-oxidising CTMIO in Conditioned Media 
Culturing of LNCaP cells in a T75 cm2 flask, treatment with 100 µM CTMIO 
for 48 hrs, and collection of conditioned media were carried out according to the 
procedure described for the CTMIO and DCTEIO conditioned media experiments 
(Section 2.7.2). K3Fe(CN)6 was added to 1 mL of conditioned media to give final 
concentrations of 2, 5 and 10 mM. Samples were mixed and incubated for 15 min at 
room temperature to allow any reduced CTMIO to re-oxidise prior to EPR 
measurements being undertaken.  
2.7.5 Incubation of Culture Media from Cells with CTMIO 
PC-3 and LNCaP cells were cultured in T175 cm2 flasks for 3 days and were 
approximately 85% confluent at the end of this period. Culture media was removed 
from the cells and centrifuged at 1000 rpm for 5 min to remove any cellular debris. 
The supernatant was transferred to a new flask and incubated with 100 µM CTMIO 
for 0, 2, 24, 48 and 96 hrs at 37oC, under a 5% CO2atmosphere. For the control 
treatment, culture media was incubated with the DMSO vehicle for 2 and 96 hrs. 
CTMIO-treated culture media (3 mL) was removed from the same flask at each time 
point, transferred to a fresh tube, which was sealed and stored at -20oC until all the 
samples had been collected. EPR spectra measurements were all undertaken in the 
same session. 
2.7.6 EPR Spectra Measurements and Data Analysis 
Where necessary, samples were thawed and mixed thoroughly prior to EPR 
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measurements.0.5–1 mL of each sample was then transferred with a syringe, through 
Teflon tubing, into an AquaX cell (Bruker Biospin, Alexandria, NSW, Australia) 
within the EPR super high Q resonant cavity.  EPR spectra were acquired on a 
multifrequency continuous wave EPR spectrometer (Bruker Biospin Elexsys E500) 
located in the Centre for Advanced Imaging at the University of Queenslandunder 
non-saturating conditions (3 mW) at room temperature (298 K), using the following 
acquisition parameters: microwave frequency, 9.878 GHz; microwave power, 2.5 
mW; modulation frequency, 100 kHz; and a modulation amplitude less than one-
tenth of the line-width at half-height (0.02 mT). Each spectrum was signal averaged 
(n=10 to n=50), to increase the signal-to-noise ratio. Magnetic field and microwave 
frequency were calibrated with an ER-035M gaussmeter and an EIP648B frequency 
counter respectively. Spectrometer tuning, signal averaging and all subsequent data 
manipulations were performed using the Xepr v2.6b.45 software (Bruker Biospin). 
The signal intensity arising from CTMIO within each sample was determined by 
double integration of the signal averaged EPR spectra using this software because it 
enables reproducible double integrals to be determined even from spectra with noisy 
baselines, by taking into account the double integral of the baseline on either side of 
the resonance being examined. 
2.8 MODELS OF OXIDATIVE STRESS 
2.8.1 Docetaxel (DTX) and CTMIO Treatments 
PC-3 and LNCaP cells were seeded at different densities onto white 96-well 
plates (PerkinElmer) in phenol red-free RPMI 1640 containing 10% FCS, and 
allowed to attach for 48 hrs. At the time of treatment, cells were approximately 10–
30% confluent. Treatments were prepared in phenol red-free RPMI 1640 containing 
10% FCS. 100 µL of the appropriate treatment media was added to each well. PC-3 
cells were treated with 0.5 nM DTX (Sigma-Aldrich), 100 µM CTMIO, DTX plus 
CTMIO or DMSO only (0.1%) for 6, 18, 24 and 48 hrs. LNCaP cells were treated 
with 500 µM H2O2 and 100 µM CTMIO, either alone or in combination as described 
in Section 2.8.2, with minor changes. Following the 1 hr treatment period, cells were 
allowed to recover in 100 µL fresh media containing 100 µM CTMIO or 0.1% 
DMSO for 5 hrs instead of 7 hrs. LNCaP cells were included in this experiment as 
positive controls. 
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2.8.2 Hydrogen Peroxide (H2O2) and CTMIO Treatments in 96-well Plates 
PC-3, LNCaP, RWPE-1 and RWPE-2 cells were seeded onto white 96-well 
plates at a density of 5.5x103, 5.5x103, 4.5x103 and 3.5x103 cells per well, 
respectively. Cells were seeded in phenol red-free RPMI 1640 containing 10% FCS 
and cultured for 48 hrs. Treatments were made up in the same media and a volume of 
100 µL was added to each well. Cells were treated with 500 µM H2O2 and 100 µM 
CTMIO, together or as individual agents for 1 hr. These treatments were 
subsequently removed and cells were cultured for a further 7 hrs in fresh media 
containing 100 µM CTMIO or 0.1% DMSO. For the control treatment, cells received 
0.1% DMSO and 0.05% PBS and were recovered in media containing 0.1% DMSO.  
2.8.3 GSH-GloTM Glutathione Assay as a Measure of Oxidative Stress 
The glutathione (GSH) concentration in DTX and CTMIO or H2O2 and 
CTMIO treated cells (Section 2.8.1 and 2.8.2), was determined using the 
luminescence-based, GSH-GloTMGlutathione Assay (Promega, Alexandria, NSW, 
Australia) with GSH standards (0.31–5 µM per well). The assay, including the 
preparation of standards and reagents, were performed according to manufacturer’s 
instructions. Briefly, the treatment media was removed from the wells and 100 µL of 
1X GSH GloTM reagent was added to each well. Plates were protected from light, 
mixed briefly on a plate shaker and incubated for 30 min at room temperature. 
Reconstituted Luciferin Detection Reagent (100 µL/well) was then added and the 
plates were again mixed and incubated for 15 min at room temperature. 
Luminescence was measured on the POLARstar plate reader with a measurement 
interval time of 0.4 sec per well. For the analysis, background luminescence from 
media only wells was subtracted from all readings. The glutathione concentration for 
each treatment was then expressed as a fold change relative to vehicle treated cells to 
facilitate comparison across treatments. 
2.9 RT2 (REAL-TIME REVERSE TRANSCRIPTION) PROFILER PCR 
ARRAYS 
2.9.1 H2O2 and Nitroxide Treatments 
T25 cm2 flasks were seeded with 3x106 LNCaP cells. After 24 hrs of 
attachment, the media was replaced with5 mL of fresh phenol red-free media 
supplemented with 500 µM H2O2 and 100 µM CTMIO, as single agents or in 
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combination. Cells were treated for 1 hr and washed gently with PBS once or twice 
before incubation with media containing 100 µM CTMIO or 0.1% DMSO for 7 hrs. 
Using the same treatment regime, cells were exposed to 500 µM H2O2, 100 µM 
DCTEIO or both compounds together for 1 hr, and then cultured for an additional 7 
hrs in media containing 100 µM DCTEIO or 0.1% DMSO. For the control treatments 
in both the CTMIO and DCTEIO experiments, cells received 0.1% DMSO and 
0.05% PBS for 1 hr and were recovered in media containing 0.1% DMSO.  
2.9.2 RNA Isolation and Quantitation 
Following the H2O2 and nitroxide treatments (Section 2.9.1 and 2.9.2), media 
was removed, cells washed once with PBS and total RNA extracted using TRIzol 
(Invitrogen). 1 mL TRIzol was added to each T25 cm2 flask, and incubated on the 
cells for 5 min at room temperature. The solution was pipetted up and down a couple 
of times at the liquid-air interface to facilitate cell lysis and transferred to RNase-free 
tubes. For each 1 mL of TRIzol, 200 µL chloroform was added and the mixture 
shaken vigorously for 30 sec. The samples were incubated for 5 min at room 
temperature to allow phase separation and then centrifuged at 12 000 x g for 15 min 
at 4 oC. The aqueous phase was transferred to a new tube and mixed with 500 µL of 
isopropanol and 100 µL 3 M ammonium acetate per mL of TRIzol, 0.1 mg/mL of 
linear polyacrylamide (Ambion, Applied Biosystems, Scoresby, VIC, Australia) and 
1 µL of glycogen. RNA was precipitated overnight at -20 oC. The precipitate was 
pelleted by centrifugation at 12 000 x g for 15 min at 4 oC. The supernatant was then 
discarded and the pellets washed briefly with 1.2 mL of ice-cold 70% ethanol. The 
samples were centrifuged for another 10 min (7500 x g) at 4 oC, after which the 
ethanol was removed and the pellets allowed to air dry. The RNA pellets were then 
resuspended in 20–40 µL of nuclease-free water (Invitrogen). RNA concentrations 
were measured using the NanoDrop 1000 spectrophotometer (Thermo Scientific, 
Biolab, Scoresby, VIC, Australia), where an A260 optical density of 1 represented 40 
µg/mL RNA. Purity of samples was determined based on the A260/280 and 
A260/230absorbance ratios which were generally 2.0 and 1.7–2.1, respectively. The 
quality of the extracted RNA was also assessed by gel analysis. 300–500 ng of each 
sample was separated on a 1% agarose/ tris-acetate-EDTA gel and electrophoresed at 
120 V for 20 min. Images were captured using a Syngene UV Illumination System 
(Geneworks, Adelaide, SA, Australia). The presence of the two distinct 28S rRNA 
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and 18S rRNA bands, with the intensity of the 28S band being double that of the 
18S, indicated high quality RNA.   
2.9.3 DNase Treatment and Clean-up of RNA Samples 
To remove any residual DNA contamination from the RNA extraction process, 
samples were subjected to DNase treatment. 10 µg of RNA per sample was diluted to 
a final volume of 80 µL with nuclease-free water and treated with 10 units (U) of 
DNase I (Invitrogen) in 1X reaction buffer (Invitrogen) for 15 min at room 
temperature. To inactivate the reaction, samples were incubated with 10 µL of 25 
mM EDTA for 1 min at room temperature. All RNA clean-up steps were performed 
at room temperature using the Qiagen RNeasy Mini Kit (Qiagen, Doncaster, VIC, 
Australia) according to the manufacturer’s instructions. Briefly, the DNase 1 treated 
RNA samples were diluted to a final volume of 100 µL with RNase-free water and 
mixed with 350 µL of RLT buffer followed by 250 µL of 100 % ethanol.  The 
samples were transferred to RNeasy Mini spin columns that were placed in 2 mL 
collection tubes and centrifuged at 10 000 rpm for 15 sec. The flow-through was 
discarded and the spin column membrane washed by the addition of 500 µL of RPE 
buffer and centrifugation at 10 000 rpm for 15 sec. This step was repeated with 
centrifugation at 10 000 rpm for 2 min, after which the spin columns were placed in 
new collection tubes and centrifuged at 14 000 rpm for 1 min to eliminate any 
carryover of RPE buffer or residual flow-through remains. The spin columns were 
again transferred to new collection tubes and 40 µL RNase-free water was added 
directly to the spin column membrane and incubated on the membrane for 15 min at 
room temperature. To elute the RNA, the columns were centrifuged at 10 000 rpm 
for 1 min. The concentration and quality of the cleaned RNA samples were re-
assessed using the spectrophotometer and by gel electrophoresis as described earlier 
(Section 2.9.3).Only RNA samples which had passed gel analysis and had A260/280and 
A260/230  ratios of at least 2.0 and 1.7, respectively, were used in the RT2 Profiler PCR 
Arrays (SABiosciences, QIAGEN, Doncaster, VIC, Australia). All RNA samples 
were stored at -80 oC. 
2.9.4 Complementary DNA (cDNA) Synthesis 
400 ng of total RNA per sample was reverse transcribed to cDNA using the 
RT2 First Strand Kit (SABiosciences, Qiagen, Doncaster, VIC, Australia), as 
described by the manufacturer. RNA samples were mixed with 2 µL of 1X Genomic 
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DNA Elimination (GE) buffer and diluted to a final volume of 10 µL with RNase-
free water. The GE mix was then incubated for 5 min at 42 oC and chilled on ice 
immediately after for at least 1 min. To each 10 µL of GE mixture, 10 µL of Reverse 
Transcriptase (RT) Cocktail containing 4 µL 5X RT Buffer 3, 1 µL Primer and 
External Control Mix, 2 µL of RT Enzyme Mix 3 and 3 µL RNase-free water was 
added. The samples were incubated for 15 min at 42 oC and inactivated by heating 
for 5 min at 95 oC. The resulting cDNA samples were diluted to a final volume of 
111 µL with RNase-free water and stored at -20 oC. 
2.9.5 Human Oxidative Stress and Antioxidant Defence RT2 ProfilerTM PCR 
arrays 
Human RT2 ProfilerTM PCR Arrays (Format E, PAHS-065Z, SABiosciences), 
containing primer sets for 84 genes involved in oxidative stress and antioxidant 
defence, were used to investigate changes in gene expression in LNCaP cells 
exposed to H2O2 and nitroxide. These arrays combine the multiple gene profiling 
capabilities of a microarray to simultaneously screen a number of pathway genes 
with the quantitative precision of real-time PCR, using SYBR Green technology. 102 
µL of each cDNA sample was mixed with 650 µL of the 2X RT2 SyBr Green ROX 
FAST Mastermix (SABiosciences) and made to a total volume of 1300 µL with 
nuclease-free water. Each sample was then added to the 384-well RT2 ProfilerTM 
PCR Array plate, with 10 µL (~0.3 ng) dispensed per well. The PCR arrays were run 
on an ABI 7900HT Real-time PCR System (Applied Biosystems, Scoresby, VIC, 
Australia) with the following cycling parameters: 95 oC for 10 min then 40 cycles of 
95 oC for 15 sec and 60 oC for 1 min followed by a dissociation step. To calculate the 
threshold cycle (Ct) for each well, baseline and threshold values were automatically 
and manually assigned, using the ABI 7900 SDS 2.4 software (Applied Biosystems). 
The controls in the datasets were then checked to ensure there was minimal genomic 
DNA contamination or inhibition of RT reaction and PCR efficiency, according to 
the criteria described by the manufacturer. For inclusion in data analysis, Ct values 
≥35 were noted, as these are generally not considered reliable expression values, and 
undetermined Ct values were assigned a Ct of 40. Relative gene expression compared 
to a control sample was determined using the comparative Ct (∆∆Ct) method and 
expressed as a fold change 2-∆∆Ct (Schmittgen & Livak, 2008). For this approach, the 
Ct value of each gene was normalised to the average Ct of the five housekeeping 
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genes present on the array (B2M, HPRT1, RPL13A, GAPDH and ACTB) to obtain the 
ΔCt. The difference between the ΔCt of the control cells and the ΔCt of treated cells 
was used to calculate the ∆∆Ct value for each gene. 
2.9.6 Heatmaps of Published Microarray Data and PCR Array Data 
Publically available microarray data from the works of Zhao and co-workers 
(Zhao et al., 2005a) (GDS1699) and Varambally and colleagues (Varambally et al., 
2005) (GDS1439) were downloaded from the Genome Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) using R 2.11.1 (http://www.r-project.org/) with 
BioConductor (http://www.bioconductor.org/) and GEO query installed. The Log2 
expression values for the PCR array genes were extracted from these datasets then 
normalized, median centred and displayed as a heatmap with row and column 
clustering. Each column of the heatmaps represented an individual sample while 
each row represented a specific gene. Normalisation was performed so that the mean 
expression level of the genes in the samples equalled 0 and the SD equalled 1. This 
enabled direct comparisons to be made between the data in the absolute quantitated 
datasets and the relative dataset. Fold change values from the CTMIO and DCTEIO 
datasets were converted to Log2 expression values and imported into R 2.11.1. 
Values were then median centred and displayed as a heatmap with row and column 
clustering. 
2.9.7 Functional Network Analysis 
Functional network analyses were undertaken using Ingenuity Pathways Analysis 
(IPA) tools (Ingenuity® Systems, Redwood City, CA, USA). IPA is a web-delivered 
application developed for gene expression and proteomics data that enables users to 
query molecular interactions, biological functions, and diseases for generating 
customized pathways and analysis. Lists of differentially expressed genes (P<0.1 or 
fold change ≥2) from the PCR array datasets, together with their gene identifiers 
(GenBank accession numbers) were uploaded into the application. Each gene 
identifier was mapped to its corresponding gene object, called focus gene, in the 
Ingenuity Knowledge Base. Focus genes were then used as a starting point for 
generating biological networks based on their connectivity to each other and to 
upstream transcription regulators or downstream molecules of interest. The 
interactions/ relationships (connectivity) between the genes of interest, as well as 
their molecular and cellular functions and disease involvement were identified using 
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information in the Ingenuity Knowledge Base, an extensive, manually curated 
repository of biological interactions and functional annotations extracted from primary 
literature sources, including peer-reviewed publications and biomedical databases. 
Biological functions and diseases and disorders were identified as having a 
significant association with the genes of interest based on the Fisher’s exact test 
score, a numerical value calculated by the IPA system. 
2.9.8 Statistical Analysis 
Where comparisons were made between multiple means, one-way analyses of 
variance (ANOVA) with Tukey’s Post-Hoc tests were performed using VassarStats: 
Website for Statistical Computation (Lowry, 1998). P values <0.05 were considered 
statistically significant. For the PCR array datasets, statistical calculations were 
performed using GraphPad PRISM software v6 (San Diego, CA, USA) and were 
based on ∆Ct values. Outliers were identified using the ROUT test under the most 
stringent settings, and replaced with the arithmetic mean of the remaining two 
biological replicates. Following this, repeated measures two-way ANOVAs with 
Dunnett’s Post-Hoc tests were used to compare each treatment group to the control 
group. Differences were considered significant at P value below 0.1.  
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Chapter 3: Comparison of the Pro-oxidant 
Property of the Piperidine and 
Isoindoline Family of Nitroxides 
in Prostate Cancer Cells 
3.1 INTRODUCTION 
In advanced, metastatic disease, where prostate cancer has progressed to 
become castrate-resistant, many of the currently available therapies are simply 
palliative, or at best, achieve short-term benefits (Tannock et al., 1996; Petrylak et 
al., 2004; Tannock et al., 2004; Berthold et al., 2008; Tran et al., 2009; De Bono et 
al., 2010; De Bono et al., 2011; Mottet et al., 2011; Cabot et al., 2012; Parker et al., 
2013; Ryan et al., 2013). Hence, there is the need for more effective treatments 
without the added burden of general or organ toxicity.  
Low molecular weight, membrane permeable, stable nitroxide free radicals 
(Samuni et al., 1988; Mitchell et al., 1990) may be useful as a novel therapy or 
adjuvant in the treatment of prostate cancer, as they exhibit greater potency against 
tumour cells compared to normal cells (Gariboldi et al., 1998). Traditionally used as 
contrast agents for medical imaging (Brasch et al., 1983; Bennett et al., 1987a; 
Benett et al., 1987b) and as spin labelled probes for biophysical and biochemical 
studies (Berliner, 1979; Mehlhorn & Packer, 1983; Morse & Swartz, 1985; Swartz, 
1986; Strzalka et al., 1990), nitroxides have been shown to function as antioxidants 
in protecting many biological systems against diverse oxidative insults including 
radiation (Mitchell et al., 1991; Hahn et al., 1992b; Mitchell & Krishna, 2002), 
cytotoxic drugs (Krishna et al., 1991; DeGraff et al., 1994; Monti et al., 1996) and 
post-ischemic reperfusion injury (Gelvan et al., 1991; Samuni et al., 1991b), due to 
their ability to scavenge free radicals and to inhibit their production (Krishna & 
Samuni, 1994; Krishna et al., 1996). Interestingly, there is also evidence that 
nitroxides may exhibit pro-oxidant properties, depending on conditions such as 
concentration, exposure time and the specific microenvironment (Offer et al., 2000). 
Such dual, and seemingly paradoxical behaviour is not uncommon among 
antioxidants (Chinery et al., 1998; Della Ragione et al., 2000). 
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The toxicity of several six-membered ring nitroxides were first noted in 
different bacterial strains, where exposure to high concentrations (1–50 mM) led to 
mutagenic (Sies & Mehlhorn, 1986; Gallez et al., 1992) and bactericidal or 
bacteriastatic effects (Wang et al., 1996). Later studies found that Tempol (Figure 
3.1A) also inhibited the growth of cultured cell lines derived from various human 
malignancies, although in a dose and time-dependent manner (Gariboldi et al., 1998; 
Monti et al., 2001; Gariboldi et al., 2003). Treatment with Tempol at concentrations 
≥1 mM for 24 hrs triggered apoptosis, which was accompanied by changes in the 
intracellular redox state and disruption of mitochondrial events (Monti et al., 2001). 
Coinciding with these findings, an increase in caspase 3 and 9 expression, as well as 
alterations in morphological features characteristic of apoptosis was apparent in 
prostate cancer cells following treatment with Tempo (Figure 3.1B), the non-
hydroxylated analogue of Tempol (Suy et al., 2005). Nevertheless, Tempol has also 
been reported to have substantial chemopreventative effects in cancer-prone mice, 
which was associated with a reduction in oxidative stress and damage, and an 
increase in latency to tumourigenesis (Schubert et al., 2004; Erker et al., 2005; Zhang 
et al., 2008).  
Of interest to this study is the novel isoindoline nitroxide CTMIO (Figure 
3.1D) because of the advantages this family of nitroxides have over the commonly 
used pyrrolidine and piperidine species due to their fused aromatic structure. These 
include resistance to ring-opening reactions that are significant decomposition 
pathways for the pyrrolidine and piperidine nitroxides (Keana et al., 1971; Harrison 
et al., 1984), excellent thermal and chemical stability in polymers and enhanced 
radical scavenging properties (Rizzardo et al., 1982; Griffiths et al., 1982a; Moad et 
al., 1982a; Griffiths et al., 1982b). In a biological context, CTMIO has been shown to 
protect against oxidative stress in Atm-deficient mice affected by the disease A-T, 
and to promote the survival and differentiation of neuronal cells from these animals 
in vitro (Chen et al., 2003). Furthermore, CTMIO dramatically delayed the onset of 
thymic lymphomas in Atm-deficient mice and corrected for neurobehavioural deficits 
in these animals (Gueven et al., 2006). In doing so, CTMIO outperformed other 
antioxidants previously studied (Browne et al., 2004; Schubert et al., 2004). The 
efficacy of CTMIO is further substantiated by its lack of toxicity in vivo, making it 
ideal for biological use.  
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In spite of these promising results, to date, the role of CTMIO in other cell 
types and disease models has not been well characterized (Gueven et al., 2006). In 
addition, little is known regarding the effects of other nitroxides, such as the 
pyrrolidine and piperidine species on prostate cancer cells (Suy et al., 1998). In this 
study, which has a particular focus on prostate cancer, the cytotoxicity of CTMIO in 
cultured cells was investigated prior to establishing its utility as an anti- or pro-
oxidant and potential therapeutic agent. This was carried out by assessing cell 
viability following treatment with CTMIO compared to treatment with Tempo and its 
derivatives, Tempol and C-Tempo (Figure 3.1C). The impact of CTMIO on cell 
cycle progression was also examined. Finally, the signal strength of CTMIO in the 
culture medium and within cells was measured using electron paramagnetic 
resonance (EPR) spectroscopy to determine the half-life of this compound, and in 
turn its stability. 
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Figure 3.1. Piperidine and Isoindoline nitroxides 
a) 4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (Tempol), b) 2,2,6,6-tetramethylpiperidine-1-
oxyl (Tempo), c)  4-Carboxy-2,2,6,6-tetramethylpiperidine-1-oxyl (C-Tempo), d) 5-carboxy-
1,1,3,3-tetramethylisoindolin-2-yloxyl (CTMIO) and e) 1,1,3,3-tetraethyl-5,6-
dicarboxylisoindoline-2-yloxyl (DCTEIO)
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3.2 MATERIALS AND METHODS 
For full details of the experimental procedures used in this chapter refer to 
Sections 2.5–2.7.6. The following is a brief description of the treatment conditions 
used in the cell survival assays that are pertinent to this chapter. 
3.2.1 Cell Survival Assays Involving Nitroxides 
Following standard procedures described in Section 2.5, a panel of prostate cell 
lines representing a spectrum of normal prostate (RWPE-1) to malignant prostate 
cells (RWPE-2 DU-145, LNCaP, PC-3) were seeded at the appropriate densities onto 
96-well plates and incubated overnight. The medium in each well was then replaced 
with 100 µL fresh media (phenol-red free) containing either a) Tempo (250–5000 
µM); b) Tempol (250–5000 µM); c) C-Tempo (0.1–1000 µM) or d) CTMIO (0.01–
1000 µM). Control wells received 0.1% DMSO or ethanol alone. Cells were exposed 
to these treatments continuously for 2–96 hrs. In addition, CTMIO assays were 
performed where the treatment media was replaced every 24 hrs over a 96 hr period. 
Cell survival following the various treatments was assessed using the WST-1 and/or 
CyQUANT®NF assays. 
3.2.2 Determining Basal Mitochondrial Activity of Prostate Cell Lines 
DU-145, LNCaP, PC-3, RWPE-1 and RWPE-2 cells were each seeded at the 
following densities: 1x104, 5x103, 1x103 and 1x102cells per well, onto 96-well plates. 
Cells were allowed to attach for 4 to 6 hrs, after which the media was removed from 
the plates and 100 µL of a1:10 concentration of WST-1 solution (prepared as per 
Section 2.5) was added to each well. WST-1 was incubated on the cells for 10–120 
min at 37oC, 5% CO2. Plates were allowed to equilibrate to room temperature prior 
to measuring the absorbance, as previously outlined in Section 2.5.  
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3.3 RESULTS 
3.3.1 At High Doses Piperidine Nitroxides Tempo and Tempol are Cytotoxic 
toward Prostate Cell Lines 
It has been reported that Tempo treatment of prostate cancer cells leads to a 
dose-dependent loss of cell viability (Suy et al., 2005). In that study, the LNCaP, 
DU-145 and PC-3 cell lines were employed as representative hormone responsive or 
HRPC models, in which to assess the toxicity of Tempo following exposure to 
increasing concentrations (250–5000 µM) for 24 or 48 hrs. The aim of the current 
study was to reproduce and expand upon these findings so that an effective assay 
could be established for evaluating the impact of the other nitroxides on prostate 
cancer cells. Accordingly, the aforementioned cell lines as well as the RWPE-1 
(normal/non-malignant prostate) and RWPE-2 (malignant prostate) cell lines were 
treated with 250–5000 µM of Tempo over a 96 hr period, as opposed to only 24 or 
48 hrs. Cell survival was assessed using the metabolic WST-1 assay. In our hands, 
Tempo treatment resulted in growth inhibition or cell death in a dose and time-
dependent manner, compared to ethanol treated cells (Figure 3.2). Following short-
term exposure (2 hrs) to Tempo at high doses (2500 and 5000 µM), the survival of 
LNCaP, RWPE-1 and RWPE-2 cells was significantly reduced (Figure 3.2A, 
P<0.01). Over time, cell killing at these concentrations became more pronounced and 
extended to the other cell lines. In comparison, there was no appreciable decrease in 
cell survival at the lower doses of 250 and 500 µM until after 72 and 96 hrs of 
treatment (Figure 3.2 E & F). Even so, this was observed only for LNCaP (250 µM 
P<0.05, 72 hrs; 500 µM P<0.01, 96 hrs) and RWPE-1 cells (500 µM P<0.01, 96 
hrs). Interestingly, these two cell lines were already more sensitive to Tempo 
compared to DU-145, PC-3 and RWPE-2 cells after 48 hrs of treatment (Figure 
3.2D). This pattern of selective toxicity became more apparent at the longer time 
points and correlated to mitochondrial succinate dehydrogenase (SDH) activity, 
which was measured using the WST-1 assay. In this assay, the tetrazolium salt WST-
1 is reduced to the formazan dye by SDH present in viable cells. The three cell lines 
that were more resistant to Tempo had higher levels of SDH activity compared to 
LNCaP and RWPE-1 cells (Figure 3.3A & B), suggesting that the cytotoxic effects 
of this compound are dependent on the rate at which it is metabolised or reduced by 
mitochondrial enzymes. These results indicate that at high doses Tempo is 
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Figure 3.2. Decreases in the survival of prostate cell lines following Tempo treatment 
DU-145, LNCaP, PC-3, RWPE-1 and RWPE-2 cells were treated with ethanol or 250 –5000 µM 
Tempo for A – 2 hrs (#: LNCaP P<0.01, RWPE-1 P<0.01; ##: LNCaP P<0.01, RWPE-1 P<0.01, 
RWPE-2 P<0.01), B – 6 hrs (*: LNCaP P<0.05; **: LNCaP P<0.01, RWPE-1 P<0.05; ***: DU-
145 P<0.05, LNCaP P<0.01, RWPE-1 P<0.01), C– 24 hrs (#: LNCaP P<0.01, PC-3 P<0.01; ##: 
LNCaP P<0.01, PC-3 P<0.01, RWPE-1 P<0.05; ###: all cell lines P<0.01), D – 48 hrs (*: 
LNCaP P<0.01, RWPE-1 P<0.01, RWPE-2 P<0.05; **: all cell lines P<0.01), E – 72 hrs (a: 
LNCaP P<0.05; b: LNCaP P<0.01; c: LNCaP P<0.01, RWPE-1 P<0.01; d: DU-145 P<0.01, 
LNCaP P<0.01, PC-3 P<0.05, RWPE-1 P<0.01; e: DU-145 P<0.01, LNCaP P<0.01, PC-3 
P<0.01, RWPE-2 P<0.05) and F – 96 hrs (a: LNCaP P<0.05; b: LNCaP P<0.01, RWPE-1 
P<0.01; c: DU-145 P<0.05, LNCaP P<0.01, PC-3 P<0.05, RWPE-1 P<0.01, RWPE-2 P<0.01; 
d: all cell lines P<0.01). Cell survival was determined using the metabolic WST-1 assay and 
plotted as a percentage of the ethanol control at each time point, with error bars representing 
SEM. Experiments were performed three to six times, each with four to six replicates. One-Way 
ANOVA and Tukey’s post hoc analysis were used to determine differences between treatment 
groups and the ethanol control.   
cytotoxic against a broad spectrum of prostate cells. Furthermore, the DU-145, 
LNCaP and PC-3 cell survival data from our study coincided with that previously 
reported (Suy et al., 2005). 
Following the discovery that Tempol (4-hydroxyl derivative of Tempo), in 
addition to its antioxidant properties was able to exert cytotoxic effects, this nitroxide 
has been studied extensively in cell lines derived from solid and haematological 
malignancies (e.g. breast, ovary, colon, liver, leukemia and glioma) of human or 
rodent origin (Voest et al., 1992; Hahn et al., 1992a; Gariboldi et al., 1998; Gariboldi 
et al., 2000; Monti et al., 2001; Gariboldi et al., 2003; Mitchell et al., 2003). 
However, there is limited knowledge regarding the potential role of Tempol in 
eliciting cell death in prostate cancer cells. Thus, the selected panel of prostate cell 
lines was treated with 250–5000 µM Tempol for 48 and 96 hrs (Figure 3.4A & B) to 
compare the effects seen with Tempo. Only these two time points were used in this 
experiment, as they coincided with when a marked effect with Tempo was first noted 
and the longest treatment period. By 48 hrs of treatment, Tempol significantly 
induced cell death in DU-145 (P<0.01), LNCaP (P<0.05), PC-3 (P<0.01) andRWPE-
1 (P<0.01) cells at 2500 µM and in all cell lines at 5000 µM (P<0.01) (Figure 3.4A). 
Continuous exposure to the nitroxide for 96 hrs resulted in a potent loss of cell 
viability across all five cell lines at these concentrations (Figure 3.4B; P<0.01). The
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Figure 3.3. Basal mitochondrial Succinate Dehydrogenase (SDH) activity in prostate cell 
lines 
A – Mitochondrial SDH activity in DU-145, LNCaP, PC-3, RWPE-1 and RWPE-2 cells was 
determined based on their ability to metabolise the WST-1 reagent over time (10, 30, 60, 90 and 
120 min). B – SDH activity in prostate cells is directly proportional to cell number. This was 
measured using the WST-1 assay, following incubation with the cells for 120 min. Error bars 
represent SEM of two independent experiments, each performed with seven replicates. 
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Figure 3.4. Decreases in the survival of prostate cell lines following Tempol treatment 
Survival of DU-145, LNCaP, PC-3, RWPE-1 and RWPE-2 cells treated with ethanol or 250 – 
5000 µM Tempol was assessed using the metabolic WST-1 assay at 48 hrs (A) and 96 hrs (B). 
Cell survival is expressed as a percentage of ethanol treated cells, with error bars representing 
SEM. Experiments were repeated five to six times, with four to six replicates per experiment. *: 
PC-3 P<0.01; **: DU-145, PC-3 and RWPE-1 P<0.01, LNCaP P<0.05; ***: all cell lines 
P<0.01; #: PC-3 P<0.01; ##: DU-145 P<0.05, PC-3 P<0.01; ###: DU-145, PC-3 and RWPE-1 
P<0.01; ####: all cell lines P<0.01, compared to ethanol control using One-Way ANOVA and 
Tukey’s post hoc analysis. C – Phase contrast photomicrographs depicting changes in cellular 
morphology with increasing concentration of Tempol, after 48 hrs of treatment. 
effect of Tempol treatment was reflected in an alteration in cell morphology with 
increasing concentration of Tempol. Following treatment at the highest dose (5000 
µM) for 48 hrs, DU-145, RWPE-1 and RWPE-2 cells took on a more rounded shape, 
and were more condensed and fragmented compared to the ethanol treated cells 
(Figure 3.4C). In contrast, LNCaP and PC-3 cells displayed a more swollen 
appearance and a loss of membrane integrity. 
PC-3 cells were the most susceptible cell line to the lower concentrations of 
Tempol (250–1000 µM), with a 12–44% decrease in cell survival occurring after 48 
hrs of treatment and a 22–52% reduction after 96 hrs. However, at both time points, 
at concentrations exceeding 1000 µM, Tempol was better tolerated in PC-3 cells 
compared to RWPE-1 and DU-145 cells. RWPE-2 and LNCaP cells were the most 
resistant to Tempol, with >30% of cells still surviving after 96 hrs of treatment with 
2500 µM Tempol. However, unlike Tempo, the responsiveness of the different cell 
lines to this nitroxide was not dependent on the basal activity of mitochondrial SDH 
(Figure 3.3A). Together, these results demonstrate that Tempol is also capable of 
eliciting cell death in prostate cancer cells. 
3.3.2 CTMIO Displays Limited Toxicity towards Prostate Cell Lines than Other 
Nitroxides 
To investigate the effect of the isoindoline nitroxide CTMIO on the five 
prostate cell lines over a time-course of 96 hrs, a lower and potentially more 
clinically relevant range of concentrations (0.01–1000 µM) to that of the piperidine 
nitroxides was chosen (Figure 3.5A–F). Due to the solubility limits of CTMIO in 
DMSO, 1000 µM was the highest concentration that could be used. Unlike both 
Tempo and Tempol, CTMIO displayed minimal cytotoxicity in all cell lines over the 
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Figure 3.5. Treatment of prostate cell lines with different doses of CTMIO over 96 hrs 
DU-145, LNCaP, PC-3, RWPE-1 and RWPE-2 cells were treated with DMSO or 0.01–1000 µM 
CTMIO for 2, 6, 24, 48, 72 and 96 hrs (A–F). Cell survival was determined using the metabolic 
WST-1 assay and expressed as a percentage of the DMSO control at each time point. Error bars 
represent SEM of two to eight independent experiments, each performed with four to six 
replicates. #: LNCaP P<0.01, PC-3 P<0.05; ##: DU-145 and RWPE-1 P<0.05, PC-3 P<0.01, 
compared to DMSO control using One-Way ANOVA and Tukey’s post hoc test. G – Survival of 
prostate cell lines over 96 hrs, with CTMIO treatment media replacement every 24 hrs. Error bars 
represent SEM of one experiment with four replicates. 
 
range of concentrations used. Indeed, it appeared to have a slight proliferative effect 
at 2–48 hrs (Figure 3.5A–D). At the end of 96 hrs treatment with CTMIO, the 
survival of all five prostate cell lines at the highest dose was ≥75% (Figure 3.5F). In 
these experiments, CTMIO was added to the cells 16 hrs after seeding and was not 
removed for the duration of the treatment period. In order to verify whether the lack 
of cytotoxicity observed for CTMIO treated cells was potentially due to the 
compound having a short half-life, an experiment was performed where the treatment 
media was replaced every 24 hrs over a period of 96 hrs, which corresponded to the 
longest exposure time (Figure 3.5G). The results obtained were comparable to the 
experiments where the treatment media was not replaced, suggesting that the 
minimal cell killing demonstrated by CTMIO over 96 hrs is not due to this 
compound being metabolised or reduced to its corresponding hydroxylamine. This is 
of significance, as hydroxylamines display lower efficacy compared to the nitroxide 
radicals in inducing cell death (Gariboldi et al., 1998). 
The CyQUANT® NF assay was used as an additional measure of cell survival 
following CTMIO and Tempol treatment at 48 and 96 hrs. The advantage of this 
assay over the WST-1 assay is that it is not dependent on cellular metabolic activity, 
which may be affected by drug or chemical treatments, resulting in changes that are 
unrelated to cell number. In comparison, the CyQUANT® NF dye is incorporated 
into the DNA of cells, providing an accurate indication of cell numbers. The CTMIO 
cell survival results from the CyQUANT® NF assay at both 48 and 96 hrs (Figure 
3.6A & B) were comparable with the WST-1 assay (Figure 3.5D & F), confirming 
that CTMIO has minimal cytotoxicity against prostate cells. In contrast, after 48 hrs 
of treatment with 1000–5000 µM Tempol, the degree of cell killing as depicted by 
the CyQUANT® NF assay (Figure 3.6C) was not as pronounced as that shown using 
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the WST-1 assay (Figure 3.4A). This may be due to the fact that although cell 
numbers remained unchanged following Tempol treatment at these concentrations, 
(indicating that cells were still viable), mitochondrial enzyme activity was inhibited, 
therefore limiting metabolism of the WST-1 reagent. Nevertheless, by the end of the 
96 hrs treatment period, the CyQUANT® NF assay results (Figure 3.6D) matched 
that of the WST-1 assay (Figure 3.3B), with 28% to nearly 100% cell death 
occurring for all cell lines from 1000–5000 µM. These findings demonstrate that 
together, the WST-1 and CyQUANT® assays provide an accurate readout of the 
response of cells to nitroxide treatment and further reinforces that CTMIO, in 
contrast to the piperidine nitroxides, has minimal cytotoxicity. 
3.3.3 Nitroxide Ring Structure and 4-Position Functional Group Influences 
Compound Cytotoxicity 
The differential response of the prostate cell lines to the piperidine nitroxides 
but not to CTMIO may be due to the structural differences between these 
compounds. In light of this, the nitroxide C-Tempo, which bears structural similarity 
both to Tempo and CTMIO due to its six-membered ring structure and 4-position 
carboxyl group, was chosen next for cell survival studies to investigate the 
importance of the nitroxide ring structure and the contribution of the 4-position 
functional group or substituent towards compound cytotoxicity. The survival of DU-
145, LNCaP and RWPE-1 cells was determined using the WST-1 assay following 
treatment with C-Tempo for 2–96 hrs, at concentrations similar to those used in the 
Tempo and CTMIO studies. For DU-145 cells, significant cell death was observed at 
the highest concentration of C-Tempo (1000 µM) from 24–96 hrs (24 hrs P<0.05; 48 
hrs P<0.01; 72 hrs P<0.05; 96 hrs P<0.01), with minimal cytotoxicity occurring at 
the lower concentrations compared to the DMSO treated cells (Figure 3.7A). The 
LNCaP cells responded in a similar manner to C-Tempo but with an initial decrease 
in cell survival already detected following 2 hrs of treatment (Figure 3.7B). At 48 
hrs, 1000 µM had no detrimental effect on the survival of RWPE-1 cells (Figure 
3.7C). However, prolonged treatment over 96 hrs with this concentration resulted in 
a 17% decrease in cell viability, which was comparable to that observed for the other 
cell lines. Consistent with this decrease in RWPE-1cell viability, a greater number of 
dead and condensed cells were visible upon 1000 µM treatment compared to the 
lower 250 µM dose and the DMSO control (Figure 3.7F). At this concentration,
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Figure 3.6. DNA-based CyQUANT® assay as a measure of cell survival 
DU-145, LNCaP, PC-3, RWPE-1 and RWPE-2 cells were treated with DMSO or 0.01–1000 µM 
CTMIO for 48 (A) and 96 hrs (B) and ethanol or 250 – 5000 µM Tempol for 48 (C) and 96 hrs 
(D). Graphs depict cell survival assessed using the CyQUANT® assay and plotted as a 
percentage of the control treatment at each time point. Error bars represent SEM of three 
independent experiments performed in quadruplicate. *: DU-145 P<0.05; **: DU-145 P<0.01; 
***: DU-145 and LNCaP P<0.01; ****: DU-145, LNCaP and RWPE-2 P<0.01; #: DU-145 
P<0.05; ##: DU-145 and PC-3 P<0.01; ###: DU-145, PC-3 and RWPE-1 P<0.01; ####: all cell 
lines P<0.01, compared to control using One-Way ANOVA and Tukey’s post hoc test.   
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Figure 3.7. Changes in survival of prostate cell lines in response to C-Tempo treatment 
Cell survival following DMSO or 0.1–1000 µM C-Tempo treatment for 2–96 hrs was assessed in 
DU-145, LNCaP and RWPE-1 cells  using the metabolic WST-1 assay (A–C). Graphs portray 
cell survival as a percentage of DMSO treated cells at each time point, with error bars 
representing SEM. Experiments were repeated two to three times, each with six replicates. #: 24 
hrs P<0.05, 48 hrs P<0.01, 72 hrs P<0.05, 96 hrs P<0.01; *: 6 hrs P<0.05, compared to DMSO 
control using One-Way ANOVA and Tukey’s post hoc analysis. D – Phase contrast images of 
prostate cells exposed to DMSO, 250 µM or 1000 µM C-Tempo for 96 hrs. Scale bars equal 100 
µm.  
RWPE-1 cells also appeared less defined structurally, and were beginning to lose 
their tight cell-to-cell contact. In contrast, there were no obvious changes in DU-145 
and LNCaP cell morphology after 96 hrs of exposure to 1000 µM of C-Tempo 
(Figure 3.7D & E). Nonetheless, the extent of prostate cell killing demonstrated by 
C-Tempo was greater than that for CTMIO, yet less than that seen with Tempo and 
Tempol. These results suggest that the piperidine ring structure of nitroxides confers 
greater cytotoxicity than the isoindoline ring structure. In addition, the type of 
functional group present on the 4-position of this ring structure further enhances or 
reduces nitroxide potency; Tempol which has a hydroxyl group displayed similar 
potency to the parent compound Tempo, whereas the carboxylic acid derivative C-
Tempo was not as cytotoxic. 
3.3.4 CTMIO Treatment Causes Cell Cycle Arrest in Prostate Cells Whereas 
Tempol has Minimal Effect on Cell Cycle Progression 
Although CTMIO displayed minimal cytotoxicity towards prostate cells in short-
term cell survival assays, it has been shown to delay tumour development in vivo, 
suggesting that it may exert a cytostatic rather than cytotoxic effect on cancer cells 
by affecting their progression through the cell cycle (Gueven et al., 2006). To assess 
this, flow cytometry analysis was carried out. Treatment of RWPE-1 cells with 100 
µM CTMIO for 24 hrs caused 18% of cells to accumulate in the G0/G1 phase, and a 
corresponding decline in the S and G2/M phase fractions (Figure 3.8A). Similarly, 
LNCaP cells exposed to increasing concentrations of CTMIO for 24 hrs had a dose-
dependent increase in the G0/G1 population, reaching 80% at 500 µM. However, 100 
µM CTMIO had the reverse effect on PC-3 cells, with a 13% reduction in the G0/G1 
cell population and a proportional increase in the S phase population noted after 24 
hrs. Treatment of LNCaP cells with CTMIO for 48 hrs, in particular with 100 µM,
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Figure 3.8. Cell cycle distributions of prostate cells following CTMIO treatment 
Exponentially growing RWPE-1, LNCaP and PC-3 cells were treated with DMSO or 10, 100 and 
500 µM CTMIO for 24 (A) or 48 hrs (B). Cells were collected, fixed and stained with 2 µg/mL 
propidium iodide for flow cytometric analysis. The percentage of cells in each phase of the cell 
cycle was determined using the Dean-Jett-Fox mathematical model in FlowJo. C – A 
representative cell cycle DNA histogram of LNCaP cells treated with DMSO (G0/G1: 62.74%; S: 
34.32%; G2/M: 1.35%) or 10 µM (G0/G1: 65.91%; S: 31.59%; G2/M: 0.67%), 100 µM (G0/G1: 
74.56%; S: 14.78%; G2/M: 9.36%) and 500 µM (G0/G1: 75.84%; S: 15.21%; G2/M: 5.87%) 
CTMIO for 48 hrs 
depleted the S phase fraction by 20% and caused a concomitant rise in the G0/G1 and 
G2/M population (Figure 3.8B and C). Interestingly, the cells continued to 
accumulate in the G0/G1 phase up to 500 µM CTMIO. CTMIO treatment at this 
concentration for 48 hrs also arrested PC-3 cells in S phase and in turn, blocked the S 
to G2/M transition. 
In comparative studies performed with Tempol, it was observed that 48 to 96 
hrs of treatment with this nitroxide had minimal effect on cell cycle progression, 
regardless of the concentrations used. Initially, prostate cells were treated with 
Tempol concentrations ranging from 10 to 1000 µM, with the high doses used 
coinciding with that reported in the literature (Gariboldi et al., 2000; Gariboldi et al., 
2003; Gariboldi et al., 2006). In replicate experiments however, the maximum dose 
was reduced to 250 µM, to be more clinically relevant. Seemingly, 250 µM Tempol 
treatment of RWPE-1 cells led to a higher percentage of cells in the G0/G1 phase and 
a decreased S phase population after 48 hrs (solid lines, Figure 3.9A). Likewise, it 
appeared that the G0/G1 fraction was depleted and cells were arrested in S phase 
when PC-3 cells were treated with the same concentration of Tempol (dotted lines, 
Figure 3.9C). However, these effects were not consistent across replicate 
experiments and hence, the data was inconclusive. Nevertheless, treatment of DU-
145 cells with 250 µM Tempol for 48 hrs caused cells to accumulate at S and G2/M, 
whilst there was a 16% drop in the G0/G1 fraction (Figure 3.9D). This effect was 
only observed at 250 µM, for with 1000 µM Tempol; the block in the G1/ S 
transition was re-established. The time-dependent increase in the sub-G1 population 
following treatment with 1000 µM Tempol, as reported by Gariboldi and colleagues 
(Gariboldi et al., 2000) in their study with the HL-60 promyelocytic leukemic cell 
line, was not as evident in the prostate cell lines we tested (data not shown).  
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Figure 3.9. Cell cycle distributions of prostate cells after 48 Hrs of Tempol treatment 
Exponentially growing RWPE-1 (A), LNCaP (B), PC-3 (C) and DU-145 (D) cells were exposed 
to ethanol or 10, 250 and 1000 µM Tempol for 48 hrs. Cells were collected, fixed and stained 
with 2 µg/mL propidium iodide for flow cytometric analysis. The percentage of cells in each 
phase of the cell cycle was determined using the Dean-Jett-Fox mathematical model in FlowJo. 
The solid lines on the graphs indicate the n=1 experiment and the broken lines, the n=2 
experiment. E – A representative cell cycle DNA histogram of LNCaP cells treated with ethanol 
(G0/G1: 39.6%; S: 21.57%; G2/M: 23.63%) or 10 µM (G0/G1: 48.78%; S: 15.48%; G2/M: 23.7%) 
and 250 µM (G0/G1: 47.59%; S: 14.39%; G2/M: 23.57%) Tempol for 48 hrs.  
Together, these results indicate that CTMIO but not Tempol, affects the progression 
of prostate cells through the cell cycle.  
3.3.5 CTMIO is Present in the Conditioned Media of PC-3 and LNCaP Cells 
but Cannot be detected Within Whole (Intact) Cells 
As the changes elicited by CTMIO within prostate cells were more subtle 
(cytostatic not cytotoxic), the stability of CTMIO both in conditioned media (spent 
media harvested from cultured cells) and intracellularly over the time course used in 
the cell survival experiments was assessed, by measuring the intensity of the 
nitroxide EPR signal. EPR spectroscopy specifically detects chemical species with 
one or more unpaired electrons, making this technique ideal for use in detecting 
nitroxide in its free radical (active) form. However, once the nitroxide is oxidised or 
reduced, it loses its unpaired electron and can no longer be detected using EPR. 
Hence, the loss of an EPR signal is a good indication of nitroxide degradation or 
metabolism by cells. 
PC-3 and LNCaP prostate cancer cells were cultured in media containing 
various concentrations of CTMIO (10–500 µM) or DCTEIO (10 and 100 µM) for 
24–96 hrs. The nitroxide DCTEIO, a CTMIO derivative (Figure 3.1E) was used as a 
positive control of a stable EPR signal because of its hindered structure, which 
prevents it from being readily reduced by biological molecules (Fairfull-Smith et al., 
2009). Following treatment with these nitroxides, the conditioned media was 
removed from the cells and EPR measurements were undertaken to determine 
nitroxide signal strength. Our results showed that EPR signal intensity directly 
correlated to nitroxide concentration (Figure 3.10A–C). Furthermore, in CTMIO-
containing media, there was a decrease in nitroxide signal intensity over the 96 hrs 
treatment period, whereas the signal intensity of DCTEIO remained relatively 
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unchanged (Figure 3.10A).As can be seen in the initial 24 hrs following incubation 
with 100 µM CTMIO, there was a rapid decay (>50%) in nitroxide signal intensity in 
the conditioned media from PC-3 cells (Figure 3.10B).Subsequently, there was a 
slight but progressive loss in signal intensity, until at the end of 96 hrs only 27% of 
the original signal remained. A corresponding decline in nitroxide signal strength 
from the media controls (media containing CTMIO but which had not been 
incubated with cells) was also observed, suggesting that in the absence of cells, 
CTMIO undergoes spontaneous reduction, possibly via reducing equivalents found 
in the tissue culture media or as a result of changes in oxygen level within the 
incubator. Likewise, with the decrease in CTMIO signal intensity in the conditioned 
media from LNCaP cells, there was a parallel decrease in the media control (Figure 
3.10C). Notably for both cell lines, the rate of CTMIO reduction in the conditioned 
media was greater than in the media controls. For PC-3 cells, this was most evident 
after 24 and 48 hrs of exposure to 500 µM CTMIO (Figure 3.10B). However by 96 
hrs, nitroxide signal intensity in the conditioned media was the same as that in the 
media control. In conditioned media from LNCaP cells, there was initially a 5% 
decrease in the 500 µM CTMIO signal from 24 to 48 hrs, which increased to a 36% 
loss after 96 hrs of treatment (Figure 3.10C). Conversely, in the media control, 83% 
of the original signal still remained at the end of the treatment period. 
These results demonstrate that the CTMIO EPR signal is still detectable in 
conditioned media samples after 96 hrs, indicating that this compound is not 
completely metabolised or reduced by prostate cancer cells but retains its free radical 
activity for the duration of the experiments, and is thus likely to be taken up by the 
cells.  
To evaluate CTMIO stability in the intracellular environment, PC-3 and 
LNCaP cells were treated with 10, 100 and 500 µM CTMIO for 24, 48 and 96 hrs. 
An EPR signal for CTMIO could not be detected within whole cells at these 
concentrations or time points (data not shown). Neither was there a radical signal in 
PC-3 cells treated at the highest dose of 1000 µM for 96 hrs. Since this could have 
resulted from the rapid decay of the CTMIO signal intracellularly, becoming 
undetectable after 24 hrs, as has been reported with Tempol in the past (Gariboldi et 
al., 1998), the EPR signal in 100 µM CTMIO treated PC-3 cells was measured after 
1 hr incubation. However, no signal could be detected. Experiments with PC-3 
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Figure 3.10. Signal intensity of DCTEIO or CTMIO in the conditioned media ofPC-3 and 
LNCaP cells 
A – PC-3 cells were treated with 10 and 100 µM DCTEIO or CTMIO for 24 and 96 hrs. 
Nitroxide signal strength in the conditioned media was measured using EPR. CTMIO signal 
strength in the conditioned media (broken lines) of PC-3 (B) and LNCaP cells (C) treated with 
10, 100 and 500 µM CTMIO over a time course of 96 hrs, in comparison to CTMIO signal 
strength in the media controls (solid lines) incubated under the same conditions. Data represents 
one of four to five independent experiments. EPR signal intensity is given in arbitrary units. 
 Chapter 3: Comparison of the Pro-oxidant Property of the Piperidine and Isoindoline Family of Nitroxides in 
Prostate Cancer Cells 63 
and LNCaP cells treated with 100 µM CTMIO for 2, 24 and 96 hrs were also 
performed in tissue culture flasks (25 and 75 cm2) rather than 6-well plates, in order 
to verify that the lack of CTMIO signal in treated cells was not due to low cell 
number. Again, no signal was observed (data not shown). 
3.3.6 The CTMIO Signal Could Not be Re-oxidised in Lysed Cells or in the 
Conditioned Media 
The absence of a CTMIO EPR signal in intact cells may have been due to a 
large portion of the compound being retained in the plasma membrane or localized 
within intracellular compartments. To test this hypothesis, following treatment with 
500 µM CTMIO for 24 hrs, as these conditions corresponded to the greatest CTMIO 
signal intensity observed in previous experiments, PC-3 cells were separated from 
the conditioned media and lysed. No EPR signal could be detected in these cells 
(data not shown). Hence, they were incubated with increasing concentrations of 
K3Fe(CN)6 (10–2000 µM) in order to re-oxidise the CTMIO signal. Since this did not 
recover the nitroxide signal, H2O2(50 µM), a stronger oxidizing agent was used. 
Again, no EPR signal was readily detectable under these conditions (data not 
shown). Likewise, attempts to recover the signal intensity in conditioned media 
obtained from PC-3 cells treated with 500 µM CTMIO for 24 hrs to that of the media 
control, with 10 µM K3Fe(CN)6  or 50 µM H2O2,was unsuccessful (Figure 3.11A). 
Furthermore, the addition of  K3Fe(CN)6 in concentrations exceeding 2 mM to 
conditioned media from LNCaP cells treated with 100 µM CTMIO for 48 hrs prior, 
did not reverse the 33% decay in CTMIO signal strength (Figure 3.11B). 
3.3.7 CTMIO is Not Metabolised by Secreted Factors in the Conditioned Media 
To determine whether any factors secreted by prostate cells were responsible 
for the reduction in CTMIO signal intensity observed in the conditioned media, 
culture media in which PC-3 and LNCaP cells were grown for 48 hrs, were removed 
from the cells and incubated with 100 µM CTMIO for 2–96 hrs prior to EPR 
measurements. The signal intensity of CTMIO treated PC-3 culture media remained 
relatively stable over 96 hrs. In contrast, there was a 16% decrease in the CTMIO 
EPR signal from the LNCaP culture media after 2 hrs (Figure 3.12). But by 48 hrs, 
the EPR signal had recovered to its original intensity. The loss in CTMIO signal 
strength from 2–48 hrs is likely the result of a technical issue when running the 
samples through the EPR spectrometer rather than a true phenomenon, otherwise, 
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there would have been a greater decay in the CTMIO signal from the LNCaP 
conditioned media sample compared to the media control at 24 hrs than that 
previously noted (Figure 3.10C).  Hence, it can be concluded that the changes in 
CTMIO signal intensity observed in the earlier conditioned media experiments 
(Figure 3.10) is not due to the compound being degraded or metabolised by factors 
secreted by the cells, but rather through cellular uptake of the compound from the 
media.
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Figure 3.11.  Re-oxidising the CTMIO signal in PC-3 and LNCaP conditioned media 
A – The conditioned media from PC-3 cells treated with 500 µM CTMIO for 24 hrs was 
incubated with 50 µM hydrogen peroxide (H2O2) or 10 µM potassium ferricyanide (K3Fe(CN)6).  
CTMIO signal strength in the conditioned media and in the media control, which is depicted on 
the graph as CTMIO CM (500 µM) negative and with no oxidizing agents, was measured using 
EPR. B – EPR signal intensity in CTMIO-treated LNCaP conditioned media incubated with 
increasing concentrations of K3Fe(CN)6 (2, 5 and 10 mM) compared to the CTMIO media 
control, which is shown on the graph as CTMIO CM (100 µM) negative and K3Fe(CN)6  
negative. LNCaP cells were treated for 48 hrs with 100 µM CTMIO prior to removing the 
conditioned media for incubation with K3Fe(CN)6. Both the LNCaP and PC-3 experiments were 
performed once. EPR signal intensity is given in arbitrary units.  
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Figure 3.12. Incubation of culture media containing secreted cellular factors with CTMIO 
PC-3 and LNCaP cells were allowed to grow for 3 days in RPMI media containing 10% FCS to 
near confluence. The media was then removed from the cells and incubated with 100 µM 
CTMIO at 37 oC for 2, 24, 48 and 96 hrs before measuring CTMIO signal intensity (arbitrary 
units) using EPR. 
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3.4 DISCUSSION 
Prostate cancer in its early stages is curable but for advanced metastatic 
disease, there still remain only palliative therapies, or therapies that reap merely 
short-term survival benefits. Nitroxides have been used extensively in various 
biological systems including cancer models, with positive outcomes, yet little is 
known regarding their effects in prostate cancer. This study extends previous 
research by examining the effect of two structurally different groups of nitroxides, 
the piperidines and isoindolines, across a broad spectrum of prostate cell lines. 
Cell survival of both normal (RWPE-1) and malignant prostate cells (RWPE-2, 
LNCaP, PC-3 and DU-145) was examined using the WST-1 metabolic assay 
following treatment with the piperidine nitroxide Tempo. A decrease in the survival 
of all five cell lines occurred in a dose-dependent manner over 96 hrs. In particular, 
the loss in viability of LNCaP and PC-3 cells at 24 hrs and DU-145 cells at 48 hrs 
coincided with that reported by Suy and colleagues (Suy et al., 2005). The shortfall 
in their study was that survival for these cells was assessed only at these time points. 
In contrast, our study assessed survival for all prostate cells over a period of 96 hrs, 
enabling comparison of the effects of Tempo between each cell line at any one time 
point. 
Given that the WST-1 assay is based on the cleavage of the tetrazolium salt 
WST-1 to formazan by the mitochondrial enzyme SDH, it was interesting to note 
that castrate-resistant or tumourigenic cells (DU-145, PC-3 and RWPE-2), with a 
higher basal activity of this enzyme, were more resistant to Tempo after 48–96 hrs of 
treatment, compared to an androgen dependent cell line (LNCaP) and androgen 
responsive line (RWPE-1) with lower SDH activity. In addition to being a functional 
member (Complex II) of the mitochondrial electron transport chain (ETC), SDH 
plays an important role in the tricarboxylic acid cycle in catalysing the conversion of 
succinate to fumarate, which in turn is converted to malate by FH (Ackrell, 2000; 
King et al., 2006). Germline mutations in nuclear genes that encode these enzymes 
cause predispositions to certain neoplastic syndromes (Gimenez-Roqueplo et al., 
2001; Baysal, 2002; Gimenez-Roqueplo et al., 2002; Tomlinson et al., 2002; Baysal 
et al., 2004; Neumann et al., 2004; Vanharanta et al., 2004; Gottlieb & Tomlinson, 
2005; Schiavi et al., 2005; Benn et al., 2006), or severe neurological dysfunctions 
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(Leigh, 1951; Bourgeron et al., 1994; Parfait et al., 2000). In these tumours lacking 
SDH or FH, high HIF activity was manifested under normoxic conditions (Gimenez-
Roqueplo et al., 2001; Dahia et al., 2005; Maxwell, 2005; Pollard et al., 2005) due to 
an impairment to the HIFα degradation pathway (Isaacs et al., 2005; Selak et al., 
2005). Indeed, stable and functional HIF-1α protein expression and DNA binding 
activity was detected in normoxic PC-3 cells and further enhanced under hypoxic 
conditions (Zhong et al., 1998). At the mRNA level, HIF-1α was constitutively 
expressed in human and rat prostate cell lines but not in the normal prostate, with 
higher levels in those cells exhibiting faster growth and high metastatic potential. Yet 
the lowest HIF-1α gene expression or protein levels were observed in the androgen-
dependent cell lines, G and LNCaP, respectively (Zhong et al., 1998). Together these 
data suggest that HIF-1α may be important in the prostate cancer neoplastic 
phenotype, and may be up-regulated in the process of cell transformation and disease 
progression. The correlation between SDH deficiency and high HIF-1α activity 
under normoxic conditions, in particular in PC-3 cells, is in opposition to our study 
where the more aggressive, HRPC cells, including PC-3, displayed high basal SDH 
activity. Although it is known that the majority of tumours arising from SDHB or 
SDHD mutations have very weak to non-detectable enzymatic activity(Gimenez-
Roqueplo et al., 2001; Gimenez-Roqueplo et al., 2002; Douwes Dekker et al., 2003), 
and likewise, in Leigh syndrome, a neurodegenerative disorder with mutations in 
SDHA(Bourgeron et al., 1994; Ackrell, 2000; Parfait et al., 2000), the difference 
between  our study and previous reports may be reconciled by the fact that not all 
mutations in the nuclear gene, which encodes the four subunits of SDH, lead to a 
complete loss of enzyme activity. 
The relationship between inherent enzyme activity and sensitivity to nitroxide 
treatment has also been observed in tumour and non-tumour cell lines derived from 
rat liver. The high levels of detoxifying enzymes present in these cell lines rendered 
them less responsive to Tempol (4-hydroxyl analogue of Tempo) cytotoxicity, 
compared to cell lines derived from other organs(Gariboldi et al., 1998). 
Interestingly, a study by Suy and colleagues published around the same time, 
reported that Tempol, unlike Tempo, was non-cytotoxic in MDA-MB 231 breast 
cancer cells (Suy et al., 1998). In other studies where Atm mutant mice (Schubert et 
al., 2004) or cancer-prone p53-deficient mice (Erker et al., 2005) were treated with 
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Tempol, there was an increase in latency to tumourigenesis, resulting in extended life 
span of the mice. By delaying the onset of epithelial tumours, Tempol also increased 
tumour-free survival time in Faconi Anemia mice (Zhang et al., 2008). Furthermore, 
long-term administration of Tempol in the diet of C3H mice, prevented these animals 
from becoming obese and decreased age-related spontaneous tumour incidence 
(Mitchell et al., 2003). Many others have also reported on the role of Tempol and 
other nitroxides in protecting against diverse oxidative damage induced at the 
cellular, isolated organ and systemic level, for example by reperfusion injury (Gelvan 
et al., 1991; Samuni et al., 1991b),  mechanical trauma to the brain (Beit-Yannai et 
al., 1996), chemically induced gastric mucosal damage (Rachmilewitz et al., 1994), 
experimental colitis (Karmeli et al., 1995), radiation (Mitchell et al., 1991; Degraff et 
al., 1992; Hahn et al., 1992a; Xavier et al., 2002; Cotrim et al., 2007) and quinone-
based chemotherapeutic drugs (Krishna et al., 1991; DeGraff et al., 1994; Monti et 
al., 1996).  
However, in our hands, Tempol was found to elicit cell death in both androgen 
responsive and hormone-refractory prostate cancer cells, with PC-3 cells being the 
most sensitive, even at sub-millimolar concentrations. The dose-dependent decrease 
in cell viability was evident after 48 hrs of treatment with Tempol and correlated to 
changes in cell morphology. In DU-145, RWPE-1 and RWPE-2 cells, the 
morphology observed pointed to an apoptotic mode of cell death, whereas the 
swelling and loss of membrane integrity in LNCaP and PC-3 cells at high 
concentration, was likely to be due to necrosis taking place. However, in these cells, 
it cannot be ruled out that the mechanism of cell death was potentially late-stage in 
vitro apoptosis (secondary necrosis). Our results are in line with previous findings, 
where it has been demonstrated that at least 24 hrs of treatment was necessary for 
Tempol to induce irreversible cell damage (Gariboldi et al., 1998). It is plausible that 
apoptosis is the mechanism of cell death occurring, as Tempol triggered a rapid and 
dramatic apoptotic response in C6 glioma cells, which was accompanied by a 
concentration-dependent increase in p21WAF1/CIP1 levels (Gariboldi et al., 2003). In 
HL-60 cells, the induction of apoptosis by Tempol involved depletion of glutathione 
pools, a decrease in mitochondrial membrane potential, inhibition of Complex I, and 
to a lesser extent Complex II and IV of the ETC and consequently, oxidative 
phosphorylation (Monti et al., 2001).  
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The ability of Tempol to specifically target enzymes of the mitochondrial ETC 
and modulate their activity may explain why the responsiveness of the different 
prostate cells to Tempol did not correlate with basal levels of Complex II (SDH) 
activity. Moreover, since Tempol is water soluble and therefore evenly distributed 
throughout the cell, it may potentially affect other cellular components in addition to 
the mitochondria. On the other hand, Tempo has a greater tendency to accumulate in 
the cell membrane due to its lipophilic nature (Kocherginsky et al., 1995).  
In the panel of prostate cells tested, Tempol did not display selectivity in cell 
killing, unlike that previously described for cell lines derived from breast, ovary, 
colon and liver of human or rodent origin, where Tempol was more effective in 
inhibiting the growth of neoplastic versus non-neoplastic cells of a similar lineage 
(Gariboldi et al., 1998).  However, in comparison to Tempo, Tempol was less 
cytotoxic towards the normal prostate cell line RWPE-1. 
Notably, this is the first time that such an extensive cell survival study 
involving Tempol has been undertaken in prostate cells. Our results demonstrate the 
cell killing role of Tempol in prostate cancer cells, suggesting that this nitroxide may 
be useful in cancer therapy, particularly if apoptosis is the pathway through which 
cell death is occurring. While Schubert and colleagues postulated that the 
chemopreventative effect of Tempol in Atm-deficient mice was mediated through a 
reduction in cell proliferation, they did not investigate further whether this was in 
fact a decrease in cell viability (Schubert et al., 2004). Nonetheless, evidence exists 
that Tempol inhibits tumour growth in nude mice through the induction of apoptosis 
(Gariboldi et al., 2003).  
The ability of nitroxides to exert either cytoprotective or cytotoxic effects 
depends on the specific microenvironment, and the treatment dose and exposure time 
employed (Voest et al., 1992; Gariboldi et al., 1998). In MCF-7/WT cells, a 2 h 
exposure to Tempol at concentrations up to 10 mM did not induce irreversible cell 
damage (Gariboldi et al., 1998). Neither were stress-activated protein kinase 
pathways stimulated at this concentration (10 mM) but rather activation in ERK1 
signalling, indicative of growth and survival, was observed (Suy et al., 1998). 
Furthermore, studies have shown that at least 5–10 mM Tempol is required to 
provide in vitro radioprotection and that the most significant enhancement to cell 
survival was achieved with a 100 mM dose, although treatment with Tempol was for 
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a shorter time interval (min) (Mitchell et al., 1991; Degraff et al., 1992; Hahn et al., 
1992a). As mentioned earlier, long-term administration of Tempol via the diet had a 
chemopreventative effect on cancer-prone mice (Mitchell et al., 2003; Schubert et al., 
2004; Erker et al., 2005; Zhang et al., 2008). In these studies, Tempol was mixed 
with the mouse food at a concentration equivalent to 58 mM (10 mg/g of food). The 
requirement for high concentrations of Tempol in an in vivo setting is likely due to 
the rapid reduction of the nitroxide to its hydroxylamine intracellularly both 
enzymatically (Keana et al., 1987; Chen & Morse, 1988a; Iannone et al., 1990b) and 
non-enzymatically (Swartz & Timmins, 2000; Kuppusamy et al., 2002; Saphier et 
al., 2003; Bobko et al., 2007). 
Yet an opposing effect with nitroxides has been observed in other experimental 
models, where cells were incubated with Tempo or Tempol at lower concentrations 
for extended periods (Gariboldi et al., 2000; Monti et al., 2001; Gariboldi et al., 
2003; Suy et al., 2005). In keeping with the results from these studies, we 
demonstrated that in prostate cells, there was an increased loss in cell viability 
following prolonged treatment (24 h or greater) with 250–5000 µM Tempo or 
Tempol. This pro-oxidative or cytotoxic effect of nitroxides can be attributed to the 
hypothesis that when present in excess, nitroxides are converted by superoxide to 
highly oxidizing oxoammonium cations that readily attack cellular components 
essential to various biological processes, rather than being reduced back to nitroxides 
in subsequent reactions with superoxide radicals (Offer et al., 2000). Alternatively, 
nitroxides may cause damage to biomolecules indirectly, through the production of 
ROS (Gariboldi et al., 1998; Monti et al., 2001).  
The cytotoxic effects of nitroxides in tumour cells may also be potentiated by 
the presence or structure of substituent(s) at position 4 of the piperidine nitroxide 
ring (Metodiewa et al., 1999a; Koceva-Chyla et al., 2000; Metodiewa et al., 2000a; 
Wu et al., 2006). We found that C-Tempo, which possesses a carboxyl group at this 
position, exhibited markedly reduced cytotoxicity in prostate cells compared to the 
parent compound Tempo. In contrast, the (4-position) hydroxyl group substituted 
derivative Tempol, displayed a similar level of potency to Tempo. The underlying 
theory that substituent structure influences nitroxide potency extends to other forms 
of nitroxides with substituents introduced at a different position of the nitroxide 
radical. For example, in a study comparing 3-substituted pyrrolidine-N-oxyls 
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(proxyls) instead of 4-substituted piperidine nitroxides, the authors demonstrated 
varying degrees of in vivo radioprotection and distribution to bone marrow by the 
compounds, due to the type of substituents (hydroxymethyl, carbamoyl or 
methoxycarbonyl) present at the 3-position of the proxyl ring (Anzai et al., 2006). 
Furthermore, the size of the nitroxide ring may also influence nitroxide activity. In 
our study, we showed that C-Tempo (six-membered ring) exerted a greater degree of 
cell killing than the isoindoline nitroxide CTMIO (aromatic ring fused with a five-
membered ring), despite both nitroxides possessing a carboxy functional group, 
albeit at different positions of the nitroxide ring, suggesting that the piperidine ring 
structure confers greater cytotoxicity than the isoindoline ring structure.  
The lack of CTMIO toxicity towards prostate cells in some respects is not 
surprising, as CTMIO has been shown to have a protective effect in A-T, a disease 
which predisposes to lymphoid tumours, including prolonging the survival of Atm-
deficient mice by delaying tumour formation (Gueven et al., 2006) and enhancing the 
survival of A-T cells post-irradiation  (Hosokawa et al., 2004). CTMIO has also been 
demonstrated to promote the branching and elongation of neuronal cells obtained 
from Atm-deficient mice, in vitro(Chen et al., 2003). This proliferative effect, 
although not as extensive, was reproduced in prostate cells treated with CTMIO for 
2–48 h. In all these studies where CTMIO had a significant impact, the doses used 
were within the concentration range employed in our study. While it can be 
speculated that higher concentrations of CTMIO may induce greater cell killing, the 
solubility limits of this compound at 1 M as opposed to ≥5 M for the piperidine 
nitroxides, and the need to keep solvent concentration to a minimum (0.1%), 
prevented this from being tested. Furthermore, even though higher concentration of 
the piperidine nitroxides were used in cell survival studies, a gradual decline in cell 
survival was already noticeable from 6 hrs at the lower concentrations (250–1000 
µM), which was not as evident with CTMIO, suggesting that higher doses of this 
nitroxide may likewise be ineffective.  
Treatment of prostate cells with CTMIO for 24 and 48 hrs resulted in a dose-
dependent accumulation of cells in the G0/G1 phase of the cell cycle and a 
corresponding decrease in the other fractions. Since the first DNA damage 
checkpoint is located at the end of the G1 phase of the cell cycle, just before entry 
into S phase and is responsible for deciding whether the cells should divide, delay 
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division or enter a resting phase, our results suggest that CTMIO induced a damage 
assessment mechanism within the cells. Nonetheless, this damage must have been 
recognized as repairable by the cells, as their progression through the cell cycle was 
only temporarily slowed, probably in an attempt to repair the damage and cell death 
was not triggered. This is supported by the finding that there was no marked increase 
in the percentage of sub-G1 cells (data not shown) and there was no adverse effect on 
cell viability following treatment with CTMIO.  
While the cell cycle data we obtained for Tempol treated prostate cells was 
inconclusive, other investigators have reported a concentration-dependent arrest in 
the G1 phase and a parallel decrease in the G2/M cell population at 24 hrs with MCF-
7 (Gariboldi et al., 1998) and HL-60 cells (Gariboldi et al., 2000). However, with 
longer exposure times (96 hrs), the percentage of MCF-7 cells in the G1 phase was 
depleted. The different experimental systems used may account for the differences in 
findings. 
The lack of effect observed with CTMIO in prostate cells raises the question of 
whether this nitroxide was capable of entering the cells. Yet evidence that CTMIO is 
taken up by the cells is seen in our EPR studies, where there was a greater loss in 
CTMIO signal intensity in the conditioned media samples compared to the media 
controls. Although the signal could not be detected intracellularly this could be due 
to several limitations in the experimental design, some of which were beyond our 
control, such as signal loss during the washing steps of sample preparation; samples 
not being equilibrated under oxygen-free argon in order to remove any traces of 
oxygen, consequently, further redox reactions could have taken place after the 
experimental end-point; samples not usually frozen at collection; the time between 
sample collection and EPR signal measurement, as the EPR instrument was located 
off-site; and the time required to measure nitroxide signal in each sample. The time 
delay between sample collection and measurement of nitroxide signal was further 
impacted by the concentration and time course nature of the experiments which 
resulted in multiple samples. All these factors may have compromised the quality or 
intensity of the nitroxide signal present in the cell samples.  
In addition, it is known that nitroxides have a short half-life intracellularly due 
to rapid bioreduction (Gariboldi et al., 1998; Swartz & Timmins, 2000), contributing 
to the difficulty in detecting the CTMIO EPR signal within cells. A time course 
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assessment of Tempol signal decay in MCF-7/WT cells revealed that the intracellular 
nitroxide concentration fell away rapidly within a few hours of Tempol removal from 
the medium and was no longer measurable after 24 hrs (Gariboldi et al., 1998). This 
is further highlighted in studies showing that nitroxides afforded maximum 
radioprotection in vivo when administered 5–10 min but not 24 hrs before irradiation, 
coinciding with when nitroxide concentration in blood peaks, post administration 
(Hahn et al., 1992a; Anzai et al., 2006). 
Despite the rapid reduction of nitroxides intracellularly to their hydroxylamines 
or metabolism to non-paramagnetic products, under an oxidative atmosphere, 
hydroxylamines can be oxidised back to nitroxides (Chen & Swartz, 1988b; 
Quaresima et al., 1993; Matsumoto et al., 2004). Thus, nitroxides can exist either in 
the radical form or as hydroxylamines intracellularly, depending on the oxygen status 
of the microenvironment and the reducing equivalents present. This is supported by 
studies demonstrating that under reducing conditions, such as in hypoxic tumours, 
reoxidation of the hydroxylamine to the nitroxide is less efficient, resulting in 
increased nitroxide decay rates (Berliner & Wan, 1989; Ishida et al., 1989; Minetti & 
Scorza, 1991; Ilangovan et al., 2002; Kuppusamy et al., 2002). Nonetheless, 
hydroxylamines themselves are also antioxidants but do not protect or are less 
effective in protecting against ionizing radiation (Mitchell et al., 1991; Hahn et al., 
1992a; Krishna et al., 1998; Mitchell et al., 2000; Xavier et al., 2002). 
Furthermore, the possibility that factors secreted by the cells degraded CTMIO 
prior to its entry into the cells is ruled out by our results showing that the signal 
intensity of CTMIO in PC-3 and LNCaP culture media is maintained over a 96 h 
period. Hence, from the EPR data, it can be concluded that CTMIO did get into the 
cells. The lipophilic nature of CTMIO, as indicated by its octanol-water partition 
coefficient (log Kow = 0.69) provides further evidence that CTMIO is able to cross 
the cell membrane (Bottle et al., 1999). However, it is plausible that CTMIO is only 
transiently present within the cells or freely diffuses in and out of the cells, but is not 
retained.  
The cell survival results presented in our study indicate that a strong 
relationship exists between nitroxide structure and the observed differences in 
nitroxide potency, coinciding with the literature (Krishna et al., 1998). Taking into 
account that nitroxides are able to function also in an antioxidant capacity, further 
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experiments were undertaken, as detailed in subsequent chapters, to delineate the role 
of CTMIO in protecting against oxidative stress. 
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Chapter 4: Finding Models of Stress or 
Oxidative Stress 
4.1 INTRODUCTION 
In the previous chapter, we noted that CTMIO displayed minimal toxicity 
towards prostate cancer cells. However, given the dual nature of nitroxide 
compounds, the role of CTMIO as an antioxidant warranted further investigation. 
Therefore, the aim of the present work was to identify a suitable model of stress or 
oxidative stress that could be used to assess the antioxidant capacity of CTMIO in 
prostate cancer cells. 
Cancer cells compared to normal cells are under intrinsic oxidative stress, 
producing high levels of ROS due to the presence of constant oncogenic signals 
(Benhar et al., 2001; Vafa et al., 2002; Behrend et al., 2003; Hlavatá et al., 2003), 
alterations in metabolic activity and dysfunction of the mitochondrial respiratory 
chain (Carew & Huang, 2002; Copeland et al., 2002; Carew et al., 2003). To cope 
with such sustained oxidative stress, it is reasonable to speculate that cancer cells 
would be highly dependent on antioxidant enzymes and other adaptive antioxidant 
defences. Accordingly, exposing these cells to antioxidant inhibitors or further 
oxidative insults such as ROS-generating agents may push the ROS level beyond a 
‘threshold’ and exhaust the cellular antioxidant capacity, leading to irreversible 
damage and apoptosis (Kong & Lillehei, 1998; Kong et al., 2000; Gorrini et al., 
2013).  
Chemotherapy drugs that increase free radical formation (Cone et al., 1976; 
Bachur et al., 1978; Doroshow, 1986) are thought to rely, in part, on using this stress 
mechanism to kill cancer cells. However, increased oxidative stress has also been 
linked to the severe and often debilitating side effects of chemotherapy (Conklin, 
2000). One approach to addressing this problem could be to combine antioxidants 
with chemotherapy treatment. This raises an important and controversial question 
because it has long been a concern that antioxidants, which can decrease oxidative 
stress, may also decrease chemotherapy effectiveness or increase resistance to 
chemotherapy, particularly if the chemotherapy drugs work by strongly promoting 
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oxidation (Lamson & Brignall, 1999; Prasad et al., 1999; Seifried et al., 2003; 
Combinations, 2007; Simone et al., 2007; D'Andrea, 2008; Lawenda et al., 2008; 
Ladas & Kelly, 2010). While some antioxidants are clearly not beneficial for use 
during chemotherapy (Omenn et al., 1996b; Bracke et al., 1999; Miyajima et al., 
1999; Conklin, 2004; Sieja & Talerczyk, 2004), there is overwhelming evidence that 
many other antioxidants can reduce the severity of side effects without interfering 
with the drug’s antineoplastic activity (Conklin, 2000; Quiles et al., 2002; Drisko et 
al., 2003; Pace et al., 2003; Weijl et al., 2004). Certain antioxidants may even help 
improve the overall effectiveness of chemotherapy treatment (Hofmann et al., 1988; 
Yoshinori et al., 1990; Matsukawa et al., 1993; Scambia et al., 1994; Perumal et al., 
2005). Thus, it is important to recognise that the interaction between antioxidants and 
chemotherapy is more complex than simply promoting or inhibiting oxidative stress. 
Careful consideration needs to be given to which antioxidants should be used and at 
what dosages. Alternatively, a common practice to improve treatment efficacy and 
reduce chemotherapy related side effects is combination therapy utilising multiple 
drugs. The promising clinical activity of docetaxel (DTX) against advanced HRPC 
(Picus & Schultz, 1999; Beer et al., 2001; Berry et al., 2001) has prompted 
considerable interest in combining this drug with other antitumour agents (Savarese 
et al., 2001; Beer et al., 2003; Petrylak et al., 2004; Tannock et al., 2004; Karabulut 
et al., 2009). Yet several problems are encountered during DTX treatment, including 
serious side effects in most of the patients (Schrijvers et al., 1993; Cortes & Pazdur, 
1995)and the emergence of drug-resistant cancer cells (Geney et al., 2002). 
Combination treatments are also associated with a certain degree of dose-related 
toxicity (Petrylak et al., 2004; Tannock et al., 2004). For this reason, novel 
therapeutic strategies need to be developed that can enhance tumour response to 
DTX-based treatments without toxicity.  
Pathways associated with cancer cell energy metabolism deviate significantly 
from those of normal tissues. Cancer cells are metabolically active and exhibit an 
increased dependency on glycolysis to meet their ATP need (Warburg effect), 
perhaps reflecting a compromised and inadequate ATP generation in the 
mitochondria due to multiple intrinsic and/ or extrinsic factors (Warburg et al., 1924; 
Warburg, 1956; Carew & Huang, 2002; Chen et al., 2007b). In particular, 
malfunction of the mitochondrial respiratory chain arising from mutations in the 
 Chapter 4: Finding Models of Stress or Oxidative Stress 79 
 
mitochondrial DNA may increase electron leakage, leading to more free radicals 
being produced (Carew et al., 2003). Given that glucose metabolism gives rise to 
pyruvate and NADPH, which are integrally involved with the detoxification of 
intracellular hydroperoxides (Tuttle et al., 1992; Averill-Bates & Przybytkowski, 
1994; Nath et al., 1995), cancer cells may increase the metabolism of glucose to 
compensate for increased hydroperoxide production caused by defects in respiration. 
Thus inhibiting glucose metabolism is an attractive therapeutic strategy to 
preferentially kill cancer cells.   
Indeed it has been found that depriving human cancer cells of glucose in 
culture compromises their ability to detoxify hydroperoxides, resulting in steady-
state increases in mitochondrial superoxide and H2O2 that contribute to cytotoxicity 
and oxidative stress (Lee et al., 1998; Blackburn et al., 1999; Lee et al., 2000b; 
Ahmad et al., 2005). Furthermore, these effects were more pronounced in 
transformed cells compared to normal cells (Blackburn et al., 1999; Spitz et al., 
2000). Likewise, treatment with the glucose analogue 2-deoxy-D-glucose (2DG) has 
been suggested to be selectively cytotoxic to fully transformed cells (Lin et al., 
2003), via a mechanism that involves hydroperoxide-mediated oxidative stress 
(Andringa et al., 2006). 2DG is believed to mimic the effects of glucose deprivation 
(Laszlo et al., 1960; Shenoy & Singh, 1985) by competitively inhibiting glucose 
metabolism (Landau & Lubs, 1958). As a result, it has been used to create a drug-
induced state of glucose deprivation both in vitro and in vivo, where it is not possible 
to completely deprive cells of glucose. In the presence of the thiol antioxidant, N-
acetylcysteine (NAC), glucose deprivation-induced cytotoxicity, prooxidant 
production, as well as disruptions in thiol metabolism were suppressed (Lee et al., 
1998; Blackburn et al., 1999; Lin et al., 2003; Simons et al., 2007), supporting the 
hypothesis that metabolic oxidative stress is causally related to the effects of glucose 
deprivation in transformed cells. 
Oxidative damage caused by free radicals is responsible for many human 
diseases (Baynes & Thorpe, 1999; Griendling & FitzGerald, 2003; Klaunig & 
Kamendulis, 2004; Halliwell, 2005; Madamanchi et al., 2005; Lin & Beal, 2006). To 
better understand the oxidative stress mechanisms underlying the disease process, 
hydrogen peroxide (H2O2) is often used as an experimental source of oxygen-derived 
free radicals. Depending on the specific dosage and treatment time frame, H2O2 can 
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trigger a myriad of events ranging from an increase in intracellular ROS and nitric 
oxide production, induction of cell signalling, changes in membrane integrity, 
damage to DNA, proteins and lipids, to a loss in cell viability (Horakova et al., 2003; 
Grant et al., 2005; Maher & Hanneken, 2005; Wijeratne et al., 2005; Kim et al., 
2006; Chen et al., 2007a; Ezoulin et al., 2008; Choi et al., 2010; Choi et al., 2011; Xu 
et al., 2011). Nonetheless, simultaneous treatment with antioxidants or compounds 
with antioxidant properties have been shown to attenuate these effects.   
Therefore, in this chapter the models of stress or oxidative stress that will be 
used to assess the antioxidant capacity of CTMIO in prostate cancer cells are 
treatment with 1) DTX, 2) 2DG and 3) H2O2. 
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4.2 MATERIALS AND METHODS 
The experimental procedures used in this chapter are described in full in 
Sections 2.8–2.8.3 of Chapter 2. The following provides the details of the treatment 
conditions and concentrations of the various compounds used in the cell survival 
assays. 
4.2.1 DTX and Nitroxide Treatments 
Cell survival assays were carried out according to standard procedures (Section 
2.5) in an Isoclean Negative Pressure Pharmaceutical Isolator (ESCO, Camfil Farr, 
Richlands, QLD, Australia). In dose and time-response optimization studies, PC-3, 
LNCaP and DU-145 cells were seeded at a density of 3x103, 3.5x103 and 2x103 cells 
per well respectively, onto clear 96-well plates, a day before treatment. Cells were 
cultured in media containing 0.01–100 nM DTX for 24, 48 and 72 hrs. In subsequent 
experiments, PC-3 cells were seeded at a density of 5x103 cells per well, onto clear 
96-well plates or black 96-well ViewPlates. PC-3 cells were allowed to attach 
overnight prior to 48 hr treatment with a) a single dose of CTMIO or Tempol (100 
µM) plus various concentrations of DTX (0.01, 0.05 and 0.5 nM) or b) increasing 
concentrations of CTMIO (50, 100 and 200 µM) in combination with a fixed DTX 
dose (0.5 nM). For the controls in each experiment, cells were treated with 0.1% 
DMSO, DTX or nitroxide alone. Treatments were prepared in phenol red-free RPMI 
1640 media containing 10% FCS. Cell survival following treatment was determined 
using both the WST-1 and CyQUANT® assays. 
4.2.2 2DG, CTMIO and NAC Treatments 
Cell survival assays were performed as previously described (Section 2.5). PC-
3 and RWPE-1cells were seeded onto clear 96-well plates or black 96-well 
ViewPlates, at a density of 6x103and 1.4x104 cells per well, respectively, in phenol 
red-free media. Cells were grown for 24 hrs and subsequently exposed to media 
supplemented with different 2DG concentrations (1–50 mM), in the presence or 
absence of fixed nitroxide concentrations (1, 10 and 100 µM), according to the 
treatment schedules depicted in Figure 4.1 and briefly described here: a) 2DG for 2, 
4, 8, 18, 24 and 48 hrs; b) CTMIO pre-treatment for 0.5–24 hrs then 2DG and 
CTMIO concurrently for 24 hrs; c) 2DG for 24 hrs before combination treatment 
with 2DG and CTMIO for 24 hrs and d) 2DG for 24 hrs followed by CTMIO or 
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Tempol for an additional 24 hrs. To compare the effects of CTMIO and Tempol to 
the known thiol antioxidant NAC in the 2DG model, PC-3 cells were treated with 1 
mM NAC according to schedules c, d, and e) NAC (1, 15 and 30 mM) for 1 hr before 
combined treatment with 2DG and NAC for 24 hrs. The appropriate controls (0.1% 
DMSO, media, or 2DG, nitroxide and NAC as single agents) were included in each 
experiment. Cell survival was assessed following the various treatments using either 
or both the WST-1 and CyQUANT®assays. However, because WST-1 interacts 
directly with sulfhydryl compounds, in the NAC experiments, the wells of the plates 
were washed twice with PBS to remove NAC prior to using this assay. 
 
 
 
 
 
 
 
 
Figure 4.1. 2DG and nitroxide or NAC combination treatment schedules used in cell 
survival assays 
A – 2DG for 2–48 hrs. B – CTMIO pre-treatment for 0.5–24 hrs followed by 2DG and CTMIO 
simultaneously for 24 hrs. C – 2DG for 24 hrs followed by 2DG and CTMIO, or 2DG and NAC 
for 24 hrs. D – 2DG for 24 hrs followed by CTMIO, Tempol or NAC for 24 hrs. E – NAC pre-
treatment for 1 hr followed by 2DG and NAC for 24 hrs. Schedules A–E refer to those used in 
Figures 4.6–4.12.
2DG 
CTMIO 
2DG + CTMIO 
NAC 
2DG + NAC 
Tempol 
A Figure 4.6 
B Figure 4.7
Figure 4.11
Figure 4.11
Figure 4.10
Figure 4.9D 
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4.3 RESULTS 
4.3.1 Inducing Oxidative Stress in Prostate Cancer Cells Using DTX 
DTX Decreases Cell Survival in a Dose and Time-Dependent Manner 
Firstly, to examine the growth inhibitory effect of DTX as a single agent, 
prostate cancer cell lines (DU-145, LNCaP and PC-3) which differ in aggressiveness 
and androgen responsiveness, were treated with various concentrations of DTX 
(0.01–100 nM), similar to those used in other in vitro studies (Muramaki et al., 2004; 
Ullen et al., 2005; Ting et al., 2007; Karabulut et al., 2009), for 24, 48 and 72 hrs. 
Cell survival was assessed using the metabolic WST-1 assay. As shown in Figure 
4.2, DTX induced cell death in a dose and time-dependent manner. After 24 hrs of 
treatment, there was a significant decrease in the survival of DU-145 cells at 1 
(P<0.05), 10 (P<0.01) and 100 nM (P<0.01), as compared with the DMSO solvent 
control (Figure 4.2A). By 48 hrs, a significant reduction in cell survival at these 
concentrations was also noted for the other cell lines (Figure 4.2B, P<0.01). Initially, 
PC-3 cells demonstrated a marked decrease in viability from 84% at the lowest DTX 
dose (0.01 nM) to 44% at 1 nM (P<0.01) at this time-point. But no substantial 
differences in PC-3 cell killing were observed between 1 nM and the higher 
concentrations of DTX (10 and 100 nM). LNCaP cells responded in a similar 
manner, although with the longer periods of exposure (48 and 72 hrs), this cell line 
was found to be the most sensitive to DTX-induced cytotoxicity (Figure 4.2B & C). 
In contrast, PC-3 cells displayed the greatest resistance to DTX, with >30% of cells 
still surviving at the highest concentration at the end of the 72 hr treatment period 
(Figure 4.2C). Given that chemotherapy often fails due to cancer cells becoming 
resistant to the therapeutic drug, this cell line was chosen for use in subsequent DTX 
and CTMIO combination treatment experiments. 
CTMIO Protects Against Cell Death Induced by Low but Not High Doses of 
DTX 
PC-3 cells were treated with DTX (0.01, 0.05 and 0.5 nM) in the presence of 
100 µM CTMIO for 48 hrs to investigate the effect of DTX and CTMIO in 
combination on cell survival. The doses of DTX used corresponded to the IC10, 
IC25 and IC50 concentrations, which were determined from the 48 hr cell survival 
curve (Figure 4.2B). When exposed to 0.01 nM DTX simultaneously with CTMIO, a 
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Figure 4.2. Dose and time-dependent decrease in the survival of prostate cells treated with 
DTX 
DU-145, LNCaP and PC-3 cells were treated with increasing doses of DTX (0.01–100 nM) for 
24, 48 and 72 hrs (A–C). Cell survival was determined using the metabolic WST-1 assay and 
expressed as a percentage of the DMSO control at each time point. Error bars represent SEM of 
three independent experiments, each performed with six replicates. *: DU-145 P<0.05; **: DU-
145 P<0.01; #: DU-145 P<0.05; ##: PC-3, LNCaP and DU-145 P<0.01; a: PC-3 and DU-145 
P<0.05; b: PC-3, LNCaP and DU-145 P<0.01, compared to control using One-Way ANOVA and 
Tukey’s post hoc analysis. 
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significantly greater percentage of cells survived compared to treatment with 0.01 
nM DTX alone, as observed using the WST-1 assay (Figure 4.3A, P<0.05). 
However, when CTMIO was combined with the higher doses of DTX (0.05 and 0.5 
nM), it was not able to reverse the cell toxicity induced by this compound. Indeed, it 
would appear that CTMIO with 0.5 nM DTX further increased cell toxicity (Figure 
4.3B).  
To further evaluate the protective effect of CTMIO in DTX treated cells, PC-3 
cells were exposed to increasing concentrations of CTMIO (50, 100 and 200 µM) 
together with a single dose of DTX (IC50) for 48 hrs. However, CTMIO did not 
rescue the cells from the cytotoxic effect of 0.05 nM DTX. This may have been 
because the slight protective effect elicited by CTMIO was masked by the significant 
cell death occurring at this concentration of DTX (Figure 4.3C & D, P<0.05 and 
P<0.01, respectively). 
Tempol Prevents the Inhibition of Cellular Metabolic Activity by Low but Not 
High Concentrations of DTX 
Next we extended our study to look at the more potent nitroxide Tempol, 
which has been shown to protect V79 lung fibroblasts against cytotoxicity imposed 
by the anticancer drug streptonegrin (DeGraff et al., 1994). Conversely, others have 
reported that treatment with Tempol potentiated doxorubicin (DOX) cytotoxicity in 
breast and colon cancer cells (Ravizza et al., 2004; Gariboldi et al., 2006). PC-3 cells 
were treated with the previously determined concentrations of DTX in the presence 
of 100 µM Tempol for 48 hrs. Cell survival in the Tempol and 0.01 nM DTX 
treatment group was 22% greater compared to DTX alone, indicating that Tempol 
recovered the cells from the cytotoxic effect of DTX (Figure 4.4A, P<0.05). This was 
confirmed using the CyQUANT® assay (a direct measure of cell viability), 
suggesting that treatment with 0.01 nM DTX likely caused an inhibition of cellular 
metabolic activity or metabolic stress rather than cell death per se (Figure 4.4B). 
However, higher concentrations of DTX (0.05 and 0.5 nM) induced irreversible 
inhibition of cell growth, which could not be recovered with Tempol treatment. The 
response of PC-3 cells to these combination treatments was similar to DTX alone. 
 
 86 Chapter 4:Finding Models of Stress or Oxidative Stress 
 
 
Figure 4.3. Effects of DTX and CTMIO combined treatments in PC-3 cells for 48 hrs 
PC-3 cells were exposed to various concentrations of DTX (0.01–0.5 nM) and 100 µM CTMIO 
simultaneously for 48 hrs (A & B), or increasing concentrations of CTMIO (50–200 µM) 
combined with a fixed DTX concentration (0.5 nM) for 48 hrs (C & D). Graphs A & C are cell 
survival results determined using the WST-1 assay, whereas graphs B & D are results obtained 
from the CyQUANT® assay. Cell survival is expressed as a percentage of DMSO treated cells, 
with error bars representing SEM. Experiments were repeated three to four times, with six 
replicates per experiment. Differences between treatment groups were determined using One-
Way ANOVA and Tukey’s post hoc test. *P<0.05 and **P<0.01, versus control; #P<0.05, 
versus 0.01 nM DTX. 
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Figure 4.4. Tempol reverses growth inhibition induced by low DTX dose in PC-3 cells 
Cell survival following treatment with different doses of DTX (0.01–0.5 nM), 100 µM Tempol or 
concurrent treatment with the two compounds was determined using both the WST-1 (A) and 
CyQUANT® (B) assays, and plotted as a percentage of the DMSO control. Error bars represent 
SEM of three independent experiments, each performed with six replicates. *P<0.05 and 
**P<0.01, compared to control; #P<0.05, compared to 0.01 nM DTX, as determined using One-
Way ANOVA and Tukey’s post hoc analysis. 
 88 Chapter 4:Finding Models of Stress or Oxidative Stress 
 
Long-Term Treatment with DTX Induces Oxidative Stress in PC-3 Cells  
The ability of both CTMIO and Tempol to reverse DTX-induced cytotoxicity in PC-
3 cells, albeit at low concentrations, may be due to their antioxidant function. In view 
of this, it was necessary to ascertain whether DTX treatment placed cells under a 
condition of oxidative stress. In cells and tissues, a change in glutathione (GSH) 
levels is often the first indication of oxidative stress. Therefore, GSH levels in PC-3 
cells were measured using the GSH-Glo assay following treatment with 100 µM 
CTMIO, 0.5 nM DTX or DTX together with CTMIO for various time intervals (6, 18 
and 48 hrs). In cells treated with DTX alone, there appeared to be a time-dependent 
decrease in GSH levels, which was significant at 48 hrs (Figure 4.5, P<0.01). While 
this time-dependent decrease in GSH levels was also evident in the CTMIO and 
DTX combined treatments, there were comparatively higher concentrations of GSH 
in these cells than in the DTX only treatments, suggesting that CTMIO protected 
against DTX-induced oxidative stress to some degree. Yet this data needs to be 
interpreted with caution, as prolonged exposure to DTX was accompanied by 
changes in cell morphology and a decrease in cell number, indicating that cell death 
was increasing over the time course of the treatment. As a result, depleted GSH 
levels in the 48 hr DTX treatment may in fact be due to a fewer number of cells 
being present rather than a direct consequence of oxidative stress. These results 
remain to be validated using different oxidative stress assays. In turn, this model was 
not used to evaluate the antioxidant capacity of CTMIO any further. 
4.3.2 2DG as a Stress-Inducing Agent in Prostate Cells 
2DG Treatment Produces a Dose and Time-Dependent Decrease in Cell 
Growth 
Studies have shown that glucose deprivation causes oxidative stress in cancer 
cells via disruptions in thiol metabolism (Lee et al., 1998; Blackburn et al., 1999; 
Spitz et al., 2000). Since the glucose analogue 2DG is believed to mimic the effects 
of glucose deprivation by inhibiting glucose metabolism (Laszlo et al., 1960; Shenoy 
& Singh, 1985; Lin et al., 2003; Andringa et al., 2006; Coleman et al., 2008), 
experiments were designed to determine whether CTMIO protected against 2DG-
induced cytotoxicity. Dose-response curves were initially performed in the normal 
prostate cell line RWPE-1 and in PC-3 cells, at concentrations ranging from 1–50 
mM, in order to optimise the dose of 2DG for combinations treatments with 
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Figure 4.5. Treatment with DTX and CTMIO depleted glutathione levels in PC-3 cells 
PC-3 cells were treated with 100 µM CTMIO, 0.5 nM DTX or DTX in the presence of CTMIO 
for 6–48 hrs. Glutathione levels were measured using the GSH-Glo assay and displayed as 
average fold changes relative to the DMSO control at each time point, with error bars 
representing SEM. Experiments were performed three times, each with three replicates. Asterisks 
indicate a significant difference between DTX and DMSO, as determined using One-Way 
ANOVA and Tukey’s post hoc analysis; **P<0.01. 
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CTMIO (Figure 4.6A–D). Cells were treated with 2DG for various time intervals (2, 
4, 8, 18, 24 and 48 hrs). PC-3 cells exhibited greater sensitivity to 2DG treatment 
from 8–48 hrs compared to the shorter time-points (2 and 4 hrs), with significant 
growth inhibition observed at all concentrations (Figure 4.6A, 1 mM P<0.05, 5–50 
mM P<0.01). While the CyQUANT assay also demonstrated a dose-dependent 
decrease in PC-3 cell growth, this was not significant, indicating that the 
concentrations of 2DG used were not toxic to the cells (Figure 4.6B). Similar to PC-3 
cells, a sharp decrease in RWPE-1 cell growth began at the lowest 2DG dose (1 
mM), followed by a gradual decline at concentrations thereafter (Figure 4.6C, WST-
1 assay). This pattern of growth inhibition was observed from 4 hrs of treatment 
onwards. With longer periods of exposure (24 and 48 hrs), it appeared that 2DG 
induced cell death and not merely growth inhibition in RWPE-1 cells (Figure 4.6D, 
CyQUANT assay). Interestingly, at these time points, the fraction of cells surviving 
remained at approximately 65% and 36% (24 and 48 hrs, respectively), despite the 
increasing 2DG concentrations (5–50 mM). Taken together, these results suggest that 
the metabolic activity of RWPE-1 and PC-3 cells is affected by 2DG treatment, 
resulting in growth inhibition. However, 2DG is relatively well tolerated in these 
cells, with cell death not being induced unless they are exposed to the compound for 
long periods (≥24 hrs). Since at 24 hrs, 10 mM 2DG was able to significantly inhibit 
PC-3 cell growth without having an adverse impact on cell survival (>90%), these 
conditions were selected for use in downstream combination treatments with 
CTMIO.  
CTMIO Pre-Treatment Does Not Hinder 2DG from Suppressing Cell Growth  
To examine whether CTMIO protected against the growth inhibitory effects of 
2DG, PC-3 cells were pre-treated with various concentrations of CTMIO (1, 10 and 
100 µM) for 0.5–24 hrs, and during exposure to 10 mM 2DG for an additional 24 hrs 
(Figure 4.7A–E). Pre-treatment with CTMIO followed by combination treatment 
with CTMIO did not prevent 2DG from inhibiting PC-3 cell growth. Indeed, 
comparable results were obtained at all pre-treatment intervals and CTMIO 
concentrations, suggesting that pre-treatment with CTMIO does not contribute to its 
protective effect in 2DG treated cells. 
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Figure 4.6. Response of prostate cells to dose and time-course treatment with 2DG 
PC-3 (A & B) and RWPE-1 (C & D) cells were exposed to increasing concentrations of 2DG 
over a period of 2–48 hrs. Data depicts cell survival graphed as a percentage of the media 
controls at each time point with SEM. Experiments were repeated two to five times, with six 
replicates per experiment. The differences between treatment groups and the control were 
determined using One-Way ANOVA and Tukey’s post hoc test;  PC-3 cells (a: 8 hrs P<0.05, 24 
and 48hrs P<0.01; b: 4 hrs P<0.05, 8, 24 and 48 hrs P<0.01; c: 2, 4, 8, 24 and 48 hrs P<0.01; d: 
4, 8, 24 and 48 hrs P<0.01; e: 2 hrs P<0.05, 4, 8, 24 and 48 hrs P<0.01); RWPE-1 cells (WST-1, 
a: 4, 24 and 48 hrs P<0.01, 8 hrs P<0.05; b: 4, 8, 24 and 48 hrs P<0.01; c: 2 hrs P<0.05, 4, 8, 24 
and 48 hrs P<0.01; d: P<0.01 for all time-points; CyQUANT, *: 24 and 48 hrs P<0.01). 
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Figure 4.7. Treatment with CTMIO before and during exposure to 2DG did not protect 
against 2DG-induced growth inhibition 
PC-3 cells were pre-treated with various doses of CTMIO (1, 10 and 100 µM) for 0.5–24 hrs 
before treatment with 2DG (10 mM) and CTMIO together for 24 hrs (Schedule B in Figure 4.1). 
Cells treated with CTMIO or 2DG as individual agents were included as controls. Cell survival 
was assessed using the WST-1 assay and plotted as a percentage of DMSO treated cells. Error 
bars represent the SEM of two independent experiments, performed in quadruplicate. *P<0.05 
and **P<0.01, versus control, as determined using One-Way ANOVA and Tukey’s post hoc 
analysis.  
2DG Pre-treatment and Treatment Together with CTMIO Inhibited Cell 
Survival in Prostate Cells 
Next, PC-3 cells were exposed to 10 mM 2DG for 24 hrs prior to concurrent 
treatment with 1–100 µM CTMIO for 24 hrs. A significant reduction in cell survival 
was observed in cells treated with both compounds (Figure 4.8A & B, P<0.01). In 
addition, when compared with cells treated with 2DG alone, there appeared to be a 
slight additive effect in the combined treatments with increasing concentrations of 
CTMIO (Figure 4.8B). Thus, the cytotoxic effect of 2DG and CTMIO in the 
combination treatments cannot be attributed solely to 2DG but is influenced by the 
presence of CTMIO, although CTMIO alone had negligible effect on cell growth. To 
compare the response of PC-3 cells to that in normal prostate cells, RWPE-1 cells 
were treated under the same conditions. However, there was little difference in cell 
survival between the combined treatments and 2DG alone, as demonstrated using 
both the WST-1 and CyQUANT® assays (Figure 4.8C & D, ~20% and ~30%, 
respectively). Collectively, these results indicate that using this treatment schedule, 
CTMIO was not able to reverse the cytotoxic effects of 2DG. 
CTMIO and Tempol Do Not Recover Cell Survival Following Inhibition by 
2DG 
In the above experiments, cells were exposed to CTMIO usually in the 
presence of 2DG. Alternatively, CTMIO treatment would precede treatment with 
both compounds together. Under these treatment regimes, any protective effect that 
CTMIO may have had on cellular metabolic activity or cell survival is potentially 
negated by the addition of 2DG. Based on this hypothesis, the third series of 
experiments were performed where PC-3 cells were recovered in media containing 
increasing doses of CTMIO (1–100 µM) for 24 hrs following exposure to 10 mM 
2DG for 24 hrs (Figure 4.9A & B). However, CTMIO was not able to improve cell
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Figure 4.8. 2DG Pre-treatment and concurrent treatment with CTMIO inhibited cell 
survival in prostate cells 
PC-3 (A & B) and RWPE-1 (C & D) cells were exposed to 10 mM 2DG for 24 hrs prior to 
concurrent treatment with 2DG and CTMIO (1, 10 and 100 µM) for an additional 24 hrs 
(Schedule C in Figure 4.1). Cell survival was measured using both the WST-1 (A & C) and 
CyQUANT® (B & D) assays and expressed as a percentage of control treatment with SEM. 
Experiments were repeated one to three times, with four replicates in each experiment. 
Differences between treatment and control were determined using One-Way ANOVA and 
Tukey’s post hoc test; *P<0.01. 
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survival, suggesting that 2DG had residual growth-limiting effects even after it was 
removed from the cells. This was also seen in PC-3 cells treated with Tempol (1–100 
µM) instead of CTMIO, indicating that the inability to suppress the toxic effects of 
2DG is not limited to the isoindoline nitroxide but may potentially be shared by all 
nitroxides (Figure 4.10 A & B). Likewise, the survival of RWPE-1 cells treated with 
Tempol following the 2DG insult was not significantly different from cells treated 
with 2DG alone(Figure 4.10 C & D). 
NAC Treatments Do Not Abolish the Adverse Effects of 2DG in PC-3 Cells 
Although the nitroxide antioxidants used in this study could not reverse the cell 
killing elicited by 2DG, evidence exists that antioxidant treatment is able to 
counteract 2DG-induced cytotoxicity in cells derived from pancreatic (Coleman et 
al., 2008), cervical (Lin et al., 2003) and head and neck squamous carcinomas 
(Simons et al., 2007). To test whether NAC, the thiol antioxidant employed in these 
studies also had similar protective effects in our model system, PC-3 cells treated 
with 10 mM 2DG for 24 hrs were exposed to 1 mM NAC for an additional 24 hrs, 
with or without 2DG (Figure 4.11A & B or C & D, respectively). However at 1 mM, 
NAC did not afford protection against the cytotoxic effects of 2DG. The decrease in 
the percentage of viable cells noted in the 2DG treatment remained low even after 
treatment with NAC. In addition, it did not appear to make a difference whether cells 
were exposed to NAC alone or together with 2DG. Therefore, PC-3 cells were 
subjected to increasing concentrations of NAC (1–30 mM) for 1 hr prior to, and 
during the 24 hr treatment with 1 or 10 mM 2DG (Figure 4.12A & B or C & D, 
respectively). NAC had little effect on cellular metabolic activity at 1 and 15 mM 
(Figure 4.12 A & C), while at the highest dose (30 mM), cellular metabolic activity 
was significantly abrogated (P<0.01). However, this result was not replicated using 
the CyQUANT® assay, suggesting that NAC only inhibited metabolic activity at this 
higher dose but still was not cytotoxic to PC-3 cells (Figure 4.12 B & D). 
Furthermore, when combined with 1 or 10 mM 2DG, NAC did not significantly 
improve cell growth above that in the 2DG treatment. In fact, metabolic activity of 
cells exposed to 2DG in the presence of 30 mM NAC was further inhibited (P<0.01).  
Thus, it can be concluded that pre-treatment with NAC followed by combined 
treatment with both agents also has little impact on alleviating 2DG-induced stress in 
PC-3 cells. Seeing that even NAC did not perform as expected in the 2DG treatments 
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Figure 4.9. CTMIO treatment following 2DG exposure did not reverse 2DG-induced 
cytotoxicity 
PC-3 cells were pre-treated with CTMIO at 1, 10 and 100 µM for 24 hrs before exposure to 10 
mM 2DG for 24 hrs (Schedule D of Figure 4.1). Cells were also treated with CTMIO and 2DG 
alone. Following treatment, cell survival was assessed using A – the WST-1 and B – 
CyQUANT® assays, and plotted as a percentage of the DMSO control. Error bars represent SEM 
of three to six independent experiments, each performed with four replicates. *P<0.05 and 
**P<0.01, compared to control, using One-Way ANOVA and Tukey’s post hoc analysis.  
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Figure 4.10. Tempol treatment following 2DG treatment did not rescue prostate cells from 
2DG-induced cell death 
PC-3 (A & B) and RWPE-1 (C & D) cells were first exposed to 10 mM 2DG for 24 hrs and then 
subsequently treated with Tempol (1, 10 and 100 µM) for another 24 hrs (Schedule D in Figure 
4.1). Survival of treated cells was determined using the WST-1 (A & C) and CyQUANT® (B & 
D) assays and displayed as a percentage of ethanol treated cells with SEM. Experiments were 
repeated three times, with four replicates per experiment. One-way ANOVA and Tukey’s post 
hoc test were used to determine differences between treatment groups and the ethanol control; 
#P<0.05; ##P<0.01.  
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Figure 4.11. NAC treatment did not protect PC-3 cells from 2DG-induced cytotoxicity 
PC-3 cells were pre-treated with 10 mM 2DG for 24 hrs and then treated with 1 mM NAC for an 
additional 24 hrs, in the presence (A & B, Schedule C in Figure 4.1), or absence of 10 mM 2DG 
(C & D, Schedule D in Figure 4.1). Cells treated with either NAC or 2DG alone were included as 
controls. Cell survival was assessed using the WST-1 (A & C) and CyQUANT® (B & D) assays 
and plotted as a percentage of the media control.  Error bars represent SEM of two to five 
independent experiments, performed in quadruplicates. *P<0.01, versus controls, as determined 
using One-Way ANOVA and Tukey’s post hoc analysis. 
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Figure 4.12. Treatment with NAC before and during exposure to 2DG did not prevent 
2DG-induced growth inhibition 
PC-3 cells were exposed to increasing concentrations of NAC (1, 15 and 30 mM) for 1 hr prior to 
combined treatment with 1 mM (A & B) and 10 mM (C & D) of 2DG for 24 hrs (Schedule E in 
Figure 4.1). The WST-1 (A & C) and CyQUANT® (B & D) assays were used to determine cell 
survival following treatment.  Graphs depict cell survival expressed as a percentage of the media 
controls with SEM. Experiments were repeated three times, with four replicates per experiment. 
Differences between treatment groups were determined using One-Way ANOVA and Tukey’s 
post hoc analysis. *P<0.05 and **P<0.01, compared to control; #P<0.01, compared to 2DG. 
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and thus an appropriate control was not available, this model was deemed not 
suitable for use in subsequent experiments. 
4.3.3 H2O2 Elicits Oxidative Stress in LNCaP Cells 
H2O2 has been used extensively as an inducer of oxidative stress in vitro to 
provide a model system in which to study the mechanisms of oxidative damage 
associated with various human diseases. Hence, PC-3 and other prostate cell lines 
(LNCaP, RWPE-1 and RWPE-2) were exposed to 500 µM H2O2 together with 100 
µM CTMIO for 1 hr, after which the treatment was removed and cells allowed to 
recover for 7 hrs in media containing 100 µM CTMIO (Chuang et al., 2002). To 
evaluate the antioxidant capacity of CTMIO in this model, GSH levels were 
measured using the GSH-Glo assay following the recovery period. A significant 
reduction in GSH levels was seen in H2O2 treated LNCaP cells but not in the other 
cell lines, indicating that only LNCaP cells were susceptible to H2O2-induced 
oxidative stress (Figure 4.13 P<0.01). However, exposure to CTMIO during the 
recovery period could not rescue these cells from the oxidative stress inflicted by 
H2O2 (depicted by the fourth set of bars). Even so, it cannot be ruled out that as an 
antioxidant, CTMIO elicited subtle changes at the gene level to protect the cells from 
the damaging effect of H2O2that was not evident from this assay. 
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Figure 4.13 Changes in glutathione levels in prostate cells treated with H2O2 and CTMIO 
LNCaP, PC-3, RWPE-1 and RWPE-2 cells were exposed to 500 µM H2O2, 100 µM CTMIO or H2O2 
in the presence of CTMIO for 1 hr. Cells were then allowed to recover in fresh media supplemented 
with 100 µM CTMIO or DMSO for 7 hrs. Glutathione levels were measured using the GSH-Glo assay 
and plotted as average fold changes normalised to the control, with SEM. Experiments were performed 
on four to five separate occasions, each with three replicates. *P<0.01, versus control, as determined 
using One-Way ANOVA and Tukey’s post hoc test.  
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4.4 DISCUSSION 
Cancer cells generate high levels of free radicals due to their active metabolism 
associated with the dysregulation of various cellular events, and in turn are under constant 
oxidative stress. Given these observations, it has been postulated that these cells would be 
more vulnerable to further oxidative stress by ROS-generating agents, compared to 
normal cells. In this chapter, we sought an appropriate model system in which to evaluate 
the antioxidant capacity of CTMIO. However, of the three stress, or oxidative stress 
models tested 1) DTX treatment; 2) 2DG treatment; and 3) H2O2 treatment, only the latter 
was considered suitable for use in further experiments. The reasoning behind why these 
treatment regimes were initially selected and how the data from this study coincide with 
literature findings are discussed below.   
4.4.1 CTMIO Did Not Protect Against Oxidative Stress and Cytotoxicity Elicited by 
DTX 
The promising results of two large phase III clinical trials demonstrating 
significantly improved survival in HRPC patients treated with DTX (combined with 
estramustine or prednisone) has led to this compound being currently approved as the 
first-line standard for metastatic disease (Petrylak et al., 2004; Tannock et al., 2004; 
Berthold et al., 2008). Yet the use of DTX therapy is overshadowed by its severe side 
effects in most patients, particularly in the elderly men most at risk of this advanced stage 
of prostate cancer (Bruno et al., 2001; Hurria et al., 2006). Additionally, DTX-based 
treatments containing other anti-tumour agents are associated with a certain degree of 
dose-related toxicity. This has prompted active research with the critical goal of 
developing novel therapeutic strategies that enhance the efficacy of DTX against HRPC 
without inducing toxicity. 
The nitroxide Tempo has been reported to enhance the cytotoxic effects of two anti-
cancer agents, DOX and mitoxantrone in prostate cancer cells(Suy et al., 2005). While its 
analogue Tempol was found to sensitise MDR breast cancer cells (MCF-7/ADR) to the 
cytotoxicity of DOX, especially when cells were exposed to the nitroxide prior to, or 
simultaneously with DOX treatment (Gariboldi et al., 2006). Such predisposition 
involved the induction of oxidative stress and was accompanied by typical p53-dependent 
changes: up-regulation of p21 and Bax and down-regulation of Bcl-2 levels. Likewise, the 
activation of the p21 pathway by Tempol potentiated DOX cytotoxicity in colon cancer 
cells (Ravizza et al., 2004). Intriguingly in both studies, the increase in p21 expression 
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was observed in p53-deficient cell lines, suggesting that Tempol can exploit p53-
independent pathways for p21 induction. This is worthy of note, because p53 function is 
frequently lost in many cancers, giving rise to MDR (Wallace-Brodeur & Lowe, 1999). 
However, if cell death pathways downstream of p53 can be directly activated by 
mechanisms independent of p53, such as p21 by Tempol, this could significantly improve 
the response of tumour cells lacking p53, to treatment with chemotherapeutic agents (Wu 
et al., 2002; Liu et al., 2003; Satou et al., 2003; Chopin et al., 2004).  
In the present study, the prostate cancer cell line PC-3, which expresses mutant p53, 
displayed the greatest resistance to DTX treatment. When these cells were exposed to 
DTX (at the lowest dose) in the presence of Tempol, cell survival was significantly 
improved, indicating that in prostate cancer cells, Tempol protected against cell death 
induced by DTX instead of acting as a chemosensitiser. A significant improvement in cell 
survival was also observed in PC-3 cells treated simultaneously with 0.01 nM DTX and 
the isoindoline nitroxide CTMIO. Gomez and colleagues observed in their study that 
sequential addition of flavopiridol, a broad cyclin-dependent kinase inhibitor, followed by 
DTX or DTX followed by flavopiridol was required for maximal induction of apoptosis 
in prostate cancer cells (Gomez et al., 2006). But when these drugs were added 
simultaneously, there was an antagonism of apoptosis probably because of their opposing 
effects on cyclin B1-dependent kinase activity. On the same premise that sequential 
treatment optimally induces apoptosis, pre-treatment of the TRAMP C2G prostate cancer 
cell line with methylselenocysteine was found to be essential for the enhancement of 
DTX anti-tumour activity (Azrak et al., 2006). In contrast, other authors demonstrated 
that the synergistic cytotoxicity exerted by DTX and zoledronic acid on PC-3 and DU-
145 cells when added together, was also obtained regardless of which agent was applied 
first (Karabulut et al., 2009). Hence, while it may be speculated that the ability of Tempol 
to sensitise prostate cancer cells to DTX may be dependent on the dosing schedule, it 
must be kept in mind that the combination of drugs being used and the role that each may 
play on critical cell death or survival pathways would dictate the particular order (if any) 
in which the drugs are applied in a given tumour type.  
Although the mechanism by which Tempol and CTMIO protected against DTX-
induced cytotoxicity was not explored in this study, the ability of these compounds to act 
as antioxidants should not be disregarded. This is highly plausible, considering that the 
cytotoxic action of other anti-cancer drugs such as mitomycin C and streptonigrin (STN) 
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have been attributed to the generation of oxygen radicals during redox cycling of the 
semiquinone intermediate of the parent drugs (Cone et al., 1976; Bachur et al., 1979; 
Gutteridge, 1984; Doroshow, 1986). Studies on the survival of V79 lung fibroblasts 
demonstrated that STN-induced cytotoxicity was inhibited in the presence of Tempol, 
which can be explained in terms of the nitroxide ability to react with the semiquinone 
radical form of the drug, catalyse the dismutation of superoxide radicals generated, 
terminate free radical chain reactions, and maintain transition metal ions in the oxidised 
state, thereby interrupting metal-catalysed reaction of H2O2 to the highly reactive 
hydroxyl radical (Nilsson et al., 1989; Mitchell et al., 1990; Krishna et al., 1992; DeGraff 
et al., 1994). In like manner, tamoxifen (TAM) treatment induced apoptosis in estrogen 
receptor-negative cell models through a sequential pathway of ROS production, thiol 
depletion and NF-κB activation (Ferlini et al., 1999). The modulation of cellular redox 
metabolism by TAM is believed to potentiate the anti-tumour effects of other 
chemotherapeutics such as DOX, taxanes and cisplatin, when used in combination 
(Ferlini et al., 1997). While DOX also produces superoxide radicals, several lines of 
evidence suggest that this drug elicits cytotoxicity mainly through intercalation with 
double stranded DNA and inhibition of topoisomerase II activity, with minimal 
contribution from free radical pathways originating from the semiquinone intermediate 
(Voest et al., 1993; Lamson & Brignall, 1999; Conklin, 2000, 2004). Consequently, 
Tempol was not effective in protecting against DOX-induced cytotoxicity in V79 cells, 
despite its rapid reaction with superoxide and the semiquinone radical of DOX (DeGraff 
et al., 1994). Hence, although all antineoplastic agents generate some degree of oxidative 
stress as they induce apoptosis in cancer cells, the generation of free radicals may not be 
necessary for the initiation of the apoptotic process but may occur secondarily (Conklin, 
2004).  
The binding of DTX to free tubulin which promotes microtubule stabilisation, 
blocks cell division and leads to the inactivation of Bcl-2, is widely accepted as being the 
main therapeutic mode of action of this anticancer drug, while the role of free radicals in 
this process remains contentious (Parness & Horwitz, 1981; Ringel & Horwitz, 1991; 
Haldar et al., 1997; Dumontet & Sikic, 1999; Pienta, 2001; Herbst & Khuri, 2003). Yet 
there is sufficient evidence, such as the finding that pre-treatment with the radical 
scavenger NAC significantly attenuated DTX-induced apoptotic cell death, as well as the 
fact that increases in intracellular ROS levels correlated well with sensitivity to DTX 
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treatment, to justify the involvement of ROS in DTX cytotoxicity (Rabi & Bishayee, 
2009). Furthermore paclitaxel, the analogue of DTX, is known to generate superoxide 
anions via the stabilisation of microtubules in a murine cell line (Pae et al., 1998). 
Interestingly, microtubule dynamic assembly and disassembly has been linked to the 
redox regulation of cysteine residues on tubulin. In their study, Khan and Luduena 
demonstrated that the thioredoxin system was able to inhibit microtubule assembly in 
vitro by reducing a disulfide bond in the tubulin dimer (Khan, 1991). Since high 
thioredoxin expression is associated with DTX resistance, it is tantalising to speculate that 
the influence of thioredoxin on microtubule assembly may affect the antitumour activity 
of DTX (Kim et al., 2005). Another possible explanation could be that thioredoxin acts as 
a protector against oxidative stress induced by DTX (Yokomizo et al., 1995; Sasada et al., 
1996; Yamada et al., 1996; Powis et al., 2000). Others have reported that the inactivation 
of the anti-apoptotic Bcl-2 protein during DTX treatment is mediated through the 
phosphorylation of p38, JNK and Raf-1(Shiah et al., 2001; Nicolini et al., 2003; Brichese 
et al., 2004; Das et al., 2007, 2008). Indeed it has been demonstrated that DTX 
orchestrates phosphorylation of these kinases by triggering ROS production, potentially 
through the mitochondrial electron transport chain (Das et al., 2008). Alternatively, DTX 
may elevate intracellular levels of ROS through blockage of the glutathione peroxidase/ 
glutathione reductase detoxification system. Our results demonstrating that long-term 
treatment with DTX cause GSH depletion in PC-3 cells support this.  
If the induction of oxidative stress is involved in DTX cytotoxicity then the addition 
of an antioxidant to the treatment regime would appear to be intuitively contradicting. 
Nonetheless by reducing the formation of aldehydes (Clemens et al., 1997), the secondary 
products of lipid peroxidation (Esterbauer et al., 1991), and in turn their interference with 
cell cycle progression (Gavino et al., 1981; Gonzalez et al., 1991; Gonzalez et al., 1993; 
Chajès et al., 1995; Conklin, 2002), apoptotic pathways (Solary et al., 2000) and enzymes 
that carry out the apoptotic process (Hampton & Orrenius, 1997; Chandra et al., 2000) — 
all of which may account for the diminished efficacy of antineoplastic agents during 
chemotherapy-induced oxidative stress, antioxidants may actually enhance or preserve, 
rather than inhibit the cytotoxicity of anticancer drugs (Conklin, 2004). Conversely, the 
means through which Tempol increased the susceptibility of MDR breast cancer cells to 
DOX, was achieved in part by the induction of oxidative stress (Gariboldi et al., 2006). 
Antioxidants may also enhance the effectiveness of chemotherapeutic agents in 
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transformed cells through non-antioxidant or oxidative stress related mechanisms. As 
demonstrated by Chinery and colleagues, the antioxidants pyrrolidinedithiocarbamate and 
vitamin E potentiated tumour growth inhibition by 5-fluorouracil and DOX through the 
induction of p21WAF1/CIP1 via the activation of the transcription factor C/EBPβ (Chinery et 
al., 1997). Moreover, the co-administration of antioxidants with chemotherapeutic agents 
can reduce the severity of ROS-mediated side effects associated with the drugs, without 
altering their anticancer activity (Myers et al., 1977; Rajagopalan et al., 1988; Villani et 
al., 1990; Monti et al., 1991; DeGraff et al., 1994; Conklin, 2004). In this regard, 
nitroxides and their amine precursors have been shown to prevent DOX-induced 
cardiotoxicity by inhibiting lipid peroxidation, through free radical scavenging and the 
decrease of reduced transition metal ion availability (Monti et al., 1996; Hideg & Kálai, 
2007). At the present time, the impact of oxidative stress and antioxidants on the efficacy 
of cancer chemotherapy and the development of chemotherapy-induced side-effects is 
still not fully understood. Future research that is able to answer these critical questions 
may guide the design of interventions that not only enhance the cytotoxic activity of 
anticancer drugs, but also prevent or reduce the incidence of damage caused by these 
drugs.   
4.4.2 2DG Induced Cytotoxicity in Prostate Cells Could Not be Reversed with 
Antioxidant Treatment 
Slow-growing cells found in hypoxic regions of solid tumours are particularly 
resistant to conventional therapies, which are toxic only to rapidly dividing cells. 
However, the dependency of hypoxic cancer cells on glycolysis for energy production 
provides an opportunity to selectively target these cells, by using inhibitors of this 
metabolic pathway (Liu et al., 2001; Liu et al., 2002a). Interestingly, even in the presence 
of oxygen, tumour cells exhibit an increase in glycolytic activity (Warburg effect) 
compared to normal tissues, resulting in high glucose requirements to generate energy 
and support metabolic function (Warburg et al., 1924; Weber, 1977a, 1977b; Eigenbrodt 
et al., 1985). Warburg proposed that this alteration in metabolism was due to damage to 
the mitochondrial respiratory chain (Warburg, 1956). Thus, it is logical to hypothesise 
that more free radicals would be produced by tumour cells, which would cause an 
increased demand for glucose metabolism directed towards hydroperoxide detoxification 
(Spitz et al., 2000; Ahmad et al., 2005; Andringa et al., 2006; Simons et al., 2007). 
Indeed, high concentrations of glucose in tissue culture media have been shown to render 
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cells resistant to H2O2-induced cytotoxicity (Averill-Bates & Przybytkowski, 1994). 
Furthermore, several studies noted that glucose deprivation in the MCF-7/ADR breast 
cancer cell line resulted in steady-state increases in hydroperoxides and caused profound 
disruptions in thiol metabolism, which are consistent with metabolic oxidative stress (Lee 
et al., 1998; Blackburn et al., 1999). On the other hand, simultaneous treatment with the 
thiol antioxidant, NAC, was capable of suppressing glucose deprivation-induced 
cytotoxicity, parameters indicative of oxidative stress, as well as activation of signal 
transduction and gene expression pathways associated with the malignant phenotype, 
confirming that oxidative stress is responsible for the effects observed during glucose 
deprivation in human cancer cells (Lee et al., 1998; Blackburn et al., 1999).  
In the current study, 2DG was used to mimic the effects of glucose deprivation in 
prostate cells. 2DG is a clinically relevant analogue of glucose that competes with glucose 
for uptake and entry into glucose metabolic pathways (Landau & Lubs, 1958; Laszlo et 
al., 1960; Kaplan et al., 1990; Dwarkanath et al., 2001), thereby, creating a chemically-
induced state of glucose deprivation. Treatment of PC-3 cells with 10 mM 2DG for 24 hrs 
significantly inhibited cell survival. However, neither pre-treatment nor combined 
treatment with CTMIO (or Tempol), at concentrations up to 100 µM, were able to rescue 
these cells from 2DG-induced cytotoxicity. While it may be speculated that the 2DG dose 
used exceeded the repair capacity of the cells, or severely depleted the cells of energy 
(Dwarkanath et al., 2001) required to maintain normal cellular functions, including cell 
division, resulting in cells entering the resting state of the cell cycle for an extended 
period or undergoing growth arrest, this dose was necessary to competitively inhibit 
glucose metabolism in the culture medium, which contained 11 mM of D-glucose. Others 
have reported using twice the 2DG concentration used in this study for 24 hrs to 
completely hinder the uptake of media glucose by PC-3 and DU-145 cells, with minimal 
impact on cell survival (Ahmad et al., 2008). In addition, 2DG administered to mice has 
been shown to effectively inhibit glucose metabolism without toxicity until very high 
levels (>2 g/kg body weight) were achieved (Landau & Lubs, 1958), and to be well 
tolerated in humans up to 200 mg/kg (Mohanti et al., 1996).  
Surprisingly, NAC also did little to protect against the growth inhibition induced by 
2DG, contrary to what others have reported previously (Lin et al., 2003; Simons et al., 
2007; Coleman et al., 2008). However, it should be noted that in these studies, different 
methodologies, experimental conditions and cell lines were employed. For instance, 30 
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mM NAC was found to reverse 2DG-induced clonogenic cell killing and disruptions in 
glutathione metabolism in human cervical carcinoma (HeLa) cells (Lin et al., 2003). In 
these experiments, HeLa cells were treated with NAC for 1 hr before and during exposure 
to increasing concentrations of 2DG (4, 6, 8 mM) or a single dose of 2DG (6 mM) for 8 
hrs. Interestingly, using a 30 mM dose of NAC in our study proved harmful to PC-3 cells, 
as seen by the significant abrogation in cellular metabolic activity following treatment 
with this compound.  
More importantly the lack of efficacy demonstrated by NAC (even at lower 
concentrations) could potentially indicate that 2DG alone in our model was not sufficient 
to induce a condition of oxidative stress. Although we attempted to address this 
fundamental question by measuring glutathione levels in 2DG treated PC-3 cells, 
inconclusive data was obtained from the assay kit used(BioVision). By virtue of being a 
substrate for glucose-6-phosphate dehydrogenase, the phosphorylated form of 2DG can 
proceed through the first step of the pentose phosphate pathway, leading to the 
regeneration of one molecule of NADPH (Suzuki et al., 1983). However, it is incapable 
of further metabolism in this pathway (Renner et al., 1972), and cannot be metabolised 
(via glycolysis) to form pyruvate (Wick et al., 1957; Brown, 1962). In view of this, using 
2DG as a partial inhibitor of glucose metabolism may provide an effective addition to 
drug combination strategies designed to limit hydroperoxide detoxification for the 
purpose of sensitising cancer cells to metabolic oxidative stress. This approach has 
formed the biochemical basis for numerous studies which have demonstrated enhanced 
cancer cell killing in response to combination treatment with 2DG and ROS-generating 
agents such as ionising radiation (Mohanti et al., 1996; Lin et al., 2003; Coleman et al., 
2008), chemotherapeutic drugs (Maschek et al., 2004; Simons et al., 2007; Ahmad et al., 
2010), ETC blockers (Ahmad et al., 2005) and over-expression of wild-type p53 (Ahmad 
et al., 2008). While a heightened level of oxidative stress was observed in the presence of 
these agents, it must also be emphasized that treatment with 2DG alone was accompanied 
by disruptions in intracellular thiol pools and an increase in steady-state levels of 
superoxide and H2O2. Since energy production would be expected to shift from glycolysis 
to mitochondrial respiration during glucose deprivation, substantial amounts of 
hydroperoxides would be generated as a by-product of respiratory activity and use up 
glucose and NADPH stores rapidly (Lee et al., 1998; Blackburn et al., 1999). In turn, 
oxidative stress and cytotoxicity would result from the build-up of intracellular  
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hydroperoxides, and oxidised glutathione would accumulate. Glutathione synthesis is 
thought to be upregulated as an adaptive response, to maintain the redox buffering 
capacity of the intracellular reducing environment (Blackburn et al., 1999; Ahmad et al., 
2005; Andringa et al., 2006). Supporting this idea are the observations that inhibition of 
glutathione synthesis with L-Buthionine-[S,R]-sulfoximine increased end-points indicative 
of oxidative stress and sensitised cancer cells to 2DG-induced cytotoxicity (Andringa et 
al., 2006).  
When deprived of glucose, cell death resulting from respiratory dependent 
metabolic oxidative stress (Ahmad et al., 2005) has been shown to be more severe in 
cancer cells than normal cells (Blackburn et al., 1999; Spitz et al., 2000; Lin et al., 2003). 
This is likely due to the increased dependency of cancer cells on glucose metabolism for 
decomposition of excess hydroperoxides formed during mitochondrial respiration (Spitz 
et al., 2000; Ahmad et al., 2005; Andringa et al., 2006; Simons et al., 2007). In addition, 
high glucose consumption is required for rapid proliferation of most, if not all, cancer 
cells (Lo et al., 1968; Weber, 1977a). Thus, the degree to which tumour cells increase 
their metabolism of glucose is predictive of their susceptibility to glucose deprivation-
induced cytotoxicity and oxidative stress. Consistent with this hypothesis, Singh and 
others demonstrated greater growth inhibition in rapidly dividing cancer cells following 
glucose deprivation, compared to relatively slow-growing cancer cells which were less 
dependent on glucose (Singh et al., 1999; Ahmad et al., 2010). It has also been speculated 
that cancer cells may accelerate their own demise under glucose deprivation conditions 
(2DG treatment), by initially expressing high levels of the glucose transporter protein 
GLUT1 in order to increase glucose uptake (Aft et al., 2002). This stress response would 
allow more 2DG to enter the cells, leading to rapid inhibition of glycolysis, further 
depletion of intracellular energy stores and the induction of cell death. Our results 
demonstrating that 2DG induced cytotoxicity in both PC-3 (fast growing, malignant) and 
RWPE-1 (slower growing, normal) cells did not agree with these earlier studies. 
Furthermore, both CTMIO, and NAC, the gold standard antioxidant used in glucose 
deprivation studies did not recover cell survival in 2DG treated cells. Together, our data 
which showed inconsistencies with literature findings suggest that there may have been 
flaws in our experimental design (e.g. incorrect dose of 2DG and NAC, or duration of 
treatment with these compounds, as optimisation studies were not carried out for each 
specific treatment regime). Accordingly, using glucose deprivation as a model system for  
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evaluating the antioxidant property of CTMIO was not pursued further.   
4.4.3 H2O2 Treatment as a Model of Oxidative Stress 
Although free radicals may be deleterious to cell survival and are the causative 
factors of tissue injury and oxidative stress which have been implicated in the 
pathogenesis of many chronic inflammatory and degenerative diseases in humans 
(Hensley et al., 1995; Lovell et al., 1995; Harrison et al., 2003; Klein & Ackerman, 2003; 
Klaunig & Kamendulis, 2004; Shichi, 2004; Stocker & Keaney Jr, 2004; MacNee, 2005; 
Storz, 2005; Pop-Busui et al., 2006), they are also important in regulating normal cellular 
processes, including proliferation, differentiation and migration (Sundaresan et al., 1995; 
Rhee et al., 2000). Such diverse biological outcomes in response to a seemingly simple 
rise in ROS may actually reflect subtle differences in the intensity and duration of the 
oxidant burst or the cellular context that accompanies this oxidative stress (Finkel, 2003). 
In view of this and in keeping with other studies where brief exposures to sublethal doses 
of H2O2have been shown to mediate the activation of various signalling pathways (Gotoh 
& Cooper, 1998; Viard et al., 1999; Yamamoto et al., 2003; Kim et al., 2006; Sung et al., 
2006; Kimball et al., 2008; Volonte et al., 2009), prostate cells in our study were 
subjected to 500 µM of H2O2 in combination with 100 µM CTMIO for 1 hr, after which 
the cells were recovered for 7 hrs in media supplemented with the nitroxide (Chuang et 
al., 2002). Under this treatment regime, oxidative stress was observed in the LNCaP cell 
line, as evidenced by a decrease in the reduced glutathione content, which could not be 
reversed with CTMIO treatment. Interestingly, in bacteria and yeast cultures, the 
induction of antioxidants in response to a sublethal dose of H2O2 allows cells to adapt to, 
and thus survive subsequent exposure to higher doses (Collinson & Dawes, 1992; 
Jamieson, 1992; Davies et al., 1995; Lee et al., 1995; Lushchak, 2001; Gasch & Werner-
Washburne, 2002). This phenomenon could potentially occur also in mammalian cells. 
Furthermore, pre-treatment with H2O2 may increase the intracellular accumulation of 
drugs by altering the cytosolic pH (Wu et al., 1996) and plasma membrane dynamics 
(Yamaguchi et al., 1983; Wei et al., 2000; Funk & Jeffrey, 2007). Whether the cellular 
uptake of CTMIO is influenced by H2O2pre-treatment is still unknown at this stage. 
However, if this were the case, the diffusion of the weakly acidic CTMIO (Micallef, 
2001) into the cytosol would be facilitated through means other than a decrease in 
cytosolic pH, in agreement with pH-partitioning theory. Instead, it would be expected to 
occur through changes in the fluidity of the plasma membrane or if the physical integrity 
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of the membrane was compromised as a result of H2O2 treatment. The possibility of 
enhanced CTMIO accumulation in cells is an important consideration because of the 
potential impact this could have on H2O2-regulated gene expression. Hence, despite 
CTMIO not being able to protect against H2O2-induced oxidative stress, this model 
provides a suitable framework to investigate the changes elicited by this compound at the 
gene level.  
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5.1 INTRODUCTION 
The dual nature of nitroxides as both pro-oxidants (Gariboldi et al., 2000; Gariboldi 
et al., 2006; Aronovitch et al., 2007) and antioxidants (Krishna et al., 1991; Samuni et al., 
1991b; Hahn et al., 1992a; Monti et al., 1996) is well recognised. Cell survival studies 
undertaken in chapter 3 to examine the pro-oxidant property of nitroxides on a panel of 
prostate cell lines, found CTMIO to have minimal toxicity. Thus, several models of 
oxidative stress were explored, and a H2O2 model of oxidative stress established, in which 
to assess the antioxidant capacity of CTMIO (Chapter 4).   
A number of chemical mechanisms have been proposed to account for nitroxide 
antioxidant activity; these being superoxide dismutase activity (Mitchell et al., 1990), 
oxidation of reduced metals that would otherwise catalyse the formation of hydroxyl 
radicals from H2O2 (Samuni et al., 1991a), catalase mimic activity, radical-radical 
interactions and detoxification of secondary organic radicals. However in recent years, 
research has taken a turn from the whole cell or animal level to investigating how this 
class of compounds affect signal transduction pathways. Many of these studies involved 
the piperidine nitroxides Tempo or Tempol activating an apoptotic mode of cell death 
which was mediated by a dose-dependent increase in p21WAF1/CIP1 protein levels 
(Gariboldi et al., 2000; Gariboldi et al., 2003; Gariboldi et al., 2006), modulation of Bax 
and Bcl2 levels (Gariboldi et al., 2000; Gariboldi et al., 2006), increase in caspase activity 
(Suy et al., 2005; Wu et al., 2006) or induction of the MAPK signalling cascade (Suy et 
al., 1998). Although oxidative stress accompanied cell death induced by Tempol, this was 
determined by measuring survival rates following co-treatment with the thiol antioxidant 
NAC, and changes in intracellular peroxide and GSH levels rather than changes at the 
molecular level(Gariboldi et al., 2000; Gariboldi et al., 2006; Wu et al., 2006). Likewise, 
in A-T studies employing the nitroxide CTMIO, markers of oxidative stress (catalase 
activity, 3-nitrotyrosination of proteins and immunoreactivity to 4-hydroxy-2-nonenal 
Michael adducts) were used to assess protection by the nitroxide against oxidative 
damage to the cerebellum of Atm-mutant mice (Chen et al., 2003; Gueven et al., 2006). 
Hence, the molecular mechanisms underlying the antioxidant action of nitroxides in cells 
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are still largely unknown. 
In response to a rise in intracellular oxidant levels, regardless of whether the 
oxidants are produced endogenously or by way of external stimuli, the antioxidant 
defence system is activated to counteract the oxidative burden in order to maintain 
physiological homeostasis (Halliwell, 2007a; Rahal et al., 2014). This system is 
composed of enzymatic scavengers including SOD, CAT, GPX, thioredoxin, and the 
peroxiredoxin family of proteins, and non-enzymatic reducing agents such as ascorbate, 
pyruvate, glutathione and Vitamin C and E (Finkel, 2003). Nonetheless, when cellular 
production of ROS overwhelms its antioxidant capacity, damage to cellular 
macromolecules such as proteins, lipids and DNA may ensue. For many years, this was 
the traditionally held concept regarding ROS that they were only capable of behaving in a 
random and destructive manner. However, we now know that ROS have purposeful roles 
within cells as regulators of redox sensitive pathways involved in normal cell growth and 
differentiation, as well as disease progression, growth arrest and cell death (Valko et al., 
2006; Valko et al., 2007).  
With this background in mind, the aim of this chapter was 1) to identify the 
oxidative stress and antioxidant related genes induced by the three treatment groups of the 
oxidative stress model (H2O2, CTMIO, H2O2 and CTMIO). This was achieved using RT2 
PCR arrays, a technique which combines the multiple gene profiling capabilities of a 
microarray with the quantitative precision of real-time PCR for analyzing the expression 
of a panel of genes relevant to a pathway or disease state. 2) To repeat the experiments 
undertaken in aim 1 using DCTEIO, a CTMIO derivative which is not as readily reduced 
intracellularly due to its hindered structure. Consequently the oxidative stress response 
elicited by this compound may differ from that seen with CTMIO. 3) To delineate the 
mechanism of action of CTMIO and DCTEIO in prostate cancer cells by comparing the 
changes in gene expression induced by these compounds to that induced by H2O2and the 
combined treatment. 
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5.2 MATERIALS AND METHODS 
The experimental procedures used in this chapter are fully described in Sections 
2.9.1–2.9.8. 
5.3 RESULTS 
5.3.1 CTMIO & H2O2 Dataset 
Differentially Expressed Genes Identified using Oxidative Stress and Antioxidant 
Defence PCR Arrays and the Relationship between Gene Expression under 
Each Treatment Condition 
In the previous chapter, a model of oxidative stress was established by exposing 
LNCaP cells to 500 µM H2O2 and 100 µM CTMIO for 1 hr, after which the treatment 
was removed and the cells allowed to recover for 7 hrs in media containing 100 µM 
CTMIO. For the controls, LNCaP cells received either 500 µM H2O2 or 100 µM CTMIO 
alone, and were recovered in 0.1% DMSO or 100 µM CTMIO-containing media, 
respectively. To begin to understand the potential mechanisms involved in the oxidative 
stress response, we examined the expression of 84 oxidative stress and antioxidant 
defence related genes in these three treatment groups using RT2 PCR arrays (Appendix 
A). In total, 37 genes were differentially regulated (fold change ≥ 1.5 or ≤ -1.5; Figure 
5.1A& B, Table 5.1). Four genes were expressed in the CTMIO group that were not 
detected in the other treatments (Figure 5.1A). Of these, 3 were upregulated (EPHX2, 
NOX5 and SOD3) and 1 was downregulated (AOX1) (Figure 5.1B, Table 5.1). In the 
H2O2treatment group, 7 genes were upregulated (APOE, CCL5, DUSP1, EPX, GPX2 and 
NME5) and 1 was downregulated (NUDT1), whereas only 2 genes were found to be 
upregulated (PRG3 and PXDN) specifically by the combined treatment (Figure 5.1A & B, 
Table 5.1). Thus, the highest number of uniquely expressed gene transcripts was found in 
cells exposed to H2O2.  
Looking at overlapping gene expression, the greatest similarity was found between 
the H2O2 treatment and the combined treatment (Figure 5.1A). This is supported by the 
finding that the combined treatment had the least number of uniquely expressed gene 
transcripts. Eight genes were upregulated (ALOX12, DUOX1, NCF1, NCF2, NOS2, 
SRXN1, TPO and TXNDC2) and 2 were downregulated (DGKK and GPX5) by these two 
treatments (Figure 5.1A & B, Table 5.1). Another 3 genes (KRT1, LPO and PTGS1) were 
mutually expressed by both the nitroxide-containing treatments, while nine genes were 
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Figure 5.1. Genes of interest and their expression profiles in response to the various 
treatments 
A – The Venn diagram shows the number of oxidative stress or antioxidant related genes with 
overlapping and non-overlapping expression in each of the treatment groups which are 
represented as colour-coded circles (CTMIO, green; H2O2, orange; the combined treatment, 
purple). Only genes from the PCR array with at least a 1.5-fold change in expression, compared 
to the DMSO and PBS control were included. PCR arrays were repeated three times from 
treatments performed on three separate occasions. B – Genes were either similarly or 
differentially regulated by the three treatments as depicted by the colour map (blue, 
downregulation; orange, upregulation; white, no change in gene expression, that is, a fold change
Genes CTMIO H2O2  C+H 
ALOX12       
AOX1       
APOE       
CCL5       
CYBA       
DGKK       
DUOX1       
DUOX2       
DUSP1       
EPHX2       
EPX       
GPR156       
GPX2       
GPX3       
GPX5       
GPX7       
IPCEF1       
KRT1       
LPO       
MPO       
NCF1       
NCF2       
NME5       
NOS2       
NOX5       
NUDT1       
PREX1       
PRG3       
PTGS1       
PTGS2       
PXDN       
PXDNL       
SOD3       
SRXN1       
TPO       
TTN       
TXNDC2       
H2O2
CTMIO  C+H 
≥ -1.5 or ≤  1.5). 
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Table 5.1 Subset of oxidative stress and antioxidant related genes from the CTMIO H2O2 dataset with at least a 1.5-fold change in expression in one  
of the treatment groups 
   CTMIO  H2O2  CTMIO + H2O2 
GenBank 
Accession No. 
Gene 
Symbol Description Fold Change P-value 
 
Fold Change P-value 
 
Fold Change P-value 
NM_000697 ALOX12 Arachidonate 12-lipoxygenase 1.37 0.930  1.61 0.804  1.97 0.591 
NM_001159 AOX1 Aldehyde oxidase 1 -1.89 0.635  1.15 0.993  -1.30 0.958 
NM_000041 APOE Apolipoprotein E 1.18 0.989  1.78 0.699  1.09 0.998 
NM_002985 CCL5 Chemokine (C-C motif) ligand 5 1.32 0.949  2.35 0.409  1.12 0.997 
NM_000101 CYBA Cytochrome b-245, alpha polypeptide 1.73 0.729  1.97 0.594  3.83 0.099 
NM_001013742 DGKK Diacylglycerol kinase, kappa -1.00 1.000  -7.16 0.007  -1.76 0.714 
NM_175940 DUOX1 Dual oxidase 1 1.35 0.938  1.82 0.675  1.53 0.851 
NM_014080 DUOX2 Dual oxidase 2 12.55 0.000  13.29 0.000  11.68 0.001 
NM_004417 DUSP1 Dual specificity phosphatase 1 -1.01 1.000  1.65 0.778  1.28 0.965 
NM_001979 EPHX2 Epoxide hydrolase 2, cytoplasmic 1.54 0.845  1.16 0.992  1.17 0.991 
NM_000502 EPX Eosinophil peroxidase 1.44 0.896  1.77 0.709  1.42 0.909 
NM_153002 GPR156 G protein-coupled receptor 156 2.00 0.575  6.30 0.013  12.81 0.000 
NM_002083 GPX2 Glutathione peroxidase 2 (gastrointestinal) -1.05 1.000  1.59 0.814  1.14 0.994 
NM_002084 GPX3 Glutathione peroxidase 3 (plasma) 1.56 0.833  1.67 0.769  1.54 0.844 
NM_001509 GPX5 Glutathione peroxidase 5 (epididymal androgen-related   protein) 1.18 0.988  -3.08 0.200  -2.03 0.559 
NM_015696 GPX7 Glutathione peroxidase 7 -3.61 0.121  1.70 0.752  1.09 0.998 
NM_015553 IPCEF1 Interaction protein for cytohesin exchange factors 1 3.81 0.100  6.47 0.012  12.19 0.000 
NM_006121 KRT1 Keratin 1 1.90 0.633  1.41 0.911  1.62 0.800 
NM_006151 LPO Lactoperoxidase 2.83 0.255  1.33 0.945  4.99 0.036 
NM_000250 MPO Myeloperoxidase 2.60 0.321  4.78 0.043  2.23 0.461 
NM_000265 NCF1 Neutrophil cytosolic factor 1 1.19 0.987  1.86 0.656  1.57 0.825 
NM_000433 NCF2 Neutrophil cytosolic factor 2 1.18 0.989  1.75 0.721  1.62 0.797 
NM_003551 NME5 Non-metastatic cells 5, protein expressed in (nucleoside- diphosphate kinase) 1.23 0.979  1.51 0.862  1.20 0.985 
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   CTMIO  H2O2  CTMIO + H2O2 
GenBank 
Accession No. 
Gene 
Symbol Description Fold Change P-value 
 
Fold Change P-value 
 
Fold Change P-value 
NM_000625 NOS2 Nitric oxide synthase 2, inducible 1.30 0.959  1.76 0.716  1.78 0.699 
NM_024505 NOX5 NADPH oxidase, EF-hand calcium binding domain 5 1.60 0.808  1.37 0.932  1.09 0.999 
NM_002452 NUDT1 Nudix (nucleoside diphosphate linked moiety X)-type motif 1 -1.31 0.953  -1.55 0.837  -1.21 0.982 
NM_020820 PREX1 Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 3.26 0.169  2.19 0.482  4.69 0.046 
NM_006093 PRG3 Proteoglycan 3 -1.19 0.988  -1.22 0.981  1.59 0.817 
NM_000962 PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) 1.91 0.624  1.47 0.884  2.35 0.410 
NM_000963 PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 7.70 0.005  2.70 0.289  2.88 0.243 
NM_012293 PXDN Peroxidasin homolog (Drosophila) 1.26 0.972  1.07 0.999  1.56 0.832 
NM_144651 PXDNL Peroxidasin homolog (Drosophila)-like 9.80 0.001  2.81 0.261  2.69 0.292 
NM_003102 SOD3 Superoxide dismutase 3, extracellular 1.82 0.676  -1.01 1.000  1.08 0.999 
NM_080725 SRXN1 Sulfiredoxin 1 1.43 0.905  2.09 0.528  1.54 0.847 
NM_000547 TPO Thyroid peroxidase 1.10 0.998  3.11 0.193  3.26 0.168 
NM_003319 TTN Titin 1.47 0.882  1.56 0.831  1.32 0.949 
NM_032243 TXNDC2 Thioredoxin domain containing 2 (spermatozoa) -1.26 0.970  2.67 0.299  7.74 0.005 
               Significant results (P<0.1, compared to control) are noted in bold.   
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upregulated (CYBA, DUOX2, GPR156, GPX3, MPO, IPCEF1, PREX1, PTGS2 and 
PXDNL) under all three treatment conditions (Figure 5.1A & B, Table 5.1). 
Genes of Interest and Their Expression Profiles 
Among this group of differentially expressed genes, we further concentrated on 
a subset of 17 genes that were statistically significant (P<0.1) or had a change in 
mRNA expression of at least 2-fold in one of the three treatment groups, compared to 
the DMSO control (Figure 5.2A, Table 5.1). These genes were then grouped 
according to their pattern of expression in response to the various treatments (Figure 
5.2B). In group A, H2O2 treatment induced the greatest change in gene expression, 
which was attenuated in the presence of CTMIO. In particular, there was a 13.3-fold 
(P<0.001) and a 4.8-fold (P<0.05) increase in DUOX2 and MPO expression 
respectively, following exposure to H2O2 (Figure 5.2B, Table 5.1). Combined 
treatment reduced the expression of DUOX2 by 12% and MPO by 54%. In contrast, 
PXDNL in the second group was strongly upregulated (9.8-fold, P<0.01) by CTMIO. 
The expression of GPX5 and PTGS2 in group C were also stimulated by CTMIO 
treatment, although the responses were much smaller in magnitude (GPX5, 1.2-fold; 
PTGS2, 7.7-fold). In the CTMIO and H2O2 combined treatment, a decrease in GPX5, 
PTGS2, as well as DGKK expression was observed when compared with CTMIO 
alone, suggesting that H2O2 represses the expression of these genes. Group D genes 
exhibited the opposite pattern of regulation by these two treatments; a greater 
increase in LPO (5-fold, P<0.05), PREX1 (4.7-fold, P<0.05) and PTGS1 (2.4-fold) 
expression was evident in CTMIO and H2O2 treated cells compared to the CTMIO 
control (Figure 5.2B, Table 5.1). More moderate changes in the expression of these 
genes were present following H2O2 treatment. Group E consisted of genes (CYBA, 
GPR156, IPCEF1, TPO and TXNDC2) which were strongly upregulated by H2O2. A 
corresponding increase in gene expression was observed in the combined treatment. 
Indeed, the change in CYBA (3.4-fold, P<0.1), GPR156 (12.8-fold, P<0.001) and 
IPCEF1 (12.2-fold, P<0.001) expression in the combined treatment can be regarded 
as an additive effect of the two separate treatments (Figure 5.2B, Table 5.1). 
Together these results indicate that oxidative stress and antioxidant related genes are 
differentially regulated by CTMIO and H2O2 in LNCaP cells.  
Relationship between Each Treatment Condition 
Although it appears that CTMIO and H2O2 have opposing effects on gene  
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Figure 5.2. Genes of interest and their expression profiles in response to the various 
treatments 
A – Volcano plot representation of the CTMIO and H2O2 dataset, in which the log ratios (log2 
fold change) are plotted against the significance level (-log10P-values), determined using the 
repeated measures two-way ANOVA and Dunnett’s post hoc test. The vertical black lines 
represent 2-fold change ratios while the horizontal black line indicates a significance level where 
P = 0.1.  Therefore, genes located above the horizontal black line and outside the centre area 
bound by the vertical black lines are statistically significant (P<0.1), with a change in expression 
> 2-fold or < -2-fold. These genes are colour coded according to the treatment group (blue , 
CTMIO; red, H2O2; green, combined treatment) and are listed in Table 5.1. The number of genes 
that were downregulated (to the left of centre) or upregulated (to the right of centre) is shown at 
the top of the plot. B – Significant genes and genes with at least a 2-fold change in expression in 
one of the treatment groups were graphed according to their pattern of expression in response to 
the treatments. Brackets beneath the plot with letters a–e denote the different groups of genes. 
The black dotted line indicates a fold change of 1, which is equivalent to that of the DMSO and 
PBS control. Differences between treatment and control were determined using repeated 
measures two-way ANOVA and Dunnett’s post hoc analysis; *P<0.1 and **P<0.05.  
expression, linear regression revealed a slightly positive correlation between these 
two treatments (R2 = 0.393, Figure 5.3A). Notably, a large number of genes in the 
arrays were upregulated upon treatment with CTMIO or H2O2 while only a few 
genes clearly showed opposite regulation by these two compounds (Figure 5.3A). 
When comparing the combined treatment to each individual agent, a stronger 
association was observed with H2O2 (R2= 0.631, Figure 5.3B) than with CTMIO 
(R2= 0.299, Figure 5.3C), suggesting that H2O2 has a greater influence on gene 
expression in the combined treatment. 
Expression of Genes of Interest in Prostate Cell Lines and Tissue Samples 
Hierarchical clustering was used to group genes and treatment conditions 
according to their similarities in levels of gene expression. Relationships between 
treatment conditions and between expression of the genes are summarised as 
dendrograms, in which the length and subdivision of the branches reflect the 
relatedness of each group (Figure 5.4A). Gene expression patterns were highly 
similar across all three treatment groups, with the majority of genes being 
upregulated. However, downregulation of the DGKK and GPX5 sub-cluster was 
observed following exposure to CTMIO and the combined treatment. GPX7 was also 
downregulated, but in response to H2O2 alone (Figure 5.4A). 
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Figure 5.3. Comparing gene expression levels between the different experimental conditions 
using linear regression analysis 
A positive correlation was observed between the treatment groups on each graph; A – CTMIO 
treatment versus H2O2 treatment, B – combined treatment versus H2O2 treatment and C – 
combined treatment versus CTMIO treatment. The equation for the line of best fit (y = mx + b) 
and the correlation coefficient squared (R2) is shown for each graph. Lines of best fit represent 
linear regression analyses of the two treatment groups being compared, while the R2 value 
measures the percentage of variation in the y variable which can be attributed to variation in the x 
variable. Genes in the upper right quadrant of the plot are upregulated in both treatments, 
whereas those in the lower left quadrant are downregulated in both treatments. Genes in the 
upper left and the lower right quadrants show opposite regulation between the two treatments. 
To examine the expression profiles of the genes of interest in prostate cell lines 
and tissue samples, analysis was undertaken of previously reported microarray 
datasets again using hierarchical clustering. In the Zhao et al. dataset (Zhao et al., 
2005a) composed of androgen responsive cell lines (LNCaP, LAPC-4, MDA PCa 2a, 
MDA PCa 2b and 22Rv1) which express the androgen receptor (AR), and androgen 
insensitive cell lines (PC-3, PPC-1 and DU-145) which lack AR, separate clustering 
was observed for the two groups (Figure 5.4B). Genes were generally downregulated 
across androgen insensitive cells but upregulated across androgen sensitive cells, 
suggesting that similar transcriptional programs are shared within each group of cells 
but not between groups.  However, PREX1, CYBA, MPO, SRXN1 and CCL5 
exhibited varied expression which did not correlate with AR status. In LNCaP cells, 
the model system used in our study, moderate to high levels of PTGS2, PTGS1, 
MPO, SRXN1, CCL5 and GPX7 were detected; PREX1 was the only gene 
downregulated and intermediate levels of CYBA were expressed. The expression of 
the remaining 8 genes of interest could not be determined in this dataset, as there 
were no probes for these genes in the microarray chip used.  
Prostate tissue samples in the Varambally et al. dataset (Varambally et al., 
2005) were also categorised into two major clusters. Clinically localised prostate 
cancer (P1–P5) clustered with benign prostate tissues (N1–N4) on one main branch 
of the dendrogram, while hormone-refractory, metastatic prostate cancer tissues 
(W1–W4) clustered on the other main branch, suggesting that the gene expression 
profile of clinically localised prostate cancer more closely resembles that of benign 
prostate than that of metastatic prostate cancer (Figure 5.4C). Genes were frequently 
upregulated across clinically localised prostate cancer and benign prostate tissues.
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Figure 5.4. Expression patterns of genes of interest in the CTMIO and H2O2 dataset and in 
publicly available datasets 
Two-dimensional hierarchical clustering was applied to prostate cancer gene expression data 
from A – CTMIO and H2O2 dataset, B – Zhao et al. dataset of androgen sensitive (LNCaP, 
LAPC-4, MDA PCa 2a, MDA PCa 2b and 22Rv1)and androgen insensitive (PC-3, PPC-1 and 
DU-145)cell lines, and C – Varambally et al. dataset of benign prostatic tissues (N1–N4) and 
tumour samples (clinically localised prostate cancer, P1–P5; metastatic prostate cancer, W1–
W4). Each row represents a specific gene and each column represents an individual sample or 
experimental condition. Data presented in A are a measure of relative gene expression in each 
experimental condition compared to the control. In B and C, the data were normalised so that the 
mean expression level of the genes across samples equalled zero and the standard deviation 
equalled 1. Red represents high gene levels and green represents low or absent gene levels, 
relative to the median for that gene across all the samples. Therefore, black refers to intermediate 
gene levels. Dendrograms depict similarity in gene expression patterns across the experimental 
samples/conditions (top) and between the genes (left).  
Although in some instances (GPR156, PXDNL,LPO, TXNDC2, TPO and GPX5), 
differential gene expression was observed between these two classes. In comparison, 
gene expression in metastatic prostate cancer tissues was less uniform, potentially 
due to differences between individual patient samples, such as tumour grade (Figure 
5.4C). In view of this, analysis of pooled tissue extracts that were included in the 
Varambally study may have provided a more accurate representation of the gene 
expression profiles in metastatic prostate cancer. Nonetheless, careful examination of 
the dataset revealed a relationship between gene expression and prostate cancer 
progression. DUOX2, PTGS2 and CCL5 were expressed at moderate to high levels in 
clinically localised prostate cancer and benign prostate tissues but showed reduced 
expression in metastatic prostate cancer (Figure 5.4C). Hence, the loss of these genes 
may be a useful predictor of prostate cancer progression from clinically localised to 
metastatic disease.  
Functional Analysis of Genes of Interest Using Ingenuity Pathway Analysis 
(IPA)  
To assess the biological functions of the genes of interest, functional analysis 
was undertaken using IPA, a web-based application. Underlying IPA is a wealth of 
information contained in the Ingenuity Knowledge Base, including interactions 
between biological molecules, drugs, and diseases, as well as functional annotations. 
Each relationship or finding originates from scientific evidence reported in peer-
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reviewed journals and biomedical databases. The information collected is manually 
reviewed for accuracy and then structured into ontologies for relevance and 
computation by Ingenuity applications. 
Only biological functions and processes with a Fisher’s exact test score or P-
value below 0.05 and involving at least 5 genes of interest were reported. Seven 
molecular and cellular functions were identified as having a significant association 
with these genes in the CTMIO and H2O2 dataset (Figure 5.5A, Table 5.2). Of these, 
free radical scavenging was the highest ranking functional category (P-value = 1.34 x 
10-11 – 3.68 x 10-3), involving 9 out of the 17 genes of interest. This was not 
surprising, given that oxidative stress and antioxidant defence related PCR arrays 
were used in our experiments. A large number of genes were also involved in small 
molecule biochemistry and in the inflammatory response (Figure 5.5A, Table 5.2). 
Within each of these broad functional categories, genes are further categorised into 
sub-categories according to their specific functions. Seeing as this study has a 
particular focus on oxidative stress, we delved further into biological processes 
relevant to free radical scavenging. Degradation and metabolism of H2O2(P-value 
=1.34 x 10-11, 2.96 x 10-10), together with metabolism of ROS (P-value = 5.27 x 10-8) 
were the top 3 processes significantly associated with our dataset, while conversion 
of H2O2 was the least significant (P-value = 3.68 x 10-3)(Table 5.3). Interestingly, 
CYBA, DUOX2, PREX1, PTGS1, PTGS2 and TPO were classified under both 
metabolism of ROS and synthesis of ROS, suggesting that the sub-categories may 
not be as clearly defined as firstly envisioned but may overlap, in turn affecting the 
interpretation of the biological meaning in the expression data. A possible 
explanation for this could be if synonymous terminology were used to describe the 
literature findings during content acquisition into the knowledge base. 
Genes of interest were also linked to haematological system development and 
function (data not shown) and various diseases and disorders. Gastrointestinal 
disease was the most significant disease associated with the dataset (P-value = 3.07 x 
10-6 – 1.47 x 10-1), followed closely by inflammatory disease (P-value= 5.11 x 10-6 – 
4.97 x 10-2) and immunological disease (P-value = 7.67 x 10-6 – 3.31 x 10-3) (Figure 
5.5B, Table 5.4). Other high ranking diseases and disorders included cancer and 
metabolic disease, which although not as significant, involved a greater number of 
genes.  
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Figure 5.5. Gene ontology significantly associated with the CTMIO and H2O2 dataset 
Molecular and cellular functions (A) and diseases and disorders (B) were identified using IPA 
tools and ranked in order of significance according to the Fisher’s exact test score (P<0.05). 
Results represent the percentage of genes (of the 17 gene subset) involved in each function or 
disease.  
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Table 5.2 Molecular and cellular functions significantly associated with the CTMIO & H2O2 dataset 
 
 
Table 5.3 Processes relevant to free radical scavenging that are significantly associated with genes of interest from the CTMIO and H2O2 dataset 
Free Radical Scavenging Sub-Categories P-value Genes No. Genes 
Degradation of H2O2 1.34 x 10-11 LPO, MPO, PTGS1, PTGS2, TPO 5 
Metabolism of H2O2 2.96 x 10-10 CYBA, DUOX2, LPO, MPO, PTGS1, PTGS2, TPO 7 
Metabolism of ROS 5.27 x 10-8 CCL5, CYBA, DUOX2, LPO, MPO, PREX1, PTGS1, PTGS2, TPO 9 
Metabolism of superoxide 8.69 x 10-5 CYBA, PREX1 2 
Modification of H2O2 2.25 x 10-7 MPO, PTGS1, PTGS2 3 
Reduction of 15- (S) -
hydroperoxyeicosatetraenoic acid 5.12 x 10
-7 PTGS1, PTGS2 2 
Reduction of H2O2 3.98 x 10-5 PTGS1, PTGS2 2 
Catabolism of H2O2 7.59 x 10-7 MPO, PTGS1, PTGS2 3 
Synthesis of ROS 1.20 x 10-5 CCL5, CYBA, DUOX2, PREX1, PTGS1, PTGS2, TPO 7 
Biosynthesis of H2O2 1.90 x 10-5 CYBA, DUOX2, PTGS2, TPO 4 
Generation of H2O2 1.10 x 10-3 DUOX2, TPO 2 
Consumption of H2O2 2.21 x 10-3 MPO 1 
Production of ROS 3.37 x 10-3 CCL5, CYBA, PTGS1, PTGS2 4 
Conversion of H2O2 3.68 x 10-3 MPO 1 
Molecular & Cellular Functions P-value No. Genes 
Free radical scavenging 1.34 x 10-11 – 3.68 x 10-3 9 
Small molecule biochemistry 1.34 x 10-11 – 3.68 x 10-3 8 
Tissue development 5.12 x 10-7 – 3.68 x 10-3 5 
Inflammatory response 5.11 x 10-6 – 4.97 x10-2 8 
Cell-cell-signalling & interaction 9.19 x 10-5 – 4.42 x 10-3 6 
Immune cell trafficking 9.19 x 10-5 – 4.42 x 10-5 5 
Cell death & survival  7.38 x 10-4 – 2.3 x 10-1 5 
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Table 5.4 Diseases and disorders significantly associated with the CTMIO & H2O2 dataset 
Diseases & Disorders P-value No. Genes 
Gastrointestinal disease 3.07 x 10-6 – 1.47 x 10-1 6 
Inflammatory disease 5.11 x 10-6 – 4.97 x 10-2 5 
Immunological disease 7.67 x 10-6 – 3.31 x 10-3 6 
Endocrine system disorders 1.07 x 10-5 – 2.21 x 10-3 7 
Cardiovascular disease 3.36 x 10-5 – 1.00 x 10-1 5 
Cancer 3.98 x 10-5 – 6.03 x 10-2 12 
Metabolic disease 2.51x 10-4 – 4.42 x10-3 8 
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Interaction between the Genes of Interest and Upstream and Downstream 
Molecules 
We next investigated how the 17 genes of interest interacted with each other 
and with upstream and downstream molecules in the context of known biological 
responses and regulatory networks. This was achieved by mapping the gene 
identifier of each gene to its corresponding gene object in the Ingenuity Knowledge 
Base. These so-called focus genes were then used as the starting point to generate 
biological networks. Due to the potentially large return of positive ‘hits’, the search 
for connections between genes were limited mostly to direct interactions, with a 
maximum of 10 molecules being added to the network in each growth step. The 
output from the network analysis is displayed graphically as nodes (genes) with 
edges (the biological relationship between the nodes).  
Although there were relatively few interactions between the focus genes 
themselves, a number of upstream regulators formed common nodes between these 
genes. STAT1, TP53andSP3 were involved in transcriptional regulation of PTGS1, 
PTGS2, DUOX2, CCL5 and PREX1 expression (Figure 5.6). However, it is likely 
that SP3 exists higher up the signalling cascade compared to STAT1 and TP53, as it 
acted upon both these proteins, while STAT1 and TP53 interacted mutually with 
each other. Likewise, MKL1 and MKL2 are known to regulate other transcription 
factors (TAL1, CBFB and CEBPE) in addition to focus genes (CCL5 and CYBA). By 
regulating these transcription factors, MKL1 and MKL2 indirectly control MPO and 
PTGS2 expression (Figure 5.6). Alternatively, transcription regulators may work 
through other molecules, such as the peptidase LTF and the enzyme PRDX2 in order 
to activate proteins of interest (MPO and SRXN1). Together, these results suggest 
that SP3, MKL1 and MKL2 play a central role in the regulation of focus genes from 
the CTMIO and H2O2 dataset.   
5.3.2 DCTEIO and H2O2 Dataset 
Differences in Gene Expression in Response to DCTEIO H2O2 and the 
Combined Treatment between the Various Treatments 
LNCaP cells were also exposed to 100 µM of the nitroxide DCTEIO (a 
CTMIO derivative) together with 500 µM H2O2, using the same treatment regime 
described for CTMIO and H2O2 in Section 4.3.1. A comparative analysis of gene 
expression in cells treated with the combined treatment to cells treated with H2O2 or
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(Figure 5.6, see over) 
 Chapter 5:Gene Expression Profiling 132 
Figure 5.6. A functional network implicated by the CTMIO and H2O2 dataset 
Network analysis was performed using IPA and shows the interactions between genes of interest 
(focus genes) and upstream and downstream molecules. Nodes represent genes, with their shape 
representing the functional class of the gene product (see legend). The biological relationship 
between two nodes is depicted as an edge (line) with labels (see legend). All edges are supported 
by at least one published reference, or from canonical information stored in the Ingenuity 
Knowledge Base. Genes that are coloured (blue, focus genes; pink, transcription factors; green, 
downstream molecules) are key players in the network or those from the dataset with the most 
significant fold change.  
DCTEIO alone was then performed using oxidative stress and antioxidant defence 
PCR arrays. In total, 41 genes out of the 84 present on the arrays showed at least a 
1.5-fold change in response to these treatments. Only 8 genes were unique to one of 
the three treatment groups, indicating that a relatively small number of genes were 
different between the treatments (Figure 5.7A). Of the 6 genes induced by DCTEIO 
but not H2O2 or the combined treatment, 5 were downregulated (GPX4, GSR, GSS, 
NCF1 and SOD3) and 1 was upregulated (TTN) (Figure 5.7A & B, Table 5.5). 
Another 2 genes (ANGPTL7 and SGK2) were uniquely expressed in cells exposed to 
the combined treatment. However, no genes were specifically induced by H2O2 
alone. 
Looking at overlapping gene expression between the different treatments, we 
found 3 genes (DUOX1, EPHX2 and PREX1) common to both the DCTEIO and 
combined treatment (Figure 5.7A & B, Table 5.5). In contrast, nearly five times this 
number of genes were mutually expressed by cells exposed to H2O2 and the 
combined treatment. Of these, 8 (CYGB, GPX2, GPX5, GPX7, LPO, NOS2, PRNP 
and TXNRD1) were upregulated and 6 (ALB, FOXMI, GTF2I, NUDT1, PNKP and 
PXDN) were downregulated. An additional 16 genes (APOE, CYBA, DGKK, 
DUOX2, DUSP1, GPR156, IPCEF1, KRT1, MBL2, MPO, PTGS1, PXDNL, 
SCARA3, SFTPD, SRXN1 and TPO) were expressed in all three treatment groups 
(Figure 5.7A & B, Table 5.5). Together these findings suggest that there is greater 
similarity between the combined treatment and H2O2, than between the combined 
treatment and DCTEIO. 
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Figure 5.7. A global view of the DCTEIO and H2O2 dataset 
A – The Venn diagram shows the number of oxidative stress or antioxidant related genes in 
common, or uniquely expressed by each treatment (DCTEIO, green; H2O2, orange; the combined 
treatment, purple) when compared to the expression of the DMSO and PBS control group. Only 
genes from the PCR array with at least a 1.5-fold change in expression were included. PCR 
arrays were repeated three times from treatments performed on three separate occasions. B – 
Genes were either similarly or differentially regulated by the three treatments as depicted by the 
colour map (blue, downregulation; orange, upregulation; white, no change in gene expression, 
that is a fold change ≥ -1.5 or ≤ 1.5). 
Genes of Interest and Their Expression Profiles 
Of these differentially expressed genes, a subset of 27 genes that were 
statistically significant (P<0.1) or had a change in mRNA expression of at least 2-
fold in one of the treatment groups, were chosen for downstream expression and 
functional analyses (Figure 5.8A, Table 5.5). Genes with similar expression profiles 
were grouped together, resulting in 5 different groups. In group A, there was a 
progressive decrease in gene expression following treatment with DCTEIO, H2O2 
and the combined treatment. This was particularly evident with ALB and SCARA3, 
which showed baseline changes in response to DCTEIO, a 3-fold (P<0.1) and 2.2-
fold downregulation with H2O2 treatment and a further decrease with the combined 
treatment to 3.6-fold (P<0.05) and 3-fold (P<0.1), respectively (Figure 5.8B, Table 
5.5). In contrast, H2O2 strongly upregulated the expression of group B genes, 
including CYBA (4.8-fold, P<0.01), DUOX2 (11.8-fold, P<0.0001), LPO (7.3-fold, 
P<0.0001), NOS2 (6.4-fold, P<0.01) and TPO (31.9-fold, P<0.0001). These genes 
were also stimulated by the combined treatment, although to a lesser extent, 
suggesting that gene expression is attenuated in the presence of DCTEIO (Figure 
5.8B, Table 5.5). Group C genes exhibited the opposite pattern of regulation by these 
two treatments; a greater increase in GPX5 (3.8-fold, P<0.05) GPX7 (25.1-fold, 
P<0.0001), MPO (81.6-fold, P<0.0001) and PTGS1 (7.5-fold, P<0.0001) expression 
was observed in DCTEIO and H2O2 treated cells compared to the H2O2 control, 
while moderate changes in the expression of these genes were present following 
DCTEIO treatment. Group D consisted of genes (IPCEF1, KRT1, PREX1 and SGK2) 
which were also upregulated in response to DCTEIO. A corresponding rise in gene 
expression was noted in the combined treatment, suggesting that DCTEIO has a 
greater impact on gene expression in the combined treatment compared to 
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Table 5.5 Subset of oxidative stress and antioxidant related genes from the DCTEIO and H2O2 dataset with at least a 1.5-fold change in expression in one of 
the treatment groups 
   DCTEIO  H2O2  DCTEIO + H2O2 
GenBank 
Accession No. 
Gene 
Symbol Description Fold Change P-value  Fold Change P-value  Fold Change P-value 
NM_000477 ALB Albumin -1.24 0.954  -3.00 0.089  -3.58 0.038 
NM_021146 ANGPTL7 Angiopoietin-like 7 1.04 1.000  -1.29 0.927  -1.63 0.665 
NM_000041 APOE Apolipoprotein E -2.59 0.163  2.14 0.325  1.66 0.642 
NM_000101 CYBA Cytochrome b-245, alpha polypeptide 1.68 0.626  4.76 0.008  2.23 0.284 
NM_134268 CYGB Cytoglobin -1.46 0.805  2.87 0.108  2.60 0.163 
NM_001013742 DGKK Diacylglycerol kinase, kappa 1.64 0.661  1.62 0.674  -1.56 0.722 
NM_175940 DUOX1 Dual oxidase 1 -1.68 0.621  -1.02 1.000  -1.51 0.769 
NM_014080 DUOX2 Dual oxidase 2 3.08 0.079  11.75 0.000  9.80 0.000 
NM_004417 DUSP1 Dual specificity phosphatase 1 -1.70 0.609  2.87 0.109  2.79 0.121 
NM_001979 EPHX2 Epoxide hydrolase 2, cytoplasmic -1.67 0.636  1.36 0.884  -3.72 0.032 
NM_021953 FOXM1 Forkhead box M1 -1.32 0.909  -2.17 0.312  -2.20 0.298 
NM_153002 GPR156 G protein-coupled receptor 156 -1.98 0.409  -13.33 0.000  3.16 0.071 
NM_002083 GPX2 Glutathione peroxidase 2 (gastrointestinal) 1.01 1.000  1.87 0.483  1.72 0.589 
NM_002085 GPX4 Glutathione peroxidase 4 (phospholipid hydroperoxidase) -1.66 0.642  -1.20 0.972  -1.21 0.968 
NM_001509 GPX5 Glutathione peroxidase 5 (epididymal androgen-related   protein) 1.32 0.913  1.79 0.537  3.78 0.029 
NM_015696 GPX7 Glutathione peroxidase 7 -1.05 1.000  15.94 0.000  25.05 0.000 
NM_000637 GSR Glutathione reductase -1.60 0.690  -1.27 0.942  -1.33 0.903 
NM_000178 GSS Glutathione synthetase -1.54 0.742  -1.33 0.901  -1.27 0.940 
NM_001518 GTF2I General transcription factor IIi -1.35 0.893  -1.81 0.527  -1.80 0.534 
NM_015553 IPCEF1 Interaction protein for cytohesin exchange factors 1 3.39 0.050  2.03 0.380  4.56 0.010 
NM_006121 KRT1 Keratin 1 1.98 0.414  1.60 0.691  2.03 0.384 
NM_006151 LPO Lactoperoxidase -1.24 0.953  7.25 0.000  6.88 0.001 
NM_000242 MBL2 Mannose-binding lectin (protein C) 2, soluble -7.23 0.001  -1.70 0.607  -2.04 0.377 
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   DCTEIO  H2O2  DCTEIO + H2O2 
GenBank 
Accession No. 
Gene 
Symbol Description Fold Change P-value  Fold Change P-value  Fold Change P-value 
NM_000250 MPO Myeloperoxidase 4.25 0.015  46.29 0.000  81.61 0.000 
NM_000265 NCF1 Neutrophil cytosolic factor 1 -2.10 0.345  -1.43 0.828  -1.29 0.931 
NM_000625 NOS2 Nitric oxide synthase 2, inducible -1.45 0.815  6.41 0.001  5.40 0.004 
NM_002452 NUDT1 Nudix (nucleoside diphosphate linked moiety X)-type motif 1 -1.48 0.793  -1.86 0.490  -1.66 0.643 
NM_007254 PNKP Polynucleotide kinase 3'-phosphatase -1.13 0.992  -1.90 0.460  -2.03 0.384 
NM_020820 PREX1 Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 2.00 0.399  1.34 0.899  2.20 0.296 
NM_183079 PRNP Prion protein 1.20 0.971  1.83 0.509  1.77 0.554 
NM_000962 PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) -2.66 0.147  1.96 0.421  7.47 0.000 
NM_012293 PXDN Peroxidasin homolog (Drosophila) -1.05 0.999  -1.93 0.444  -1.57 0.714 
NM_144651 PXDNL Peroxidasin homolog (Drosophila)-like -2.14 0.324  -2.17 0.309  -1.89 0.469 
NM_182826 SCARA3 Scavenger receptor class A, member 3 -1.53 0.745  -2.15 0.318  -3.03 0.086 
NM_003019 SFTPD Surfactant protein D -4.63 0.009  -1.82 0.515  -2.07 0.358 
NM_016276 SGK2 Serum/glucocorticoid regulated kinase 2 1.28 0.936  1.14 0.990  2.22 0.287 
NM_003102 SOD3 Superoxide dismutase 3, extracellular -1.75 0.567  -1.31 0.917  -1.32 0.909 
NM_080725 SRXN1 Sulfiredoxin 1 -1.56 0.726  2.18 0.304  1.84 0.505 
NM_000547 TPO Thyroid peroxidase 2.88 0.106  31.88 0.000  15.67 0.000 
NM_003319 TTN Titin 1.51 0.769  1.10 0.995  1.17 0.982 
NM_003330 TXNRD1 Thioredoxin reductase 1 1.26 0.947  1.91 0.453  1.87 0.479 
 
Significant results (P<0.1, compared to control) are noted in bold.  
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Figure 5.8. Genes of interest and their expression profiles in response to the various 
treatments 
A – The DCTEIO and H2O2 dataset visualised in the form of a volcano plot. The log2 ratio of 
expression is shown on the x-axis and the negative log10 transformed P-value, from a repeated 
measures two-way ANOVA and Dunnett’s post hoc test, is shown on the y-axis. The vertical 
black lines represent 2-fold change ratios while the horizontal black line indicates a significance 
level where P = 0.1. Therefore, genes located above the horizontal black line and to either the left 
or right of the centre area marked by the vertical black lines are statistically significant (P<0.1), 
with a change in expression < -2-fold (downregulation) or > 2-fold (upregulation). These genes 
are colour coded according to the treatment group (blue, DCTEIO; red, H2O2; green, combined 
treatment) and are listed in Table 5.5. The number of genes that were downregulated or 
upregulated is shown at the top of the plot. B – Significant genes and genes with at least a 2-fold 
change in expression in one of the treatment groups were graphed according to their pattern of 
expression in a panel chart so that the relationship between the large and small fold change 
values could be clearly seen. The top panel of the chart has an axis that shows all the values, 
whereas the bottom panel has an axis that focuses on the small values in the dataset. As a result, 
the large values in this panel have been truncated at 5-fold. The colour gradient at the tops of 
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these truncated values are intended, to demonstrate that they extend beyond 5-fold. Brackets 
beneath the plot with letters a–e indicate the different groups of genes with similar pattern of 
expression in response to the treatments. Differences between treatment and control were 
determined using repeated measures two-way ANOVA and Dunnett’s post hoc analysis; *P<0.1 
and **P<0.05.  
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H2O2 (Figure 5.8B, Table 5.5). In group E, there was a gradual increase in NCF-1 
expression following exposure to DCTEIO, H2O2 and the combined treatment. From 
these results, it can be seen that many of the oxidative stress and antioxidant related 
genes, although differentially responsive, were regulated in a similar manner by both 
H2O2 and the combined treatment.   
Relationship between Each Treatment Condition 
To examine relationships between the three treatments, linear regression 
analyses were performed. DCTEIO showed a direct relationship with H2O2 (R2 = 
0.202, Figure 5.9A), and was positively correlated to the combined treatment (R2 = 
0.144, Figure 5.9C). However, the strongest association was observed between H2O2 
and the combined treatment (R2 = 0.775, Figure 5.9B). 
Expression of Genes of Interest in Prostate Cell Lines and Tissue Samples 
Unsupervised hierarchical clustering was used to group genes and treatment 
conditions on the basis of similarities in gene expression. In the dendrograms shown 
in Figure 5.10A, the length and subdivision of the branches displays the relatedness 
of the treatments (top) and the expression of the genes (left). H2O2 treatment 
clustered separately from DCTEIO, and the combined treatment. Clusters of co-
ordinately expressed genes were also observed, highlighting the relationships 
between treatments. For example, TPO, DUOX2, GPX7 and MPO were upregulated 
in both DCTEIO and the combined treatment but downregulated or not as highly 
expressed in H2O2-treated cells (Figure 5.10A). In contrast, genes in the bottom 
cluster (GPR156, SFTPD, MBL2, EPHX2, NCF1, PXDNL, PNKP, FOXM1, SCARA3 
and ALB) were downregulated across all three treatment groups.  
To examine the expression profiles of the genes of interest in prostate cell lines 
and tissue samples, the same clustering procedure was applied to publicly available 
gene expression datasets. In the Zhao et al. dataset (Zhao et al., 2005a), prostate cell 
lines were divided into two distinct groups. Androgen responsive cell lines (LNCaP, 
MDA PCa 2a, MDA PCa 2b and 22Rv1) clustered on one main branch of the 
dendrogram, while androgen insensitive cell lines (PC-3, PPC-1 and DU-145) plus 
LAPC-4 clustered on the other main branch. PNKP, FOXM1, ALB, EPHX2, GPX7 
and SFTPD were expressed at high levels in androgen sensitive cells but present at 
very low levels in androgen insensitive cells. Although expression of AR may have 
accounted for these differences in gene expression, many of the other  
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Figure 5.9. Comparing gene expression levels between the different experimental conditions 
using linear regression analysis 
A positive correlation was observed between the treatment groups on each graph: A – DCTEIO 
treatment versus H2O2 treatment; B – combined treatment versus H2O2 treatment and C – 
combined treatment versus DCTEIO treatment. The equation for the line of best fit (y = mx + b) 
and the correlation coefficient squared (R2) is shown for each graph. Lines of best fit represent 
linear regression analyses of the two treatment groups being compared, while the R2 value 
measures the percentage of variation in the y variable which can be attributed to variation in the x 
variable. Genes in the upper right quadrant of the plot are upregulated in both treatments, 
whereas those in the lower left quadrant are downregulated in both treatments. Genes in the 
upper left and the lower right quadrants show opposite regulation between the two treatments. 
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Figure 5.10. Expression patterns of genes of interest in the DCTEIO and H2O2 dataset and 
in publicly available datasets 
Two-dimensional hierarchical clustering was applied to prostate cancer gene expression data 
from A – DCTEIO and H2O2 dataset, B – Zhao et al. dataset of androgen sensitive (LNCaP, 
LAPC-4, MDA PCa 2a, MDA PCa 2b and 22Rv1) and androgen insensitive (PC-3, PPC-1 and 
DU-145) cell lines, and C – Varambally et al. dataset of benign prostatic tissues (N1–N4) and 
tumour samples (clinically localised prostate cancer, P1–P5; metastatic prostate cancer, W1–
W4). Each row represents a specific gene and each column represents an individual sample or 
experimental condition. Data presented in A are a measure of relative gene expression in each 
experimental condition compared to the control. In B and C, the data were normalised so that the 
mean expression level of the genes across samples equalled zero and the standard deviation 
equalled 1. Red represents upregulation in gene expression and green represents downregulation 
in gene expression, relative to the median for that gene across all the samples. Therefore, black 
represents intermediate gene expression levels. The dendrograms reveal similarity in gene 
expression patterns across the experimental samples/conditions (top) and between the genes 
(left).  
genes showed varied expression across the cell lines, in ways not predicted by their 
AR status. In LNCaP cells, the model system used in our study, moderate to high 
levels of GPX7, MPO, SRXN1, PTGS1, SFTPD, EPHX2, PNKP and FOXM1 were 
detected; APOE, PREX1 and SCARA3 were downregulated and intermediate levels 
of CYBA, DUSP1, MBL2 and ALB were expressed (Figure 5.10B). However, the 
absence of probes for the remaining 10 genes of interest meant that their expression 
could not be determined in this dataset.  
Cluster analysis of the Varambally et al. dataset (Varambally et al., 2005) 
revealed that tissue samples from benign prostate (N1–N4), clinically localised 
prostate cancer (P1–P5)and metastatic prostate cancer (W1–W4) were distributed on 
multiple terminal branches of the dendrogram, suggesting that gene expression 
patterns varied within, and between groups of samples. For instance, CYBA was 
upregulated in N1 and N2, but intermediate or negligible levels of this transcript 
were found in the other benign prostate tissue samples (N3 and N4). Likewise, 
metastatic prostate cancer samples showed both upregulation and downregulation in 
MPO, SRXN1, APOE and KRT1expression, whereas heterogeneous gene expression 
patterns were observed for SFTPD and MBL2 across all tissue samples. Interestingly, 
GPX5 and GPR156 were downregulated in benign prostate tissues but overexpressed 
in clinically localised disease. High levels of these genes were also expressed in a 
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number of metastatic prostate cancer samples, suggesting that an increase or gain in 
expression of GPX5 and GPR156 may be a useful predictor of prostate cancer 
progression in benign tissues. In contrast, for DUOX2, GPX7, DUSP1, EPHX2 and 
SCARA3, higher expression was observed in benign and clinically localised prostate 
cancer tissues compared to metastatic disease. Thus, the loss of these genes may also 
serve as a signature of disease progression, from a benign and clinically localised 
state to more aggressive cancer. 
Functional Analysis of Genes of Interest Using IPA 
With any gene array work, the major cellular and biological themes represented 
by a given dataset needs to be determined. Therefore, functional analysis was 
performed using IPA, on the genes of interest from the DCTEIO dataset. Many 
biological functions or processes were assigned to these genes, but only those with a 
Fisher’s exact test score below 0.05 and involving at least 5 genes of interest were 
considered significant. Free radical scavenging (P-value = 2.62 x 10-14 – 1.17 x 10-3), 
small molecule biochemistry (P-value = 1.41 x 10-13 – 1.44 x 10-3) and amino acid 
metabolism (P-value = 5.00 x 10-8 – 1.17 x 10-3) were the top 3 molecular and 
cellular functions significantly associated with our dataset (Figure 5.11A, Table 5.6). 
Other high ranking functions such as inflammatory response, cell-to-cell signalling 
and interaction, and cell death and survival involved a similar number of genes (12–
15).  
Within each of these broad functional categories, genes are further categorised 
into sub-categories according to their specific functions. Since this study has a major 
focus on oxidative stress, particular attention was given to biological processes 
relevant to free radical scavenging. Metabolism of ROS was the highest ranking 
process (P-value = 2.62 x 10-14), involving 16 out of the 27 genes of interest (Table 
5.7). A number of these genes (ALB, CYBA, DUOX2, LPO, MBL2, MPO, NCF1, 
NOS2, PREX1, PTGS1, SFTPD and TPO) were also involved in the metabolism of 
H2O2 and superoxide, suggesting that metabolism of ROS largely involved these two 
processes.  
Furthermore, functional analysis identified 6 physiological system 
development and functions that were most significantly associated with the dataset. 
These included haematological system development and function (P-value = 1.23 x 
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Figure 5.11. Gene ontology significantly associated with the DCTEIO and H2O2 dataset 
Molecular and cellular functions (A), physiological system development and function (B) and 
diseases and disorders (C) were identified using IPA tools and ranked in order of significance 
according to the Fisher’s exact test score (P<0.05). Results represent the percentage of genes (of 
the 27 gene subset) involved in each function or disease.  
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Table 5.6 Molecular and cellular functions significantly associated with the DCTEIO & H2O2 dataset 
Molecular & Cellular Functions P-value No. Genes 
Free radical scavenging 2.62 x 10-14 – 1.17  x 10-3 16 
Small molecule biochemistry 1.41 x 10-13 – 1.44 x 10-3 15 
Amino acid metabolism 5.00 x 10-8 – 1.17 x 10-3 6 
Post-translational modification 5.00 x 10-8 – 1.17 x 10-3 8 
Inflammatory response 5.65 x 10-7 – 3 80 x 10-2 15 
Cell signalling 1.03 x 10-6 – 3.90 x 10-4 10 
Embryonic development 1.92 x 10-6 – 1.17 x 10-3 7 
Organ development 1.92 x 10-6 – 1.05 x 10-2 7 
Organismal development 1.92 x 10-6 – 1.50 x 10-3 8 
Tissue development 1.92 x 10-6 – 1.17 x 10-3 7 
Energy production 2.50 x 10-6 – 1.17 x 10-3 5 
Organ morphology 3.16 x 10-6 – 3.51 x 10-3 9 
Molecular transport 3.72 x 10-6 – 1.33 x 10-3 11 
Lipid metabolism 3.96 x 10-6 – 1.44 x 10-3 10 
Tissue morphology 1.05 x 10-5 – 1.27 x 10-3 10 
Cellular compromise 1.19 x 10-5 – 1.17 x 10-3 5 
Cellular function & maintenance 1.27 x 10-5 – 2.24 x 10-3 8 
Cellular movement 5.29 x 10-5 – 3.46 x 10-2 8 
Immune cell trafficking 5.29 x 10-5 – 2.06 x 10-3 9 
Antimicrobial response 5.91 x 10-5 – 1.42 x 10-4 6 
Humoral immune response 5.91 x 10-5 – 1.05 x 10-2 6 
Cell-to-cell signalling & interaction 1.28 x 10-4 – 2.34 x 10-3 12 
Cell death & survival 1.57 x 10-4 – 1.05 x 10-2 15 
Drug metabolism 2.02 x 10-4 – 1.17 x 10-3 5 
Cellular growth & proliferation 8.12 x 10-4 – 1.17 x 10-3 7 
Cellular development 1.17 x 10-3 – 2.23 x 10-1 5 
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Table 5.7 Processes relevant to free radical scavenging that are significantly associated with genes of interest from the DCTEIO and H2O2 dataset 
Free Radical Scavenging Sub-Categories P-value Genes No. Genes 
Metabolism of ROS 2.62 x 10-14 ALB, APOE, CYBA, CYGB, DUOX2, DUSP1, LPO, MBL2, MPO, NCF1, NOS2, PNKP, PREX1, PTGS1, SFTPD, TPO 16 
Metabolism of H2O2 1.41 x 10-13 ALB, CYBA, DUOX2, LPO, MBL2, MPO, NCF1, PTGS1, SFTPD, TPO 10 
Metabolism of superoxide 5.72 x 10-9 CYBA, NCF1, NOS2, PREX1 4 
Synthesis of ROS 1.81 x 10-10 ALB, APOE, CYBA, DUOX2, DUSP1, MBL2, NCF1, NOS2, PNKP, PREX1, PTGS1, SFTPD, TPO 13 
Biosynthesis of H2O2 5.79 x 10-9 ALB, CYBA, DUOX2, MBL2, NCF1, SFTPD, TPO 7 
Generation of H2O2 1.37 x 10-8 ALB, DUOX2, MBL2, SFTPD, TPO 5 
Generation of ROS 1.04 x 10-6 ALB, CYBA, DUOX2, MBL2, NCF1, SFTPD, TPO 7 
Degradation of H2O2 3.48 x 10-8 LPO, MPO, PTGS1, TPO 4 
Modification of ROS 2.85 x 10-6 CYGB, MPO, PTGS1 3 
Modification of lipid peroxide 3.68 x 10-5 CYGB, PTGS1 2 
Modification of H2O2 1.78 x 10-4 MPO, PTGS1 2 
Quantity of ROS 3.72 x 10-6 APOE, CYBA, LPO, NCF1, NOS2, SFTPD 6 
Conversion of ROS 1.98 x 10-5 CYGB, MPO 2 
Production of superoxide 2.13 x 10-5 APOE, CYBA, NCF1, NOS2, SFTPD 5 
Production of ROS 5.25 x 10-5 APOE, CYBA, NCF1, NOS2, PNKP, PTGS1, SFTPD 7 
Formation of ROS 9.97 x 10-5 CYBA, NCF1, NOS2, PREX1 4 
Catabolism of H2O2 3.90 x 10-4 MPO, PTGS1 2 
Peroxidation of monohydroperoxy-lanoleic acid 1.17 x 10-3 CYGB 1 
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Table 5.8 Physiological system development and functions significantly associated with the DCTEIO & H2O2 dataset 
Physiological System Development & Function P-value No. Genes 
Cardiovascular system development & function 1.23 x 10-7 – 8.75 x 10-2 9 
Hematological system development & function 1.23 x 10-7 – 2.06 x 10-3 13 
Respiratory system development & function 1.92 x 10-6 – 1.44 x 10-3 6 
Digestive system development & function 1.05 x 10-5 – 1.05 x 10-2 7 
Hepatic system development & function 6.50 x 10-5 – 2.23 x 10-1 6 
Nervous system development & function 7.13 x 10-5 – 1.21 x 10-3 7 
 
 
Table 5.9 Diseases and disorders significantly associated with the DCTEIO& H2O2 dataset 
Diseases & Disorders P-value No. Genes 
Immunological disease 4.08 x 10-7 – 1.66 x 10-3 12 
Infectious disease 7.69 x 10-7 – 1.63 x 10-3 9 
Respiratory disease 1.46 x 10-6 – 4.92 x 10-2 18 
Cardiovascular disease 3.41 x 10-6 – 1.71 x 10-1 11 
Cancer 5.80 x 10-6 – 3.55 x 10-3 22 
Developmental disorder 9.77 x 10-6 – 2.55 x 10-2 9 
Skeletal & muscular disorders 9.77 x 10-6 – 1.61 x 10-1 11 
Gastrointestinal disease 1.50 x 10-5 – 6.07 x 10-2 11 
Inflammatory disease 1.50 x 10-5 – 3.80 x 10-2 13 
Endocrine system disorders 2.77 x 10-5 – 1.59 x 10-3 8 
Hepatic system disease 3.38 x 10-5 – 6.07 x 10-2 8 
Nutritional disease 3.65 x 10-5 6 
Connective tissue disorders 5.22 x 10-5 – 1.66 x 10-3 9 
Hereditary disorder 7.22 x 10-5 – 2.34 x 10-3 7 
Dermatological diseases & conditions 1.24 x 10-4 – 2.34 x 10-3 7 
Neurological disease 3.41 x 10-4 –  2.23 x 10-3 8 
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Diseases & Disorders P-value No. Genes 
Renal & urological disease 3.90 x 10-4 – 1.75 x 10-1 7 
Metabolic disease 6.41 x 10-4 – 1.59 x 10-3 9 
Psychological disorders 1.05 x 10-3 – 1.17 x 10-3 5 
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10-7 – 2.06 x 10-3), cardiovascular system development and function (P-value = 1.23 
x 10-7 – 8.75 x 10-2) and nervous system development and function (P-value = 7.13 x 
10-5 – 1.21 x 10-3) (Figure 5.11B, Table 5.8). Various diseases and disorders were 
also linked to the genes of interest. When ranked according to P-value, 
immunological disease was the most significant disease (P-value = 4.08 x 10-7 – 1.66 
x 10-3) associated with the dataset (Figure 5.11C, Table 5.9). Alternatively, if ranked 
according to the number of genes involved in each disease or disorder, cancer (22 
genes, 81%), respiratory disease (18 genes, 67%) and inflammatory disease (13 
genes, 48%) would all be ranked higher than immunological disease (12 genes, 
44%). Together, these results demonstrate that genes of interest from the DCTEIO 
dataset are involved in a broad range of cellular functions, systems, diseases and 
disorders. 
Interaction between the Genes of Interest and Upstream and Downstream 
Molecules  
Network analysis was applied to the 27 genes of interest to investigate how 
they interacted with each other and with upstream and downstream molecules in a 
biological context. This was achieved by mapping the genes to the Ingenuity 
Knowledge Base using the IPA software. Relationships between the genes were then 
identified from information contained in the Knowledge Base, an extensive, 
manually curated database of functional interactions extracted from peer-reviewed 
publications.  
NOS2 interacted extensively with the other genes of interest/ gene products 
(MPO, KRT1, SRXN1, DUSP1, PTGS1, CYBA, NCF1, PNKP, PREX1, SCARA3, 
APOE, PXDNL, ALB and LPO) (Figure 5.12). These interactions were mainly 
indirect in nature. In some cases, the shortest path between these genes involved 
other molecules such as the peptidase UCHL5, and the enzymes RAC2 and UBC. By 
interacting with NCF1 and CYBA, ALB and APOE were also linked to the closely 
interrelated NADPH oxidase family of genes. Furthermore, there were a number of 
common upstream regulators branching out to many of our gene targets. Notably, 
TP53 regulated not only PTGS1, APOE, ALB, NOS2 and DUSP1 but also other 
transcription factors including CEBPB, IFI16, FOS and JUN, as well as AR and 
UBC. CEBPB was involved in transcriptional regulation of PTGS1, ALB, SFTPD 
MBL2, NOS2and PNKP expression, and interacted directly with other transcription 
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(Figure 5.12, see over) 
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Figure 5.12. A functional network implicated by the DCTEIO and H2O2 dataset 
Network analysis was performed using IPA and shows the interactions between genes of interest 
(focus genes) and upstream and downstream molecules. Nodes represent genes, with their shape 
representing the functional class of the gene product (see legend). The biological relationship 
between two nodes is depicted as an edge (line) with labels (see legend). All edges are supported 
by at least one published reference, or from canonical information stored in the Ingenuity 
Knowledge Base. Genes that are coloured (green, focus genes; orange, transcription factors; 
fuchsia, downstream molecules) are key players in the network or those from the dataset with the 
most significant fold change. 
factors (SP3, SKP1/SKP1P2 and FOS) and with AR. On the other hand, we also 
observed multiple transcription factors (HNF1B, NKX2-1, SKP1/SKP1P2, CEBPD, 
CEBPB, TP53, IFI16 and FOXM1) converging on genes of interest (ALB and 
SFTPD). Thus, Figure 5.12 paints a complex, yet remarkably connected pathway in 
which NOS2, UBC, TP53 and CEBPB were the key players. Indeed, TP53 and UBC 
may be the most prominent interaction partners in this network because together they 
interacted with nearly all the genes of interest from the DCTEIO and H2O2 dataset. 
5.3.3 Comparisons between the CTMIO and DCTEIO datasets 
Comparison between CTMIO and DCTEIO induced gene expression  
A total of 31 genes were differentially regulated (fold change ≥ 1.5 or ≤ -1.5) 
by the two nitroxides. Six genes were uniquely expressed in cells treated with 
CTMIO (Figure 5.13A). Of these, 4 were upregulated (GPX3, LPO, NOX5 and 
PTGS2) and 2 were downregulated (AOX and GPX7) (Figure 5.13B, Table 5.1). In 
the DCTEIO treatment group, 3 genes were upregulated (DGKK, TPO and TTN) and 
11 were downregulated (APOE, DUOX1, DUSP1, GPX4, GSR, GSS, MBL2, NCF1, 
SCARA3, SFTPD and SRXN1) (Figure 5.13B, Table 5.5). Another 11 genes (CYBA, 
DUOX2, EPHX2, GPR156, IPCEF1, KRT1, MPO, PREX1, PTGS1, PXDNL and 
SOD3) were expressed in both treatments. Thus, the highest number of uniquely 
expressed gene transcripts was found in cells exposed to DCTEIO.   
Comparison between gene expression induced by the nitroxide and H2O2 
combination treatments 
Next, we compared gene expressions in the nitroxide-H2O2 combination 
treatments from both datasets. Seven genes (ALOX12, GPX3, NCF1, NCF2, PRG3, 
PTGS2 and TXNDC2) were upregulated specifically by the CTMIO and H2O2 
treatment (Figure 5.14 A & B). In contrast, there were 18 genes expressed in the 
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Figure 5.13. Comparison between CTMIO and DCTEIO induced gene expression 
A – The numbers shown in each circle of the Venn diagram depict oxidative stress or antioxidant 
related genes uniquely expressed by either the CTMIO (orange) or DCTEIO (purple) treatment 
group, while the number of genes common to both treatments is shown in the overlapping region 
of the diagram. Only genes from the PCR array with at least a 1.5-fold change in expression, 
compared to the DMSO and PBS control were included. PCR arrays were repeated three times 
from treatments performed on three separate occasions. B – Genes were either similarly or 
differentially regulated by the two treatments as depicted by the colour map (blue, 
downregulation; red, upregulation; white, no change in gene expression, that is a fold change ≥ 
1.5 or ≤ -1.5).  
 
Genes CTMIO  DCTEIO 
AOX1   
APOE   
CYBA   
DGKK   
DUOX1   
DUOX2   
DUSP1   
EPHX2   
GPR156   
GPX3   
GPX4   
GPX7   
GSR   
GSS   
IPCEF1   
KRT1   
LPO   
MBL2   
MPO   
NCF1   
NOX5   
PREX1   
PTGS1   
PTGS2   
PXDNL   
SCARA3   
SFTPD   
SOD3   
SRXN1   
TPO   
TTN   
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(Figure 5.14, see over) 
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Figure 5.14. Comparing the expression of genes between the nitroxide and H2O2 
combination treatments 
A – The Venn diagram shows the number of oxidative stress or antioxidant related genes with 
overlapping and non-overlapping expression in the two treatment groups which are represented 
as colour-coded circles (CTMIO and H2O2, orange; DCTEIO and H2O2, green). Only genes from 
the PCR array with at least a 1.5-fold change in expression, compared to the DMSO and PBS 
control were included. PCR arrays were repeated three times from treatments performed on three 
separate occasions. B – Genes were either similarly or differentially regulated by the two 
treatments as depicted by the colour map (blue, downregulation; red, upregulation; white, no 
change in gene expression, that is, a fold change ≥ -1.5 or ≤ 1.5).  
DCTEIO and H2O2 group that were not found in the first group. Of these, 8 were 
upregulated (APOE, CYGB, DUSP1, GPX2, GPX7, PRNP, SGK2 and TXNRD1) and 
10 were downregulated (ALB, ANGPTL7, EPHX2, FOXM1, GTF2I, MBL2, NUDT1, 
PNKP, SCARA3 and SFTPD). Seventeen genes were mutually expressed by the two 
treatment groups. CYBA, DGKK, DUOX2, GPR156, IPCEF1, KRT1, LPO, MPO, 
NOS2, PREX1, PTGS1, SRXN1 and TPO exhibited the same directional response to 
the two treatments, while DUOX1, GPX5, PXDN and PXDNL were differentially 
regulated (Figure 5.14B).  
Comparison between H2O2 induced gene expression from the CTMIO and 
DCTEIO datasets 
Given that the H2O2 treatments from the CTMIO and DCTEIO datasets were 
the same, there should have been a large number of genes in the overlapping region 
of the Venn diagram, and few, if any genes in the non-overlapping areas. A total of 
26 genes were uniquely expressed in the two H2O2 groups (Figure 5.15A). 
Nonetheless, many of these genes showed changes in expression which were not 
significant (Table 5.1 & 5.5). Furthermore, only 3 genes (DGKK, GPR156and 
PXDNL) out of the 16 common to both groups, demonstrated a clear opposite 
regulation (≥ 2-fold or ≤ -2-fold, P<0.05) between the two datasets (Figure 5.15B, 
Table 5.1 & 5.5). Another 4 genes (GPX5, GPX7, NOS2 and TPO) were seemingly 
upregulated to a greater extent in the DCTEIO dataset than in the CTMIO dataset 
(Figure 5.15B, Table 5.1 & 5) but this was due to a reduced DMSO baseline in the 
DCTEIO dataset (data not shown). Only for LPO and MPO was this effect still seen 
after adjusting for differences in the DMSO baseline between the two groups. 
Therefore, if we look only at genes which show a fold change of at least 2-fold with 
a P-value less than 0.1, the H2O2 response in both datasets is in fact quite similar.
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(Figure 5.15, see over) 
 
Genes  H2O2‐C  H2O2‐D
ALB     
ALOX12     
APOE     
CCL5     
CYBA     
CYGB     
DGKK     
DUOX1     
DUOX2     
DUSP1     
EPX     
FOXM1     
GPR156     
GPX2     
GPX3     
GPX5     
GPX7     
GTF21     
IPCEF1     
KRT1     
LPO     
MBL2     
MPO     
NCF1     
NCF2     
NME5     
NOS2     
NUDT1     
PNKP     
PREX1     
PRNP     
PTGS1     
PTGS2     
PXDN     
PXDNL     
SCARA3     
SFTPD     
SRXN1     
TPO     
TTN     
TXNDC2     
TXNRD1     
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Figure 5.15. Comparing the expression of genes induced by the H2O2 treatment from the 
CTMIO and DCTEIO datasets 
A – The Venn diagram shows the number of oxidative stress or antioxidant related genes in 
common, or uniquely expressed by the H2O2 treatment from each dataset (CTMIO dataset, blue; 
DCTEIO dataset, orange) when compared to the expression of the DMSO and PBS control 
group. Only genes from the PCR array with at least a 1.5-fold change in expression were 
included. PCR arrays were repeated three times from treatments performed on three separate 
occasions. B – Genes were either similarly or differentially regulated by the two treatments as 
depicted by the colour map (blue, downregulation; red, upregulation; white, no change in gene 
expression, that is a fold change ≥ 1.5 or ≤ -1.5). Genes in bold demonstrated a clear opposite 
regulation between the two datasets, in response to H2O2 treatment, while genes in red were 
upregulated to a greater extent in the DCTEIO dataset compared to the CTMIO dataset. 
Together these results also indicate that H2O2 treatment is an appropriate internal 
control between the CTMIO and DCTEIO datasets, enabling comparisons to be 
accurately made between the two datasets.  
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5.4 DISCUSSION 
In addition to their role as pro-oxidants within cells, nitroxides have been 
shown to protect against diverse oxidative insults including radiation (Mitchell et al., 
1991; Goffman et al., 1992; Hahn et al., 1992a; Hahn et al., 1992b), cytotoxic drugs 
(Krishna et al., 1991; DeGraff et al., 1994; Monti et al., 1996), and post-ischemic 
reperfusion injury (Gelvan et al., 1991; Samuni et al., 1991b) due to their ability to 
scavenge oxygen free radicals and to inhibit their production (Krishna & Samuni, 
1994; Krishna et al., 1996).  The data presented in chapter 3 indicated that unlike the 
piperidine nitroxides Tempo and Tempol, CTMIO exhibited minimal toxicity in 
prostate cancer cells. Nevertheless, evidence of their protective effects prompted us 
to investigate their potential antioxidant activity in an experimental model of 
oxidative stress.  To this end, LNCaP cells were exposed to H2O2 in the presence or 
absence of the nitroxides CTMIO and DCTEIO. Seventeen oxidative stress and 
antioxidant related genes were identified to be differentially expressed (2-fold 
change, and/or P<0.1) in response to at least one of the three treatment groups (H2O2, 
CTMIO, combined treatment) of the CTMIO and H2O2 dataset when compared to the 
control, while 27 genes of the same pathway were differentially expressed in the 
DCTEIO and H2O2 dataset. Functional analysis revealed these genes to be 
significantly associated with biological functions such as small molecule 
biochemistry, the inflammatory response, cell-cell-signalling and interaction and 
haematological system development and function. Of particular relevance to our 
studies, many of the genes identified (18) have previously reported roles in free 
radical scavenging and biosynthesis.  
Moreover, cancer, inflammatory, immunological, gastrointestinal and 
cardiovascular disease were some of the high-ranking diseases common to both 
datasets. This is in line with the current and prevailing concept that oxidative stress is 
involved in the pathogenesis of many human diseases (Halliwell, 1994; Baynes & 
Thorpe, 1999; Beatty et al., 2000; Dhalla et al., 2000; Finkel & Holbrook, 2000; 
Heitzer et al., 2001; Jenner, 2003; Klaunig & Kamendulis, 2004), because when 
produced in excess, ROS can cause tissue injury. Interestingly, tissue injury itself 
(regardless of the cause) can lead to increased generation of ROS by means of the 
recruitment and activation of inflammatory cells, release of transition metal ions, 
arachidonic acid and haem proteins from damaged cells, and interference with 
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antioxidant defence systems (Halliwell, 1994; Aruoma, 1998; Finkel & Holbrook, 
2000). The resulting oxidative stress could then contribute to a worsening of the 
injury, or it may be irrelevant. Therefore, whether oxidative stress is a primary cause 
or merely a downstream consequence of the disease process remains to be elucidated 
(Baynes & Thorpe, 1999; Jenner, 2003; Andersen, 2004).  
In this discussion we will focus on the functions and interactions of 9 
genes/gene products, namely PTGS1, PTGS2, NOS2, DUOX2, LPO, MPO, CYBA, 
MBL2 and SFTPD, identified to be significantly expressed in response to the H2O2, 
nitroxide or combined treatments from the two datasets (Table 5.10). These genes 
will be discussed in relation to their role in free radical scavenging and biosynthesis 
and in the context of cancer or prostate cancer where applicable.    
PTGS1 and PTGS2 
Prostaglandin-endoperoxide synthase (PTGS), also known as cyclooxygenase 
(COX) is the rate-limiting enzyme in prostaglandin (PG) synthesis and exists as two 
distinct isoforms (Xie et al., 1991). PTGS1 is constitutively expressed in most human 
tissues and mediates normal physiological functions (Pairet & Engelhardt, 1996; 
Hussain et al., 2003b), whereas PTGS2 is largely absent but is rapidly induced by 
pro-inflammatory stimuli such as bacterial endotoxin (O'Sullivan et al., 1992), 
cytokines (Jones et al., 1993), and growth factors (Smith et al., 1996; Dubois et al., 
1998)via reactive oxygen intermediates produced by inflammatory cells (Feng et al., 
1995). During PG synthesis, oxidation of fatty acids results in the generation of 
highly reactive free radicals that can potentially damage biological macromolecules 
(Marnett et al., 1999; Nikolic & van Breemen, 2001). This may explain why high 
intake of unsaturated dietary fat such as arachidonic acid and its precursor, linoleic 
acid (major ingredients of animal fat and many vegetable oils) in the typical western 
diet may be relevant to the pathogenesis of prostate cancer (Giovannucci et al., 1993; 
Godley et al., 1996; Tjandrawinata et al., 1997; Hughes-Fulford et al., 2001). Dietary 
fat may also increase serum androgen levels, thereby increasing prostate cancer risk 
(Ross & Henderson, 1994; Gann et al., 1996; Thompson et al., 2003; Andriole et al., 
2010). Interestingly, some studies have suggested that PTGS2 expression may be 
androgen-regulated (McKanna et al., 1998; Kirschenbaum et al., 2000). However, 
whether an increase in androgen levels leads to an increase in PTGS2 expression 
during the development and progression of prostate cancer is still  
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Table 5.100 Similar and differential pattern of gene expression in response to nitroxides H2O2 and the 
nitroxide-H2O2 combined treatments 
Genes CTMIO Dataset  DCTEIO Dataset 
 CTMIO H2O2 CTMIO + H2O2  DCTEIO H2O2 DCTEIO + H2O2 
PTGS1 ↑ – ↑  ↓ ↑ ↑ 
PTGS2 ↑ ↑ ↑  – – – 
NOS2 – ↑ ↑  – ↑ ↑ 
DUOX2 ↑ ↑ ↑  ↑ ↑ ↑ 
LPO ↑ – ↑  – ↑ ↑ 
MPO ↑ ↑ ↑  ↑ ↑ ↑ 
CYBA ↑ ↑ ↑  ↑ ↑ ↑ 
MBL2 – – –  ↓ ↓ ↓ 
SFTPD – – –  ↓ ↓ ↓ 
↑ upregulation; ↓ downregulation; – no change in gene expression i.e. < 2-fold change 
unknown. Nonetheless data exists showing that PTGS2 is overexpressed in many 
human cancers (Eberhart et al., 1994; Ristimäki et al., 1997; Hida et al., 1998; 
Tucker et al., 1999; Soslow et al., 2000; Ristimäki et al., 2002), including prostate 
cancer (Gupta et al., 2000; Lee et al., 2000a; Madaan et al., 2000; Yoshimura et al., 
2000; Uotila et al., 2001). Furthermore, evidence of its inflammatory (Subbarayan et 
al., 2001), anti-apoptotic (Liu et al., 1998; Hsu et al., 2000) and growth stimulating 
(Tjandrawinata & Hughes-Fulford, 1997; Liu et al., 2002b) effects in prostate cancer 
has implicated a role for this enzyme in the disease process. PTGS2 may also 
contribute to the malignant phenotype through increased production of ROS (Nikolic 
& van Breemen, 2001), decreased E-cadherin expression, matrix-metalloproteinase 
overexpression (Attiga et al., 2000) and by modulating the production of angiogenic 
factors by cancer cells (Tsujii et al., 1998; Masferrer et al., 2000). In contrast, others 
have shown an increase in PTGS2 to protect against oxidative stress and tissue injury 
(Adderley & Fitzgerald, 1999; Shinmura et al., 2000; Dowd et al., 2001) and to 
prevent cell death (Von Knethen & Brüne, 1997; McGinty et al., 2000; Yang et al., 
2000). This apparent paradox in findings can be explained by the fact that a number 
of  PG (PGD2, PGE2, PGF22α and PGI2) and thromboxanes (TXA2) are formed from 
the precursor PGH2, depending on the cell type and the inherent synthetic pathways 
(Vane et al., 1998). Furthermore, not all PG are created equal or have the same 
function (Whitehouse, 2005).  In support of this, Gilroy and colleagues demonstrated 
that PTGS2 may be pro-inflammatory during the early phase of a carrageenin-
induced pleurisy which is associated with maximal PGE2 synthesis, but may aid 
resolution at the later phase by generating an alternative set of anti-inflammatory PG 
(PGD2 and 15deoxyΔ12–14prostaglandin J2) (Gilroy et al., 1999). Likewise, the 
beneficial effects of PTGS2 in late phase preconditioning appear to be mediated by 
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the synthesis of specific PG (PGE2 and/ or PGI2) (Bolli et al., 2002). In our study, we 
found PTGS2 but not PTGS1 to be significantly upregulated in LNCaP cells in 
response to CTMIO. Exposure to H2O2 also stimulatedPTGS2 expression but not to 
the same extent as the nitroxide. While it may be speculated that overexpression of 
PTGS2 could place an additional burden on the antioxidant defences of the cell, 
particularly if basal expression of the enzyme is high, others have demonstrated an 
increase in PTGS2 expression (following the addition of exogenous PGE2) to 
stimulate prostate cancer cell growth (Tjandrawinata et al., 1997). Interestingly, the 
steady-state levels of PTGS2 mRNA began to rise soon after treatment (1–2 hrs) and 
depended upon newly synthesised PGE2, perhaps resulting from changes in local 
cellular PGE2 concentrations. Thus, given the complex pathophysiological role of 
PTGS2, further experiments need to be undertaken to determine whether this enzyme 
elicits protective or detrimental effects in our experimental model. This may be 
achieved by examining the type of PG involved in the PTGS2 response.   
NOS2 
Nitric oxide synthase 2 (NOS2) mRNA level was significantly upregulated in 
response to H2O2 treatment. However, when cells were exposed to H2O2 in the 
presence of DCTEIO, NOS2 expression was slightly attenuated. Interestingly, this 
gene was not differentially expressed in the CTMIO dataset. There are two classes of 
NOS, namely constitutive and inducible. The signal molecule nitric oxide (NO) 
which plays an important role in regulating numerous physiological processes 
including neurotransmission, cell proliferation, smooth muscle contractility and 
platelet reactivity is synthesised on demand for short periods of time (seconds to 
minutes) following enzyme activation of constitutively expressed endothelial or 
neuronal NOS (Moncada & Higgs, 1993; Knowles & Moncada, 1994). In contrast, 
inducible NOS (iNOS or NOS2) is expressed only after cell activation by endotoxins 
or cytokines (Knowles & Moncada, 1994). Once expressed, NOS2 produces large 
amounts of NO for prolonged periods of time (hours to days), which mediates the 
cytotoxic activity of macrophages during host defence and tumour-induced 
immunosuppression (Lejeune et al., 1994; Jenkins et al., 1995). However, high 
concentrations of NO may also lead to nitrosative stress (Groves, 1999; Murphy, 
1999; Klatt & Lamas, 2000), where NO and NO-derived reactive nitrogen species 
can damage DNA (Zhuang et al., 1998; Burney et al., 1999) and modify key 
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signalling molecules such as kinases and transcription factors (Patel et al., 1999; 
Schindler & Bogdan, 2001), as well as proteins involved in mitochondrial respiration 
(Brown, 1999; Beltrán et al., 2000), DNA repair (Wink & Laval, 1994), programmed 
cell death (Kim et al., 2001; Kröncke et al., 2001) and antioxidant defence (Berendji 
et al., 1999; Fujii & Taniguchi, 1999), resulting in the impairment of protein function 
or activity. These cellular events allow DNA damage to accumulate, which is 
necessary for the development and progression of inflammatory diseases and cancer 
(Payne et al., 1999; Jaiswal et al., 2001). Thus, regulated short pulsative synthesis 
versus sustained release of NO differentiates between physiological and 
pathophysiological actions of NO (reviewed in Kröncke et al., 1997). 
The role of NO during tumour development reveals a complex picture. 
Depending on the local concentration of the molecule, NO can induce either 
cytostatic or cytotoxic effects on cancer cells, or stimulate tumour growth by 
promoting angiogenesis (Andrade et al., 1992; Esumi & Tennenbaum, 1994; Jenkins 
et al., 1995; Jansson et al., 1998; Thomsen & Miles, 1998; Gradini et al., 1999; 
Ekmekcioglu et al., 2005). In addition, NO  produced by the tumour may participate 
in tumour-induced  immunosuppression, via antiproliferative or apoptotic effects on 
infiltrating lymphocytes (Lejeune et al., 1994). In the human prostate, NOS2 
expression has been studied using immunohistochemistry, with conflicting results. 
Although it has consistently been found to be expressed at high levels in prostate 
cancer tissues (Klotz et al., 1998; Aaltomaa et al., 2001; Baltaci et al., 2001; Wang et 
al., 2003), reports of NOS2 expression in adjacent normal or benign prostatic tissues 
have ranged from weakly positive staining (Gradini et al., 1999; Aaltomaa et al., 
2001) to not being detected at all (Klotz et al., 1998). Baltaci and colleagues 
extended these studies further to show that like prostate carcinoma samples, high-
grade PIN had more intense NOS2 immunostaining than low-grade PIN samples 
(Baltaci et al., 2001). Stromal macrophages and other inflammatory cells were also 
NOS2 positive (Klotz et al., 1998; Aaltomaa et al., 2000; Aaltomaa et al., 2001). This 
is not surprising considering that NO production in macrophages may provide a 
negative or positive growth signal within the tumour microenvironment (Thomsen & 
Miles, 1998). Not only so, NOS2 staining in prostate cancer biopsies correlated with 
staining for nitrotyrosine, a post-translational protein modification reflecting 
enhanced NO production, indicating that NOS2 is fully active in prostate cancer 
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(Cronauer et al., 2006). Indeed, NO was shown to inhibit AR activity and the 
production of prostate specific antigen in a concentration-dependent manner. 
Furthermore, by inhibiting the proliferation of AR-positive prostate cancer cells more 
efficiently than their AR-negative counterparts, NO may be another factor which 
provides selection pressure for the clonal expansion, and progression of more 
aggressive AR-independent prostate tumours (Cronauer et al., 2006). This would 
explain the correlation found between strong NOS2 expression and poor survival of 
prostate cancer patients (Aaltomaa et al., 2001).    
Molecular cross-talk between NOS and PTGS that may regulate tissue 
homeostasis and contribute to pathophysiological processes is well recognised. 
However, the literature is divided with respect to whether NO activates or inhibits 
prostaglandin production (Di Rosa et al., 1996; Nogawa et al., 1998; Goodwin et al., 
1999; Rahman et al., 2001; Bolli et al., 2002; Shinmura et al., 2002; Uno et al., 
2004). These conflicting observations may be attributed to the divergent effects of 
NO on the two PTGS isoforms (Clancy et al., 2000), and may depend on the local 
environment in which these pleiotropic mediators are produced. Nonetheless, Yu and 
colleagues demonstrated that both  NOS2 and PTGS2 were upregulated by a common 
upstream  pathway (JAK/STAT), which event mediated the cytoprotective effect of 
H2O2 preconditioning (Yu et al., 2012). Transcription of NOS2 is also dependent on 
NF-κB activation (Xie et al., 1994; Taylor et al., 1998; Prabhu et al., 2002), which 
can be regulated by H2O2 and NO (Peng et al., 1995). Thus, it is plausible to suggest 
that NOS2 expression may be regulated by free radicals. Consistent with this notion, 
antioxidant enzymes with activity against H2O2 were found to suppress both NOS2 
expression and NF-κB activation in LPS-stimulated macrophages (Han et al., 2001b). 
Furthermore, these results suggest that H2O2-dependent oxidative stress is involved 
in the transcriptional induction of NOS2 via NF-κB activation. In contrast, NO may 
act as a negative feedback inhibitor of NOS2 protein expression when produced in 
excess, to prevent cells from NO-induced autotoxicity (Han et al., 2001b). 
 Interestingly in our study, NOS2 expression was slightly attenuated when cells 
were exposed to H2O2 in the presence of DCTEIO. Whether this indicates a direct 
antioxidant effect by the nitroxide against H2O2-induced oxidative stress requires 
further investigation. However, it has been proposed that nitroxides attenuate the  
toxic effects of  NO-derived oxidants mainly because of their ability to react rapidly 
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with nitrogen dioxide and carbonate radicals (Augusto et al., 2008). In addition, 
cyclic nitroxides may downregulate NOS2 expression  (Linares et al., 2008). This has 
important implications as tissue injuries associated with inflammatory conditions are 
characterised by the increased production of NO and its derived oxidants 
(Thiemermann, 2003; Radi, 2004).  
Protein oxidation is another potentially damaging event in biological systems 
(Davies, 1987; Stadtman, 1990; Dean et al., 1997; Davies et al., 1999; Hawkins & 
Davies, 2001; Dalle-Donne et al., 2005; Davies, 2005), yet its prevention has 
received relatively little attention. Lam et al. demonstrated that NO and nitroxides 
(including CTMIO) rapidly scavenged protein-derived free radicals (Lam et al., 
2008), and may therefore be efficient protective agents against damage induced by 
these species (Heinecke et al., 1993; Kelman et al., 1994; Savenkova et al., 1994; 
Tschirret-Guth & de Montellano, 1996; Sturgeon et al., 1998; Gebicki & Gebicki, 
1999; Irwin et al., 1999; Luxford et al., 1999; Østdal et al., 1999; Luxford et al., 
2000; Østdal et al., 2002). 
DUOX2 
Dual oxidase 2 (DUOX2) belongs to the NOX family of NADPH oxidases, 
which are homologues of gp91phox, the catalytic subunit of the phagocyte NADPH 
oxidase. Originally described in the thyroid gland where it supplies thyroid 
peroxidase (TPO) with H2O2 to catalyse the synthesis of thyroid hormones (Dupuy et 
al., 1999; De Deken et al., 2002; Ameziane-El-Hassani et al., 2005; Wang et al., 
2005), it has since been detected at high levels in many other tissues including the 
airways (Forteza et al., 2005), salivary glands (Geiszt et al., 2003), gastrointestinal 
tract (Dupuy et al., 2000; El Hassani et al., 2005) and prostate (Gerson et al., 2000; 
Geiszt et al., 2003; El Hassani et al., 2005; Forteza et al., 2005; Wang et al., 2005). 
This extra-thyroid expression pattern has prompted considerable interest in 
examining the potential innate immune function of DUOX2 on mucosal surfaces, as 
a source of extracellular H2O2 that can support the antimicrobial activity of 
lactoperoxidase (LPO) (Gerson et al., 2000; Geiszt et al., 2003; Rada & Leto, 2008). 
In addition to this catalytic activity which is related to its NADPH oxidase domain, 
DUOX2 possesses a peroxidase domain, suggesting that it serves not only as the 
source of H2O2 but can also use the H2O2 generated as a substrate for further 
reactions (Bedard & Krause, 2007). While it is not clear whether mammalian DUOX 
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proteins have appreciable peroxidase activity, in the nematode Caenorhabditis 
elegans, this enzyme uses its dual functionality to catalyse the cross-linking of 
tyrosine residues in extracellular matrix proteins involved in cuticle formation 
(Edens et al., 2001). Thus, the DUOX enzymes are ideally suited to performing 
oxidative modifications of extracellular matrix proteins or other extracellular 
molecules (Lambeth, 2002).  
Elevated DUOX1 and DUOX2 expression in hepatocellular carcinoma tissues 
was correlated with poorer recurrence-free survival and overall survival after 
hepatectomy (Lu et al., 2011). Conversely, high levels of these enzymes were 
associated with a better prognosis in thyroid carcinoma (Pulcrano et al., 2007). 
Others have reported frequent down regulation or transcriptional silencing of both 
DUOX1 and DUOX2 in lung cancer, which is predominantly due to aberrant 
hypermethylation within the promoter region of these genes (Luxen et al., 2008). 
Therefore, DUOX1 and DUOX2 may function differently, as either an oncogene or 
tumour suppressor gene, depending on the type of tumour. The LNCaP cell line 
examined in our study expresses very low levels of both these genes (Juhasz et al., 
2009). However, we demonstrated that DUOX2 was upregulated to a similar extent 
(12 to 13-fold) in response to the CTMIO, H2O2 and the CTMIO and H2O2 combined 
treatment. In the DCTEIO dataset, higher DUOX2 expression was observed in the 
H2O2 and combined treatment than in the DCTEIO treatment. Nonetheless, the 
induction of DUOX2 by H2O2 was slightly attenuated in the presence of the 
nitroxide. An increase in DUOX2 expression may lead to increased TPO and LPO 
activity since DUOX2 is an essential H2O2-generating partner of these proteins. This 
may in turn lead to an increase in oxidative stress as LPO is also capable of 
generating free radicals. On the other hand, an increase in the activity of these 
enzymes can be viewed as an antioxidant response elicited by the cells following 
treatment to eliminate excess H2O2. At present, it can only be speculated what the 
results from our study indicate because the function of DUOX1 and DUOX2 in the 
normal prostate and in malignancy remains unclear. Nonetheless there is at least one 
study demonstrating that ROS levels in PC-3 cells are constitutively maintained by 
DUOX enzymes, and these ROS positively regulate AKT signalling through 
inactivating phosphatases, resulting in increased resistance to apoptosis (Pettigrew et 
al., 2012). A challenge for future investigations will be to determine which 
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biomolecules are targeted for oxidation by DUOX2. This would be of interest as 
oxidation of redox-sensitive cysteine residues has the potential to alter the structure 
and function of key proteins such as transcription factors, molecular chaperones, 
cytoskeletal proteins and protein tyrosine phosphatases, and thereby regulate signal 
transduction pathways and gene expression that control various cellular processes, 
including response to growth factors and hormones, induction and maintenance of 
the transformed phenotype, programmed cell death and cellular senescence, and 
oxidative stress (Rhee et al., 2000; Finkel, 2001, 2003; Barford, 2004). 
LPO 
Significant upregulation in LPO expression was observed in response to H2O2 
only treatment and to the nitroxide and H2O2 combined treatments. CTMIO alone 
also caused a rise in LPO expression whereas no change in expression was seen in 
response to DCTEIO. In secreted fluids such as milk, tears and saliva (Morrison & 
Allen, 1966), LPO catalyses the oxidation of thiocyanate ion (SCN-) by H2O2, 
producing hypothiocyanite (OSCN-)which has antimicrobial activity (Aune & 
Thomas, 1977; Hoogendoorn et al., 1977; Thomas et al., 1980). Studies have 
demonstrated that the combination of LPO, H2O2, and SCN- is much more effective 
than H2O2 alone as an inhibitor of bacterial metabolism and growth (Carlsson et al., 
1984; Thomas et al., 1994). Furthermore, by converting H2O2 to a less-potent 
oxidizing agent, this peroxidase-SCN-H2O2 system protects host tissues against the 
toxicity of H2O2(Hänström et al., 1983; Tenovuo & Larjava, 1984). However, LPO 
may also catalyse the activation of carcinogens such as aromatic and heterocyclic 
amines, in breast ductal epithelial cells, to produce reactive species that bind to 
DNA, forming DNA adducts (Gorlewska-Roberts et al., 2004). In like manner, 
estrogens can be oxidised by LPO through two one-electron reaction steps to free 
radicals (Sipe et al., 1994; Ueda et al., 2001), which can be further oxidised to DNA-
damaging quinones (Cavalieri et al., 1997; Ghibaudi et al., 2000). Alternatively, 
estrogenic radicals may interact with other chemical species present in the cellular 
environment, such as NADH and glutathione, causing their oxidation by acting as a 
redox cycling intermediate between them and the LPO enzyme (Sipe et al., 1994; 
Ueda et al., 2001; Løvstad, 2006). The ability of LPO to thus propagate a radical 
chain reaction, leading to the formation of superoxide and H2O2, could explain the 
hydroxyl radical-induced DNA base lesions found in breast (Malins et al., 1993) and 
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prostate cancer tissues (Malins et al., 1997), suggesting that estrogens can act as 
tumour initiators by promoting a genotoxic event. In the absence of estrogens, LPO 
catalysed oxidation of thiol compounds to thiol radicals is strongly peroxide 
dependent, with either exogenous H2O2 or thiol-derived peroxides driving the 
reaction (Mottley et al., 1987). This could be of significance when applied to our 
experimental model where LNCaP cells were exposed to H2O2, as excess amounts of 
H2O2 could potentially enhance the generation of thiol radicals, resulting in oxidative 
stress. However, LPO is also known to suppress the production of the pro-
inflammatory cytokine IL-8 in human intestinal cells by eliminating 
H2O2(Matsushita et al., 2008).Moreover, SCN- in the presence of LPO protects cells 
against the harmful effects of H2O2, and prevents myeloperoxidase (MPO) from 
causing cell injuries by inhibiting the production of hypochloride (OCl-) and 
speeding its reduction(Xu et al., 2009). Together these findings indicate that LPO not 
only plays a host defensive role through antimicrobial activity and removal of H2O2 
but is also capable of inducing oxidative stress by metabolising organic substrates 
and estrogenic compounds to DNA damaging products, and is thus likely to be 
involved in carcinogenesis.    
MPO  
MPO was upregulated in all treatment groups in both datasets. Notably, the 
greatest induction was observed with H2O2, and the DCTEIO and H2O2 combined 
treatment. MPO is a haem enzyme secreted by activated phagocytes. It uses 
NADPH-derived H2O2, and plasma concentrations of chloride ions (Cl-) to generate 
hypochlorous acid (HOCl) (Harrison & Schultz, 1976; Foote et al., 1983), a potent 
oxidant which plays a critical role in killing invading pathogens. However, the 
reactive species formed by the MPO-H2O2-Cl- system may also damage normal 
tissues at sites of inflammation by initiating lipid peroxidation (Heinecke et al., 1993; 
Savenkova et al., 1994; Marquez & Dunford, 1995; Jacob et al., 1996), catalysing the 
covalent modification (Hazen et al., 1996b; Hazen et al., 1998; Anderson et al., 
1999) and cross-linking of proteins (Heinecke et al., 1993), promoting protein 
nitration (Eiserich et al., 1998; Hazen et al., 1999) and oxidising nucleic acids 
(Henderson et al., 1999), all of which result in deleterious changes that contribute to 
the pathogenesis of disease (Brownlee et al., 1988; Baynes, 1991; Berliner & 
Heinecke, 1996; Thornalley, 1996). Indeed, MPO has been reported to be present in 
 Chapter 6: Gene Expression Profiling 171 
prostatic epithelial cells, suggesting its potential involvement in the development of 
prostatic lesions (Roumeguère et al., 2012). Numerous lines of evidence also suggest 
mechanistic links between MPO, inflammation and both acute and chronic 
manifestations of cardiovascular disease (reviewed in Zhang et al., 2001; Brennan & 
Hazen, 2003). Furthermore, by means of its ability to oxidise low density lipoprotein 
(LDL) (Hazen et al., 1996a; Podrez et al., 2000; Rubbo et al., 2000; Thomas & 
Stocker, 2000; Meagher et al., 2001; Upston et al., 2002b; Pearson et al., 2003; 
Shishehbor et al., 2003) and consume NO (Upston et al., 2002a), MPO has been 
implicated as a participant in atherosclerosis. Others have reported epithelial injury 
and dysfunction in the respiratory tract of cystic fibrosis patients, as well as effects 
on extracellular targets within airway secretions, such as mucus proteins and 
antiproteinases, resulting from MPO-derived reactive oxygen and nitrogen 
intermediates (Van der Vliet et al., 2000). Through the release of ROS, MPO can 
also activate carcinogens in tobacco smoke (Mallet et al., 1991; Kadlubar et al., 
1992; Petruska et al., 1992) and catalyse the endogenous formation of carcinogenic 
radicals that lead to oxidative stress and DNA (Trush et al., 1985; Kogevinas et al., 
2008). This provides a biological rationale for the role of MPO in lung cancer 
aetiology. Likewise, exposure to known carcinogens, such as polycyclic aromatic 
hydrocarbons and aromatic amines through tobacco smoking or in the workplace are 
major risk factors for bladder cancer (IARC, 2000; Kogevinas & Trichopoulos, 
2002). A few polymorphisms have been described for the MPO gene, including a G 
to A substitution in the promoter region that has been shown to reduce transcription 
in vitro due to disruption of the SP1 transcription factor binding site (Austin et al., 
1993; Piedrafita et al., 1996). Lower MPO activity may lead to a decrease in 
carcinogen metabolism and in turn modify cancer risk. In support of this, 
epidemiological studies have found that individuals homozygous for the MPO G-
463-A variant were at reduced risk of lung cancer (Le Marchand et al., 2000; Dally et 
al., 2002; Lu et al., 2002; Schabath et al., 2002a; Schabath et al., 2002b; Wu et al., 
2003) and bladder cancer (Hung et al., 2004). The A allele has also been 
demonstrated to have a protective role in the occurrence of coronary artery disease, 
which may be linked to lower oxidation of LDL by virtue of decreased MPO activity 
(Nikpoor et al., 2001). Consistent with these findings, men with the AA genotype 
were at lower risk of aggressive prostate cancer (Choi et al., 2008). In contrast, 
women with breast cancer who were homozygous for MPO G alleles, which is 
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associated with increased transcription activity, and presumably higher levels of ROS 
had better overall survival than those with genotypes associated with less generation 
of ROS (Ambrosone et al., 2005). This may be due to the fact that genetic variants 
which result in increased oxidative stress would enhance the cytotoxic effects of 
chemotherapy and/ or radiation, leading to better efficacy of treatment, and thus 
better survival. However, it is important to note that this study assessed MPO 
variants in relation to survival and not risk, for these authors also reported decreased 
risk of breast cancer among women with low-activity A alleles, which is in 
agreement with previous studies (Ahn et al., 2004).  
Not all MPO effects are harmful or detrimental to the cell. Following 
wounding, neutrophil-delivered MPO downregulates the high H2O2 gradient 
generated at the wound margin, aiding resolution of the inflammatory response (Pase 
et al., 2012). Another inbuilt cellular homeostatic mechanism may be observed in the 
interaction between NO and MPO. On one hand the catalytic activity of MPO is 
modulated by varying concentrations of NO (Abu-Soud & Hazen, 2000b). On the 
other hand, NO serves as a physiological substrate for MPO, suggesting that MPO 
can act as a catalytic sink for this molecule, limiting its bioavailability and function 
(Abu-Soud & Hazen, 2000b, 2000a; Podrez et al., 2000; Abu-Soud et al., 2001).  
While the ability of nitroxides to suppress protein nitration by the MPO-H2O2-
NO2− system and prevent cellular damage by the MPO-H2O2-phenol system 
(Borisenko et al., 2004; Vaz & Augusto, 2008) has mainly been ascribed to their 
well-known actions as radical scavengers, recent evidence suggests that nitroxides 
can also potently inhibit MPO-mediated HOCl production and protein oxidation by 
modulating the activity of this enzyme or through destruction of the haem component 
(Rees et al., 2009). Together these findings indicate that the adverse effects of the 
MPO-H2O2-Cl- system may far surpass its positive involvement in the innate immune 
response because the generation of freely diffusible reactive species can also damage 
cellular targets in normal tissues, thereby contributing to inflammatory injury and 
deleterious changes that promote the development of disease. In our study, an initial 
rise in MPO may limit cellular oxidative stress through the removal of H2O2. 
However its downstream effects when taken into consideration, suggest that an 
increase in this enzyme is likely to have more of a pro-oxidative rather than 
antioxidative effect. 
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CYBA 
NADPH oxidases are a major source of superoxide anion in phagocytic and 
vascular cells (Mohazzab-H et al., 1994; Pagano et al., 1995; Ushio-Fukai et al., 
1996; Griendling & Ushio-Fukai, 1998; Inoue et al., 1998; Azumi et al., 1999; Perner 
et al., 2003). This is aptly demonstrated by the finding that platelets activated at sites 
of vascular injury induce NADPH oxidase, leading to the rapid and sustained 
generation of ROS, which is likely to play a pivotal role in the redox-sensitive 
regulation of proatherosclerotic genes (Görlach et al., 2000). Moreover, in Type II 
diabetes, a clinical condition characterised by increased oxidative stress, elevated 
levels of hemeoxygenase-1 and the NADPH oxidase subunit p22phox were found in 
circulating monocytes (Avogaro et al., 2003). p22phox is a key component in the 
activation of NADPH oxidases because it stabilises the large gp91phox (NOX2) 
subunit (DeLeo et al., 2000) or its homologues NOX1, NOX3 and NOX4 (Ambasta 
et al., 2004; Kawahara et al., 2005) and serves a docking function for the cytosolic 
components p47phox, p67phox and Rac-2 proteins.  
Recent interest has focused on the possible association of polymorphisms in 
the cytochrome b-245, alpha polypeptide (CYBA) gene, which encodes p22phox, 
with atherosclerosis, but the results have been conflicting (Inoue et al., 1998; Cai et 
al., 1999; Gardemann et al., 1999; Li et al., 1999; Cahilly et al., 2000). In addition, 
no functional data has addressed this hypothesis. In view of this, Guzik et al. 
undertook a study examining the relationship between the C242T allele and NADPH 
oxidase activity in human blood vessels (Guzik et al., 2000). The presence of the 
242T polymorphism was associated with significantly reduced vascular superoxide 
production, independent of other clinical risk factors for atherosclerosis, suggesting 
that genetic variation in NADPH components may play an important role in 
modulating enzyme activity in this disease. Indeed, NADPH oxidase activity in 
individuals homozygous for the T allele of the C242T polymorphism was much 
lower compared with wild-type carriers and heterozygous individuals (Wyche et al., 
2004).  
An increase in vascular superoxide production is also a feature of other disease 
states including acute renal failure (ARF), hypertension (Bouloumié et al., 1997) and 
cancer. Therefore, it is not surprising that the 242T allele which altered NADPH 
oxidase function was shown to influence plasma nitrotyrosine levels and clinical 
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outcomes in patients with ARF (Perianayagam et al., 2007). Others have reported the 
presence of functional polymorphisms in the promoter region of CYBA that greatly 
enhanced promoter activity under hypertensive conditions (Zalba et al., 2001; 
Moreno et al., 2003). However, no association was found between polymorphic 
variations in p22phox and susceptibility to colorectal cancer (Van der Logt et al., 
2005). Neither was the C242T polymorphism associated with gastric cancer 
incidence (Tahara et al., 2008), despite being shown previously to reduce the risk of 
women with H. pylori infection developing more severe intestinal metaplasia (Tahara 
et al., 2009), a well-known risk factor for gastric cancer.  
On the other hand, a major role has been proposed for p22phox-dependent 
NADPH oxidases as positive regulators of an Akt-mediated translational pathway 
necessary for maintaining HIF-2α protein expression in renal carcinoma cells (Block 
et al., 2010). Likewise, elevated levels of p22phox were found to promote prostate 
cancer cell proliferation and colony formation, as well as tumour growth and 
angiogenesis through Akt/ERK/HIF/VEGF signalling pathways (Li et al., 2013). 
These results correlated with increased levels of endogenous ROS.  In another study, 
Lu and colleagues demonstrated that enhanced generation of ROS by NADPH 
oxidases following androgen treatment resulted in oxidative stress and resistance to 
radiation  therapy (Lu et al., 2009). There are several possibilities to explain how 
androgens regulate the expression of these enzymes; by directly binding to androgen 
responsive elements within the genes (Luxen et al., 2008), or indirectly via androgen-
sensitive transcription factors such as NFκB (Huang et al., 2011).  
In our study, CYBA was upregulated by both CTMIO and DCTEIO as single 
agents. Likewise, exposure to H2O2 alone and in combination with CTMIO caused a 
significant increase in mRNA levels of this gene. Based on the findings of previous 
studies, it is conceivable that an increase in CYBA expression would lead to increased 
NADPH oxidase activity and in turn greater oxidative stress.      
MBL2 
The mannose-binding lectin (MBL) protein, coded by the MBL2 human gene 
belongs to the collectin family and is a key component in systemic and mucosal 
innate immunity (Jack et al., 2001; Kilpatrick, 2002; Garred et al., 2003; Turner, 
2003; Dommett et al., 2006; Garred et al., 2006). MBL binds to specific 
carbohydrate structures on the surface of microorganisms (including bacteria, viruses 
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and fungi) and subsequently kill them by activating the complement system and/ or 
promoting complement-independent opsono-phagocytosis. A deficiency in MBL, 
caused by single nucleotide polymorphisms (SNP) in exon 1 and the promoter 
regions of MBL2 (Madsen et al., 1995), is considered to be one of the most common 
human immunodeficiencies (Garred et al., 2003; Presanis et al., 2003). The variant 
alleles disrupt MBL oligomerization (Sumiya et al., 1991; Madsen et al., 1994; 
Wallis & Cheng, 1999)  resulting in lower serum concentrations of functional protein 
(Madsen et al., 1995; Terai et al., 2003; Larsen et al., 2004), which in turn leads to a 
decrease in complement activation and opsonization, and increased susceptibility to 
various autoimmune (Øhlenschlæger et al., 2004; Boniotto et al., 2005) and 
infectious diseases (Super et al., 1989; Madsen et al., 1994; Summerfield et al., 1995; 
Kilpatrick, 2002; Biezeveld et al., 2003; Eisen & Minchinton, 2003). Emerging 
evidence suggests that MBL2 variants may also be risk factors in human cancer. This 
was first shown by Baccarelli and colleagues in their study (Baccarelli et al., 2006) 
which evaluated stomach cancer risk in relation to individual MBL2 haplotypes 
rather than combined genotypes, due to the strong linkage disequilibrium among the 
MBL2 SNP alleles (Madsen et al., 1995; Madsen et al., 1998; Coughlin & Piper, 
1999; Lee et al., 2005). Subjects with the HYD haplotype, which encodes both a 
functionally impaired MBL protein and a lower protein serum level, were found to 
be at increased risk of stomach cancer (Baccarelli et al., 2006). Likewise, others have 
reported that an increased susceptibility to hepatitis C virus-related hepatocellular 
carcinoma (Eurich et al., 2011), colon cancer (Zanetti et al., 2012) and gastric cancer 
(Wang et al., 2008), as well as a higher incidence of malignant and benign tumours 
of the reproductive system  (Świerzko et al., 2007), is influenced by MBL2 
polymorphisms responsible for defective production of the protein. Given that in all 
these studies, bacterial or viral infections and chronic inflammation promoted the 
development of cancer (Coussens & Werb, 2002; Hussain et al., 2003a), lower levels 
of active circulating MBL protein may compromise the innate immune response by 
limiting complement activation, thus favouring the spread of infection and cancer 
progression. It is plausible therefore to suggest that higher levels of MBL would 
enhance immunosurveillance against malignancies, and in turn provide protection 
against the onset of a clinical disease. Consistent with this hypothesis, genetic 
variants encoding for high serum concentrations of MBL was linked to a lower 
incidence of breast cancer among African American women (Summerfield et al., 
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1995; Bernig et al., 2006). However, activation of the complement cascade by high 
MBL levels may also contribute to tumourigenesis through the formation and release 
of pro-inflammatory factors and the activation of inflammatory cells (Nilsson et al., 
1996; Hartmann et al., 1997; DiScipio et al., 1999). In view of this, it can be 
concluded that improved survival in lung cancer patients associated with low-activity 
MBL haplotypes is likely to result from a reduced inflammatory environment where 
tumour cells are less aggressive (Pine et al., 2007). Others have demonstrated the 
ability of MBL to inhibit meprins, tissue-specific metalloproteases, which have been 
implicated in tumour growth, invasion into surrounding tissues and metastasis (Bond 
& Beynon, 1995; Matters & Bond, 1999). This novel function of MBL may be 
responsible, at least in part for its potent anti-tumour and anti-angiogenic action in 
cancer cells (Hirano et al., 2005). Furthermore, MBL binds directly to certain 
colorectal carcinoma (Ma et al., 1999) and glioma cells (Fujita et al., 1995), targeting 
them for removal via MBL-dependent cell-mediated cytotoxicity or complement 
activation. The results from the current study which demonstrated a downregulation 
in MBL2 expression across all three treatment groups of the DCTEIO dataset, needs 
to be extended in order to determine which particular variant is involved in the 
response and the impact of this on MBL functionality. This would enable a better 
understanding of the role of MBL in prostate cancer cells. Interestingly, this may 
well be the first study in which a redox-related compound has been shown to 
modulate intracellular MBL2 levels.  
SFTPD 
Surfactant protein D (SFTPD), another member of the collectin family, plays 
an important role in innate host defence by binding and clearing inhaled 
microorganisms from the lungs (Kingma & Whitsett, 2006). SFTPD also contributes 
to surfactant homeostasis (Korfhagen et al., 1998), and regulates immune cell 
activity through multiple cellular pathways, without which increased oxidant 
production and metalloproteinase (MMP) activity by activated alveolar macrophages 
may lead to the pathogenesis of chronic inflammation and emphysema (Wert et al., 
2000). In mice lacking SFTPD, the ability to mount an inflammatory response to 
bacterial infection together with the increased release of oxygen radicals may 
perhaps compensate for the defect in opsonization, resulting in efficient bacterial 
killing similar to wild-type mice (LeVine et al., 2000). However, despite increased 
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inflammatory cell recruitment and production of pro-inflammatory cytokines 
(LeVine et al., 2001; LeVine et al., 2004), uptake and clearance of viral pathogens 
were impaired in SFTPD-deficient mice, indicating that the effects of SFTPD on 
inflammatory responses are independent of the clearance of pathogens. A more 
significant contributor to bacterial or viral killing is the production of oxidants by 
macrophages (Van Iwaarden et al., 1992). This was suppressed in SFTPD-/- mice 
following viral infection (LeVine et al., 2004) and may explain why phagocytic 
clearance of viruses was decreased whereas that for bacteria remained unchanged 
compared to wild-type mice (LeVine et al., 2000). Furthermore, oxidant-dependent 
activation of redox-sensitive transcription factors such as NFκB (Yoshida et al., 
2001) may influence the heightened inflammatory responses observed in SFTPD-/- 
mice following pulmonary infections. Clinically, serum SFTPD levels are useful 
biomarkers for a number of lung diseases characterised by increased inflammation or 
lung parenchyma damage (Postle et al., 1999; Cheng et al., 2000; Takahashi et al., 
2000; Asano et al., 2001; Ohnishi et al., 2002). However, it was not until the 
discovery of a specific SFTPD haplotype significantly associated with decreased 
serum SFTPD levels that a genetic basis for the variation in SFTPD serum levels was 
established (Heidinger et al., 2005). Genetic variation in SFTPD is also a risk factor 
for the development of interstitial pneumonia (IP) and lung cancer. A haplotype 
analysis revealed that haplotypes associated with emphysema and lung cancer 
differed from that associated with IP, suggesting a differential role for SFTPD in the 
development of these diseases(Ishii et al., 2012). We found SFTPD to be 
downregulated in response to DCTEIO, H2O2 and the DCTEIO and H2O2 treatments. 
However, changes in SFTPD expression was not observed in the CTMIO dataset. 
Given the role of SFTPD in regulating both oxidant production and inflammatory 
responses, a decrease in SFTPD expression in the presence of DCTEIO may reflect a 
decreased requirement for SFTPD; particularly if DCTEIO acts as an antioxidant in 
our oxidative stress model. Nevertheless before such a conclusion can be drawn, 
further experiments need to be undertaken at the protein level to support the current 
findings.    
Conclusion  
As can be seen from this discussion, to determine the role of the nitroxide 
compounds CTMIO and DCTEIO in terms of their regulation of oxidative stress and 
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antioxidant related genes (vs. that induced by H2O2 and the combined treatment) is 
by no means straightforward, because many of these genes are able to exert both 
beneficial and detrimental effects within the cell depending on the experimental 
setting or disease.  
Our findings demonstrate that a response to the various treatments resulted 
from the coordinated expression of multiple genes rather than the action of an 
individual gene. Predominantly, these genes and the proteins they encode participate 
in innate immunity or the inflammatory response, as well as contribute to tumour 
development through the generation of free radicals such as superoxide and H2O2or 
other potent oxidants. Furthermore, these genes can be classified into three major 
families – haem peroxidases (PTGS1, PTGS2, LPO and MPO), NOX or their 
components (DUOX2 and CYBA) and the collectins (MBL2 and SFTPD). Literature 
also suggests molecular cross-talk between NOS2 and PTGS, NO (product of NOS2) 
and MPO, and DUOX2, LPO and MPO. Although network analyses revealed 
transcription regulators including SP3, MKL1, MKL2, TP53 and CEBPB branching 
out to many of the gene targets discussed in this chapter, and interactions between 
the genes and downstream molecules such as UBC, NCF1, NCF2, NCF4, NOX1 and 
AR; how these transcription factors and downstream molecules modulate the redox 
status within cells or are induced in response to oxidative stress need to be examined, 
to provide a complete picture of the way in which they regulate or interact with the 
genes of interest.  
It is important to note that the length of H2O2 treatment (1 hr) employed in our 
experiments followed by a recovery period of 7 hrs may have been too long, 
potentially resulting in us missing the immediate early response genes. This may be 
illustrated by the results from a study investigating the effects of exogenous PGE2 on 
the expression of an immediate early response gene, PTGS2, in the PC-3 prostate 
cancer cell line (Tjandrawinata et al., 1997). A steady state increase in PTGS2 
mRNA began 1–2 hrs following the addition of PGE2. Maximal induction (8.4-fold) 
was seen at 3 hrs, after which PTGS2 mRNA levels decreased significantly although 
still detectable (3.6-fold) at the 24 hr time-point. In our study, PTGS2 expression was 
increased 7.7-fold above the control in response to the CTMIO treatment and 
increased 2.7 and 2.9-fold respectively, in the H2O2 and combined treatment groups. 
Yet it is conceivable that higher expression levels of this and other genes could have 
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been detected at earlier time-points. With this in view, the induction of oxidative 
stress and antioxidant related gene expression in response to the various treatments 
will need to be assessed using time-course experiments in the future. Interestingly, 
Tjandrawinata et al. suggested that the upregulation in PTGS2 expression was not 
due to a direct transcriptional effect of PGE2 on the PTGS2 gene, as the initial peak 
of the induction was observed 3 hrs following the addition of PGE2, whereas a direct 
transcriptional event would have occurred much earlier (15–30 mins) (Tjandrawinata 
et al., 1997). This may well explain why PTGS2 expression could still be detected in 
our experiments 8 hrs post-treatment, and in turn suggests that upstream signalling 
molecules are involved in mediating the PTGS2 response. It must also be pointed out 
that changes observed at the mRNA level within the time-frame of our study may not 
necessarily translate to changes in protein levels. This could be due to a number of 
factors including post-transcriptional and translational regulation, protein 
modification, as well as the stability of the mRNA and protein. Hence, future studies 
will be directed at validating the changes in transcript levels over a time-course and 
at the protein level.   
Nonetheless, the preliminary data presented in this study has provided for the 
first time mechanistic insights into the role of the isoindoline nitroxide CTMIO and 
its derivative DCTEIO in a prostate cancer model of oxidative stress. Similar gene 
expression patterns were observed between the two nitroxides and the H2O2 
treatment. NOS2, DUOX2, MPO and CYBA were upregulated across all treatment 
groups, whereas PTGS2 was upregulated only in the CTMIO dataset. In contrast, 
downregulation in MBL2 and SFTPD was seen only in the DCTEIO dataset. 
Together our findings indicate that these nitroxides may have a pro-oxidative role in 
prostate cancer cells, with CTMIO being more potent than DCTEIO. This is 
supported by the fact that many of the genes induced in response to the treatments 
consume H2O2 in order to generate oxidising species with antimicrobial activity. 
Thus on the one hand, an increase in the expression of these genes/ their gene 
products may serve to eliminate excess H2O2, while on the other hand they may 
promote further oxidative stress within the cells. Surprisingly, none of the classical 
antioxidant enzymes such as superoxide, catalase or glutathione peroxidase were 
differentially expressed in our model system. A possible reason could be that only a 
low-level of oxygen free radicals was induced by the nitroxide and H2O2 treatments, 
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which were readily detoxified by the host defence system, although this requires 
further research to confirm. 
 Chapter 6: General Discussion and Final Conclusions 181 
Chapter 6: General Discussion and Final 
Conclusions 
6.1 INTRODUCTION 
Prostate cancer is the second most frequently diagnosed cancer in men 
worldwide, with the highest incidence rate occurring in developed countries 
(GLOBOCAN, 2012). In Australia alone, it accounts for almost a third of all cancer 
cases in males and is the second leading cause of cancer death after lung cancer 
(AIHW & AACR, 2012). The risk of prostate cancer increases with age and it is 
estimated that 1 in 6 men will be diagnosed with this disease in their lifetime (AIHW 
& AACR, 2012; Siegel et al., 2012). Unlike localised disease which carries a 
favourable prognosis, tumours that are recurrent or have already spread beyond the 
prostate at the time of diagnosis are more challenging to treat and are often fatal. 
Over the last decade, numerous epidemiological, experimental and clinical studies 
have unequivocally demonstrated a role for oxidative stress in the development and 
progression of prostate cancer (reviewed in Khandrika et al., 2009). Consequently, 
identification of novel agents that can either reduce the inherent oxidative stress 
present in prostate cancer cells, or serve to further stress the cells by generating ROS, 
may aid in the development of better therapeutic interventions and disease 
management strategies for advanced-stage prostate cancer, and thus improve patient 
outcomes.  
A class of low molecular weight, membrane-permeable, stable free radicals 
known as nitroxides may be useful in this respect. Nitroxides have been shown to 
protect against diverse oxidative insults including radiation (Mitchell et al., 1991; 
Goffman et al., 1992; Hahn et al., 1992a; Hahn et al., 1992b), cytotoxic drugs 
(Krishna et al., 1991; DeGraff et al., 1994; Monti et al., 1996) and post-ischemic 
reperfusion injury (Gelvan et al., 1991; Samuni et al., 1991b). Paradoxically, these 
compounds may exert pro-oxidant effects under different settings (Wang et al., 1996; 
Gariboldi et al., 1998; Monti et al., 2001; Gariboldi et al., 2003), depending on 
factors such as concentration and exposure time (Offer et al., 2000). The focus of this  
project was the isoindoline family of nitroxides due to the advantages conferred by 
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their fused aromatic structure over the more commonly used pyrrolidine and 
piperidine species (Rizzardo et al., 1982; Griffiths et al., 1982a; Moad et al., 1982a; 
Griffiths et al., 1982b). In particular, CTMIO has been shown to alleviate the 
deleterious effects of oxidative stress and to delay the onset of thymic lymphomas in 
Atm-mutant mice with the disease A-T (Chen et al., 2003; Gueven et al., 2006). The 
aim of this study therefore was to investigate the impact of this and other nitroxides 
in a prostate cancer setting and to determine the mechanism by which CTMIO elicits 
its effects.   
6.2 ADDRESSING ISSUES RELATED TO OXIDATIVE STRESS 
NITROXIDE STABILTY AND CELL SURVIVAL 
We first examined the cytotoxicity of nitroxides by measuring cell survival 
following treatment with these compounds over a 96 hr period. Exposure to the 
piperidine nitroxide Tempo resulted in cell death in a dose and time-dependent 
manner, confirming the PC-3, DU-145 and LNCaP cell survival data reported by Suy 
and colleagues (Suy et al., 2005), and in turn establishing a working assay in which 
to evaluate the impact of Tempo derivatives and the isoindoline nitroxide CTMIO on 
prostate cancer cells. Tempol likewise induced significant cell death after 48 and 96 
hrs of treatment, whereas C-Tempo was considerably less potent, which is in line 
with previous findings that compound cytotoxicity is influenced by the type of 
substituent present at position-4 of the nitroxide ring (Metodiewa et al., 1999a; 
Koceva-Chyla et al., 2000; Metodiewa et al., 2000a; Wu et al., 2006). Nonetheless, 
the extent of cell killing demonstrated by C-Tempo was greater than that for CTMIO, 
suggesting that the piperidine ring structure confers greater cytotoxicity than the 
isoindoline ring structure.  
In hindsight, while CTMIO lacked toxicity towards prostate cancer cells, it 
cannot be assumed that this compound is devoid of pro-oxidant effects. This can only 
be verified by measuring levels of reactive species and oxidative damage within the 
cells before and after treatment with CTMIO. Numerous techniques are available for 
this purpose, including fluorescent probes, spin trapping and assays that measure end 
products or markers of oxidative DNA, lipid and protein damage. Even so, caution 
must be exercised in applying these methods in view of possible errors and artifacts 
in interpreting the results (reviewed in Halliwell & Whiteman, 2004). For example, 
when using dichlorofluorescin diacetate (DCFH-DA), one of the most popular 
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fluorescent probes for detecting ROS within the cell, experiments must be performed 
in serum-free media since serum contains endogenous esterase activity that could 
lead to the probe being hydrolysed outside the cell to DCFH, which is less cell 
permeable (Halliwell & Whiteman, 2004). Washing cells after loading to remove 
unreacted probe can also cause DCFH and the fluorescent product 
dichlorofluorescein (DCF) to diffuse out again into the culture media. In both cases, 
DCFH may undergo extracellular reactions with ROS to DCF (Grzelak et al., 2001; 
Halliwell, 2003). Thus results would be confounded, as fluorescence would be 
detected in the medium as well as in the cells. Furthermore, cells should be loaded 
with low concentrations of DCFDA to reduce potential artifacts that arise from 
overloading such as incomplete hydrolysis, compartmentalization and cytotoxicity, 
as well as photochemical oxidation of the probe to fluorescent products that may be 
mistaken for ROS generation(Afzal et al., 2003). 
Aromatic compounds or spin traps have been successfully employed in many 
studies examining reactive species production in cells, due to a wider range of traps 
that can be used at higher concentrations than in vivo (Halliwell & Whiteman, 
2004).Yet one must be aware of the possibility that free radical-spin trap adducts can 
be rapidly reduced to EPR-silent species by non-enzymatic antioxidants (e.g. 
ascorbate) and cellular enzymatic reducing systems (Halliwell & Gutteridge, 1999). 
Moreover, EPR of ex vivo samples to which traps have been added probably detects 
secondary radicals rather than highly reactive radicals that may have formed in vivo 
(Ferdinandy & Schulz, 2003), simply because these break down more rapidly and 
will not survive to be detected in ex vivo material (Halliwell & Gutteridge, 1999; 
Radi et al., 2001).  
Less widely appreciated is that cell culture itself imposes oxidative stress, both 
by facilitating the generation of reactive species, and by hindering adaptive 
upregulation of antioxidant defenses (reviewed in Halliwell, 2003). While this stress 
is unavoidable in in vitro studies, it can be controlled and limited during 
manipulations with the culture. For instance, when measuring the output from 
fluorescent probes, using fluorescence microplate readers has the advantage over 
other techniques such as flow cytometry because cells can be measured in situ 
without the need for trypsinisation and cell scraping, processes that induce oxidative 
stress and result in artifactual changes in fluorescence. 
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Therefore, whatever method one chooses to use for measuring reactive species 
or assessing oxidative damage, it is necessary to think carefully about how the 
method works, what is likely to confound it and how quantitative it can be; 
experiments must also be carried out with the appropriate controls. Furthermore, 
multiple methods of detection should be used to validate results. With careful 
attention to understanding these points, erroneous interpretation of the results can be 
minimized (Halliwell & Whiteman, 2004).   
Adding further complexity to our experiments, the redox activity of nitroxide 
free radicals may be affected under the highly oxidative environment in which cells 
are routinely cultured (21% O2). Careful handling of these compounds is therefore 
required to prevent non-specific oxidation. In addition, given that most cells in 
tissues are rarely if ever exposed to such high levels of O2 (normally 2–5%), it would 
be interesting to explore the effect of nitroxides in prostate cancer cells under 
hypoxic conditions, which would more closely resemble the tumour 
microenvironment.  
In EPR studies performed in chapter 3, we examined the stability of CTMIO in 
the culture media, conditioned media and intracellularly over the time course used in 
the cell survival experiments. A loss in CTMIO signal intensity was observed both in 
the conditioned media and in the media controls, suggesting that CTMIO undergoes 
spontaneous reduction, possibly via reducing equivalents found in the tissue culture 
media or as a result of changes in oxygen level within the incubator. Notably, the rate 
at which CTMIO was reduced in the conditioned media was greater than in the 
media controls, providing evidence that this compound was taken up by cells from 
the culture medium. Nitroxide signal however could not be detected intracellularly, 
potentially due to signal loss during sample preparation for EPR analysis, incorrect 
storage of samples and the time delay between sample collection and EPR 
measurements, as discussed in Section 3.4. These limitations could be overcome if 
EPR measurements of nitroxide signal strength were performed in cells real-time. 
However, cells would need to be incubated for the duration of the experiment to 
maintain viability. In addition, this technique may only be feasible for cells grown in 
suspension, as these do not need to be detached prior to assaying. The EPR 
spectrometer can thus be set up to automatically draw up samples for measurements. 
Alternatively, labelling CTMIO with a fluorescent tag or designing a derivative that 
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can be cleaved from a non-fluorescent to fluorescent form by intracellular enzymes 
may enable the intracellular location of this nitroxide to be visualised using confocal 
microscopy. Furthermore, subcellular localisation of the compound to the 
mitochondria, endoplasmic reticulum and lysosome may be examined using counter 
stains such as MitoTracker, ER Tracker or LysoTracker dyes, coloaded with the 
nitroxide.     
6.3 ASSESSING THE ANTIOXIDANT CAPACITY OF CTMIO IN 
DIFFERENT MODELS OF OXIDATIVE STRESS 
The minimal cytotoxicity displayed by CTMIO against prostate cancer cells 
prompted us to examine its antioxidant effect under oxidative stress conditions. 
Prostate cancer cell lines were treated with increasing concentrations of DTX in 
combination with CTMIO, and exposed to the glycolytic inhibitor 2-deoxy-D-
glucosein the presence and absence of CTMIO according to the dosing schedule 
depicted in Figure 4.1. However, as discussed earlier in this thesis, CTMIO was not 
able to protect against the cytotoxic effects of these agents. Inconclusive results and 
potential flaws in the experimental design of some of these studies such as not using 
the correct dose of 2DG and NAC, or the correct treatment period (refer to Section 
4.4.2) also meant that these model systems were not suitable for use. For this reason, 
LNCaP cells were exposed to 500 µM H2O2 together with 100 µM CTMIO for 1 hr, 
after which the cells were recovered for 7 hrs in media containing nitroxide alone. 
Treatment with CTMIO could not rescue the cells from H2O2-induced oxidative 
stress, as evidenced by the significantly reduced levels of GSH within the cells after 
the recovery period. GSH is the most abundant non-protein thiol found in 
mammalian cells and is readily oxidised by electrophilic substances such as ROS to 
glutathione disulfide (GSSG), which in turn is reduced back to GSH by GSSG 
reductase at the expense of NADPH. Severe oxidative stress overwhelms the ability 
of the cells to reduce GSSG to GSH, leading to an accumulation of GSSG and 
eventually depleting cellular GSH (DeLeve & Kaplowitz, 1991; Lu, 2009). Thus, the 
GSH-Glo assay which is able to detect and quantify intracellular GSH concentrations 
in situ, was considered to be a reliable measure of oxidative stress.   
While it may be speculated that the H2O2 dose used in the treatment regime or 
the length of the combined treatment may have exceeded the repair capacity of the 
cells resulting in irreversible oxidative stress, brief exposures to sub-lethal doses of 
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H2O2 have been shown to activate various signalling pathways (Yamamoto et al., 
2003; Kim et al., 2006; Sung et al., 2006; Kimball et al., 2008). In particular, Chuang 
et al. reported changes in gene expression following similar treatment conditions as 
that used in our study, albeit in breast cancer cells (Chuang et al., 2002). Hence, it 
cannot be ruled out that as an antioxidant, CTMIO elicited subtle changes at the gene 
level to protect the cells from the damaging effect of H2O2 that was not evident from 
the GSH-Glo assay. Nonetheless, dose-response and time-course experiments could 
be performed to determine whether CTMIO is capable of reversing H2O2-induced 
oxidative stress at lower concentrations and following shorter exposure times. Time-
course assessment of the CTMIO response would also be beneficial to gene 
expression studies, as it can reveal changes in gene expression, identify uniquely 
expressed genes at specific time points, as well as genes expressed across multiple 
time points which information could otherwise be missed with single time point 
experiments (Chuang et al., 2002). 
In the future, it would be interesting to explore the protective effects of CTMIO 
in other prostate cancer models of oxidative stress; for instance, against the damaging 
effects of ionising radiation (Hosokawa et al., 2004) and following exposure to 
androgens (Ripple et al., 1997; Ripple et al., 1999). 
6.4 REGULATING GENES OF THE IMMUNE AND INFLAMMATORY 
PATHWAY– A POTENTIAL MECHANISM OF ACTION OF 
ISOINDOLINE NITROXIDES IN PROSTATE CANCER CELLS? 
A total of 44 oxidative stress and antioxidant related genes were identified as 
differentially expressed in response to H2O2, the nitroxides CTMIO or DCTEIO, and 
the combined treatments. Of these, 9 (PTGS1, PTGS2, NOS2, DUOX2, LPO, MPO, 
CYBA, MBL2 and SFTPD) were selected for further review due to having the most 
significant fold changes and a similar pattern of expression across the three 
treatments (Table 5.10). Interestingly, many of these genes were involved in the 
inflammatory response or host-defence and could be broadly categorized as haem 
peroxidases (PTGS1, PTGS2, LPO and MPO), NOX or their components (DUOX2 
and CYBA) and the collectins (MBL2 and SFTPD). While an upregulation in these 
genes can be viewed simply as an adaptive response by which the cells attempt to 
remove excess H2O2 or counteract the increase in oxidative stress following the 
various treatments, what this regulation of the immune response actually implies in  
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a cancer context requires further investigation. As we are beginning to appreciate, 
complex relationship exists between immune cells and developing tumours. The 
immune system not only prevents tumour formation (cancer immunosurveillance) 
but also functions to promote or select tumour variants with reduced 
immunogenicity, thereby providing developing tumours with a mechanism to escape 
immunologic detection and elimination. This dual host-protecting and tumour 
sculpting action of the immune system on developing tumours is referred to as cancer 
immunoediting (reviewed in Dunn et al., 2002; De Visser et al., 2006; Vesely et al., 
2011). Moreover, cancer immunoediting and inflammation are not mutually 
exclusive, but rather interdependent processes (Bui & Schreiber, 2007; Vesely et al., 
2011). During acute inflammation, innate immune cells form the first line of defence 
and regulate the activation of adaptive immune responses that lead to tumour 
destruction. In contrast, during chronic inflammation, ongoing and excessive 
activation of innate immune cells contributes to cancer development by suppressing 
anti-tumour adaptive immunity on the one hand, thereby allowing tumour escape 
from immunosurveillance; while on the other, creating an attractive environment for 
tumour growth, angiogenesis, migration and metastatic spread (reviewed in Coussens 
& Werb, 2002; De Visser et al., 2006). Thus, altered interactions or an imbalance 
between innate and adaptive immunity represent underlying mechanisms that trigger 
the onset and maintenance of chronic inflammation associated with cancer 
development. Nonetheless, a greater molecular understanding of cancer 
immunoediting and tumour-promoting inflammation is required in order to develop 
more effective strategies that can restore the immune balance and in so doing, 
harness the power of immunity to protect against cancer development (Whelan & 
Kwon, 2006; Fong & Small, 2007; Gerritsen, 2012).  
From a different perspective, enhancement of the immune system of cancer 
patients undergoing chemotherapy or radiation therapy could overcome the 
immunosuppressive effects related to these treatments (Shoham et al., 1980) 
Chemotherapy-induced lymphocyte depletion predisposes patients to clinical 
complications such as opportunistic fungal and parasitic infections (Sepkowitz et al., 
1992; Mackall et al., 1994; Sepkowitz, 2002). More importantly, this raises practical 
questions about standard treatment approaches to malignant disease. Could 
successful tumour bulk reduction or remission induction achieved with cancer 
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treatments lose some of its benefits due to the treatments themselves compromising 
immune surveillance mechanisms, ultimately causing disease recurrence? 
Immunodeficiency and extreme sensitivity to ionising radiation are just a few of the 
many characteristics of the disease A-T (Boder, 1974). Yet A-T cells treated with 
CTMIO or other carboxy nitroxides prior to radiation exposure displayed enhanced 
survival, compared to untreated cells. The protective effects of these nitroxides may 
be attributed to their well recognised roles as radioprotectors and antioxidants (Hahn 
et al., 1992a; Krishna & Samuni, 1994; Mitchell & Krishna, 2002; Soule et al., 
2007). However, it is tantalising to speculate that improved survival may have also 
involved nitroxides modulating cellular immunity. Our results, demonstrating an 
increase in the expression of several immune response genes following CTMIO 
treatment lend support to this hypothesis. In addition, CTMIO has minimal 
cytotoxicity, suggesting that it may be given to patients without appreciable side 
effects (results presented in Chapter 3). This possibility deserves further research 
with a view to developing strategies that can boost immune function following 
cancer treatments or minimise treatment-induced damage to the immune response, 
thus enabling the immune system to re-establish control over residual disease. 
 Interestingly, prostate epithelial cells themselves may play a role in innate 
immunity. In a study examining their response to lipopolysaccharide, an 
inflammatory stimuli, they were found to activate NF-κB, induce the expression of 
NOS and secrete NO (Gatti et al., 2006). Moreover, numerous chemokine genes 
were upregulated in this response. These results, together with the fact that prostate 
epithelial cells constitutively express Toll-like receptors (TLR) 4 and 2, suggest that 
these cells are fully competent, and can actively participate in innate immunity by 
initiating an inflammatory response. Others have likewise shown prostate epithelial 
cells to express significant levels of TLR4 and TLR2 (Mackern-Oberti et al., 2006). 
These authors further demonstrated the ability of these cells to upregulate different 
pro-inflammatory and chemokine genes that may influence innate and adaptive 
responses during Chlamydia infections.  Enhanced production of chemokines and 
cytokines has also been observed in prostate epithelial RWPE-1 cells exposed to 
peptidoglycan, although this was mediated through an increase in β-defensin 124 
expression and NF-κB activation (Kim et al., 2014). These findings are of relevance 
to our study because the experiments were all undertaken in prostate epithelial cell  
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lines.  
In light of these considerations, it is worth comparing the basal expression of 
the 9 genes in metastatic and clinically localised prostate cancer samples to that in 
benign prostate tissues, in order to gain a better understanding of the effect of 
nitroxide treatment on prostate cancer cells. If for instance, lower levels of these 
genes were expressed in prostate cancer samples compared to benign prostate tissues, 
an increase in gene expression resulting from nitroxide treatment could potentially 
indicate a reversal of the malignant phenotype to a less aggressive state. In Section 
5.3.1 and 5.3.2, the Varambally et al dataset (Varambally et al., 2005) was used to 
examine the expression profiles of these genes. However, heterogeneous gene 
expression patterns within, and between groups of samples meant that their 
usefulness as predictors or signatures of disease progression could not be 
conclusively determined Therefore, there is still a need for this analysis to be 
performed but using microarray data compiled from several studies, which would 
provide a more comprehensive and accurate representation of gene expression across 
the different stages of disease. 
Furthermore, because the current model lacks immune cells, co-culture studies 
could be used to explore the interaction between prostate epithelial cells and immune 
cells (neutrophils, monocytes, eosinophils, lymphocytes) (Duell et al., 2011; 
Bermudez-Brito et al., 2013; Mathur et al., 2013). For example, monolayer co-
cultures of two adherent cell types, or mixed co-cultures, which typically comprise of 
adherent monolayers in combination with a suspension cell type(s). To achieve a 
suspension culture, cells could be cultured in semi-permeable transwell inserts, 
which would physically separate the two cell populations yet allow co-stimulation 
via soluble mediators. Alternatively, a 3D organotypic co-culture model could be 
employed, where cells are harvested and resuspended in a collagen solution with 
gelatine to form a basic 3D architecture. Using these matrix gels, cell differentiation, 
changes in cell structure and cell migration can be assayed.  Keeping in mind that co-
culture studies more closely mimic/reflect the dynamic biological processes that 
occur in vivo, they may yield responses in transcription and translation that are 
distinct from monoculture studies.  
However, it is pertinent that we confirm the changes observed in gene 
expression by RT-PCR and with protein studies such as western blotting, flow 
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cytometry, immunoassays and fixed time or continuous (real-time) enzyme assays, 
prior to undertaking further research. Additionally, network analyses revealed that 
MKL1, MKL2, SP3, CEBPB, CEBPD and TP53 were the major transcription factors 
regulating many of the genes of interest; either directly or indirectly, via interactions 
with other transcription factors and downstream molecules such as the enzymes LTF, 
RAC2 and UBC (Figure 6.1). Given the dual antioxidant and pro-oxidant activity of 
nitroxides, it would be interesting to examine how these specific proteins and/ 
pathways are induced in response to changes in cellular redox state. Indeed many 
proteins including transcription regulators, kinases, phosphatases, structural proteins 
and metabolic enzymes contain cysteine residues that are susceptible to oxidation by 
ROS (reviewed in Veal et al., 2007). In many cases, these reversible redox changes 
alter protein structure and activity, leading to an impact on specific signalling 
pathways or cellular processes. 
Gene knockdown or overexpression studies could also be performed to 
determine which of the 9 genes is the most important in mediating the oxidative 
stress response, following exposure to the various treatments. This gene could then 
be interrogated further to identify the particular variant responsible. Once the results 
from these experiments have been established, this study could be expanded to look 
at other derivatives of CTMIO and DCTEIO. Interestingly, while both these 
compounds elicited changes in PTGS1, DUOX2, MPO and CYBA expression, LPO 
and PTGS2 were not induced by DCTEIO (Table 5.10). Conversely, SFTPD and 
MBL2 were expressed only in the DCTEIO dataset. It is plausible to suggest that 
structural differences between these compounds may have accounted for the 
variation in gene regulation. Practically, this could indicate that CTMIO and 
DCTEIO work through slightly different pathways. 
 Chapter 6:General Discussion and Final Conclusions 191 
 
 
 
 
 
 
 
 
Figure 6.1. Network illustrating interactions between differentially expressed genes, upstream 
transcription regulators and downstream molecules 
The different families of genes are coloured accordingly - pink, haem peroxidases (PTGS1, 
PTGS2, MPO and LPO); green, NOX or their components (DUOX2 and CYBA); blue, the 
collectins (MBL2 and SFTPD); yellow, nitric oxide synthase (NOS2); while the orange colour 
highlights the key transcription factors in this network (TP53, SP3, CEBPB, CEBPE, MKL1 and 
MKL2).
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6.5 FINAL CONCLUSIONS 
In summary, despite CTMIO demonstrating minimal toxicity in prostate cancer 
cells in comparison to the piperidine nitroxides Tempo and Tempol, this nitroxide 
and its derivative DCTEIO were found to regulate the expression of a collection of 
genes involved in oxidative stress and antioxidant defense. Of these, 9 of the most 
significantly expressed genes participate also in the inflammatory response or innate 
immunity, suggesting that these nitroxides may function as immune-modulating 
agents. In addition, CTMIO and DCTEIO exhibited a similar pattern of gene 
regulation to H2O2, indicating that they may have a pro-oxidant rather than 
antioxidant role in prostate cancer cells. Together, these results have provided for the 
first time mechanistic insights into the action of isoindoline nitroxides in prostate 
cancer cells, and have identified several avenues for further research. Future studies 
may provide a greater understanding of the interactions between prostate epithelial 
cells and the immune system, as well as transcriptional regulation of the genes of 
interest and downstream molecules which could enhance our knowledge of host-
tumour interactions and cancer immunoediting. 
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Appendix A: Summary table of gene expression data from CTMIO and H2O2 PCR array experiments  
   CTMIO  H2O2  CTMIO + H2O2 
GenBank 
Accession No. 
Gene 
Symbol Description Fold Change P-value  Fold Change P-value  Fold Change P-value 
NM_000477 ALB Albumin 1.07 0.999  -1.25 0.973  -1.13 0.995 
NM_000697 ALOX12 Arachidonate 12-lipoxygenase 1.37 0.930  1.61 0.804  1.97 0.591 
NM_021146 ANGPTL7 Angiopoietin-like 7 1.45 0.895  1.30 0.957  1.17 0.989 
NM_001159 AOX1 Aldehyde oxidase 1 -1.89 0.635  1.15 0.993  -1.30 0.958 
NM_000041 APOE Apolipoprotein E 1.18 0.989  1.78 0.699  1.09 0.998 
NM_004045 ATOX1 ATX1 antioxidant protein 1 homolog (yeast) -1.04 1.000  -1.03 1.000  -1.04 1.000 
NM_004052 BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 1.03 1.000  1.16 0.992  1.07 0.999 
NM_001752 CAT Catalase 1.21 0.983  1.16 0.992  1.15 0.993 
NM_002985 CCL5 Chemokine (C-C motif) ligand 5 1.32 0.949  2.35 0.409  1.12 0.997 
NM_005125 CCS Copper chaperone for superoxide dismutase -1.02 1.000  1.03 1.000  -1.09 0.999 
NM_007158 CSDE1 Cold shock domain containing E1, RNA-binding 1.09 0.998  1.08 0.999  1.11 0.997 
NM_000101 CYBA Cytochrome b-245, alpha polypeptide 1.73 0.729  1.97 0.594  3.83 0.099 
NM_134268 CYGB Cytoglobin -1.01 1.000  1.46 0887  1.46 0.886 
NM_001013742 DGKK Diacylglycerol kinase, kappa -1.00 1.000  -7.16 0.007  -1.76 0.714 
NM_014762 DCHR4 24-dehydrocholesterol reductase -1.05 1.000  -1.16 0.992  -1.25 0.974 
NM_175940 DUOX1 Dual oxidase 1 1.35 0.938  1.82 0.675  1.53 0.851 
NM_014080 DUOX2 Dual oxidase 2 12.55 0.000  13.29 0.000  11.68 0.001 
NM_004417 DUSP1 Dual specificity phosphatase 1 -1.01 1.000  1.65 0.778  1.28 0.965 
NM_001979 EPHX2 Epoxide hydrolase 2, cytoplasmic 1.54 0.845  1.16 0.992  1.17 0.991 
NM_000502 EPX Eosinophil peroxidase 1.44 0.896  1.77 0.709  1.42 0.909 
NM_021953 FOXM1 Forkhead box M1 -1.01 1.000  -1.26 0.970  -1.34 0.944 
NM_197962 GLRX2 Glutaredoxin 2 -1.08 0.999  -1.14 0.995  -1.16 0.991 
NM_153002 GPR156 G protein-coupled receptor 156 2.00 0.575  6.30 0.013  12.81 0.000 
NM_000581 GPX1 Glutathione peroxidase 1 -1.23 0.978  -1.05 1.000  -1.06 1.000 
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NM_002083 GPX2 Glutathione peroxidase 2 (gastrointestinal) -1.05 1.000  1.59 0.814  1.14 0.994 
NM_002084 GPX3 Glutathione peroxidase 3 (plasma) 1.56 0.833  1.67 0.769  1.54 0.844 
NM_002085 GPX4 Glutathione peroxidase 4 (phospholipid hydroperoxidase) -1.02 1.000  1.01 1.000  -1.22 0.980 
NM_001509 GPX5 Glutathione peroxidase 5 (epididymal androgen-related   protein) 1.18 0.988  -3.08 0.200  -2.03 0.559 
NM_182701 GPX6 Glutathione peroxidase 6 (olfactory) -1.19 0.9888  -1.05 1.000  -1.15 0.993 
NM_015696 GPX7 Glutathione peroxidase 7 -3.61 0.121  1.70 0.752  1.09 0.998 
NM_000637 GSR Glutathione reductase 1.04 1.000  1.02 1.000  -1.13 0.996 
NM_000178 GSS Glutathione synthetase 1.17 0.991  1.03 1.000  1.04 1.000 
NM_001513 GSTZ1 Glutathione transferase zeta 1 -1.01 1.000  1.02 1.000  -1.08 0.999 
NM_001518 GTF2I General transcription factor IIi 1.31 0.953  1.29 0.963  1.14 0.995 
NM_015553 IPCEF1 Interaction protein for cytohesin exchange factors 1 3.81 0.100  6.47 0.012  12.19 0.000 
NM_006121 KRT1 Keratin 1 1.90 0.633  1.41 0.911  1.62 0.800 
NM_006151 LPO Lactoperoxidase 2.83 0.255  1.33 0.945  4.99 0.036 
NM_00242 MBL2 Mannose-binding lectin (protein C) 2, soluble 1.04 1.000  -1.34 0.945  -1.32 0.951 
NM_004528 MGST3 Microsomal glutathione S-transferase 3 1.25 0.972  1.15 0.994  1.13 0.995 
NM_000250 MPO Myeloperoxidase 2.60 0.321  4.78 0.043  2.23 0.461 
NM_002437 MPV17 MpV17 mitochondrial inner membrane protein 1.25 0.974  1.19 0.987  1.20 0.984 
NM_012331 MSRA Methionine sulfoxide reductase A -1.07 0.999  -1.14 0.994  -1.05 1.000 
NM_005954 MT3 Metallothionein 3 -1.25 0.973  1.05 1.000  1.15 0.993 
NM_004923 MTL5 Metallothionein-like 5, testis-specific (tesmin) 1.49 0869  1.33 0.947  1.14 0.994 
NM_000265 NCF1 Neutrophil cytosolic factor 1 1.19 0.987  1.86 0.656  1.57 0.825 
NM_000433 NCF2 Neutrophil cytosolic factor 2 1.18 0.989  1.75 0.721  1.62 0.797 
NM_003551 NME5 Non-metastatic cells 5, protein expressed in (nucleoside- diphosphate kinase) 1.23 0.979  1.51 0.862  1.20 0.985 
NM_000625 NOS2 Nitric oxide synthase 2, inducible 1.30 0.959  1.76 0.716  1.78 0.699 
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NM_024505 NOX5 NADPH oxidase, EF-hand calcium binding domain 5 1.60 0.808  1.37 0.932  1.09 0.999 
NM_002452 NUDT1 Nudix (nucleoside diphosphate linked moiety X)-type motif 1 -1.31 0.953  -1.55 0.837  -1.21 0.982 
NM_005109 OXR1 Oxidation resistance 1 1.27 0.968  1.30 0.957  1.36 0.936 
NM_005109 OXSR1 Oxidative-stress responsive 1 1.33 0.947  1.36 0.934  1.27 0.968 
NM_020992 PDLM1 PDZ and LIM domain 1 1.15 0.993  1.41 0.913  1.30 0.958 
NM_007254 PNKP Polynucleotide kinase 3'-phosphatase 1.21 0.982  1.00 1.000  -1.13 0.996 
NM_002574 PRDX1 Peroxiredoxin 1 -1.04 1.000  -1.05 1.000  -1.03 1.000 
NM_005809 PRDX2 Peroxiredoxin 2 -1.01 1.000  1.04 1.000  1.03 1.000 
NM_006793 PRDX3 Peroxiredoxin 3 -1.02 1.000  -1.08 0.999  -1.02 1.000 
NM_006406 PRDX4 Peroxiredoxin 4 1.24 0.975  -1.04 1.000  -1.02 1.000 
NM_181652 PRDX5 Peroxiredoxin 5 -1.02 1.000  -1.03 1.000  -1.07 0.999 
NM_004905 PDRX6 Peroxiredoxin 6 1.11 0.997  1.09 0.998  1.04  
NM_020820 PREX1 Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 3.26 0.169  2.19 0.482  4.69 0.046 
NM_006093 PRG3 Proteoglycan 3 -1.19 0.988  -1.22 0.981  1.59 0.817 
NM_000962 PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) 1.91 0.624  1.47 0.884  2.35 0.410 
NM_000963 PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 7.70 0.005  2.70 0.289  2.88 0.243 
NM_012293 PXDN Peroxidasin homolog (Drosophila) 1.26 0.972  1.07 0.999  1.56 0.832 
NM_144651 PXDNL Peroxidasin homolog (Drosophila)-like 9.80 0.001  2.81 0.261  2.69 0.292 
NM_014245 RNF7 Ring finger protein 7 -1.02 1.000  1.05 1.000  1.05 1.001 
NM_182826 SCARA3 Scavenger receptor class A, member 3 1.29 0.962  1.38 0.928  -1.14 0.994 
NM_203472 SELS Selenoprotein S 1.19 0.998  1.41 0.913  1.18 0.988 
NM_005410 SEPP1 Selenoprotein P, plasma, 1 1.21 0.984  1.15 0.993  1.21 0.983 
NM_012237 SIRT2 Sirtuin 2 1.24 0.976  1.33 0.949  1.18 0.989 
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NM_000454 SOD1 Superoxide dismutase 1, soluble 1.06 1.000  -1.09 0.998  -1.09 0.998 
NM_000636 SOD2 Superoxide dismutase 2, mitochondrial 1.21 0.983  1.39 0.921  1.13 0.995 
NM_003102 SOD3 Superoxide dismutase 3, extracellular 1.82 0.676  -1.01 1.000  1.08 0.999 
NM_080725 SRXN1 Sulfiredoxin 1 1.43 0.905  2.09 0.528  1.54 0.847 
NM_006374 STK25 Serine/threonine kinase 25 1.12 0.997  1.05 1.000  -1.05 1.000 
NM_000547 TPO Thyroid peroxidase 1.10 0.998  3.11 0.193  3.26 0.168 
NM_003319 TTN Titin 1.47 0.882  1.56 0.831  1.32 0.949 
NM_032243 TXNDC2 Thioredoxin domain containing 2 (spermatozoa) -1.26 0.970  2.67 0.299  7.74 0.005 
NM_003330 TXNRD1 Thioredoxin reductase 1 1.02 1.000  1.30 0.959  1.24 0.976 
NM_006440 TXNRD2 Thioredoxin reductase 2 -1.01 1.000  -1.21 0.983  -1.22 0.981 
 
Significant results (P<0.1, compared to control) are noted in bold.   
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   DCTEIO  H2O2  DCTEIO + H2O2 
GenBank 
Accession No. 
Gene 
Symbol Description Fold Change P-value  Fold Change P-value  Fold Change P-value 
NM_000477 ALB Albumin -1.24 0.954  -3.00 0.089  -3.58 0.038 
NM_000697 ALOX12 Arachidonate 12-lipoxygenase -1.03 1.000  -1.22 0.962  1.24 0.954 
NM_021146 ANGPTL7 Angiopoietin-like 7 1.04 1.000  -1.29 0.927  -1.63 0.665 
NM_001159 AOX1 Aldehyde oxidase 1 -1.17 0.981  1.10 0.996  -1.14 0.989 
NM_000041 APOE Apolipoprotein E -2.59 0.163  2.14 0.325  1.66 0.642 
NM_004045 ATOX1 ATX1 antioxidant protein 1 homolog (yeast) -1.17 0.982  -1.06 0.999  -1.03 1.000 
NM_004052 BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 1.08 0.998  1.39 0.859  1.26 0.944 
NM_001752 CAT Catalase -1.15 0.986  -1.21 0.967  -1.28 0.934 
NM_002985 CCL5 Chemokine (C-C motif) ligand 5 -1.46 0.804  -1.10 0.995  1.01 1.000 
NM_005125 CCS Copper chaperone for superoxide dismutase -1.06 0.999  -1.19 0.976  -1.18 0.979 
NM_007158 CSDE1 Cold shock domain containing E1, RNA-binding 1.05 1.000  -1.16 0.985  -1.15 0.988 
NM_000101 CYBA Cytochrome b-245, alpha polypeptide 1.68 0.626  4.76 0.008  2.23 0.284 
NM_134268 CYGB Cytoglobin -1.46 0.805  2.87 0.108  2.60 0.163 
NM_001013742 DGKK Diacylglycerol kinase, kappa 1.64 0.661  1.62 0.674  -1.56 0.722 
NM_014762 DCHR4 24-dehydrocholesterol reductase -1.17 0.982  -1.43 0.833  -1.41 0.847 
NM_175940 DUOX1 Dual oxidase 1 -1.68 0.621  -1.02 1.000  -1.51 0.769 
NM_014080 DUOX2 Dual oxidase 2 3.08 0.079  11.75 0.000  9.80 0.000 
NM_004417 DUSP1 Dual specificity phosphatase 1 -1.70 0.609  2.87 0.109  2.79 0.121 
NM_001979 EPHX2 Epoxide hydrolase 2, cytoplasmic -1.67 0.636  1.36 0.884  -3.72 0.032 
NM_000502 EPX Eosinophil peroxidase -1.04 1.000  1.15 0.987  1.30 0.925 
NM_021953 FOXM1 Forkhead box M1 -1.32 0.909  -2.17 0.312  -2.20 0.298 
NM_197962 GLRX2 Glutaredoxin 2 1.02 1.000  -1.24 0.953  -1.20 0.973 
NM_153002 GPR156 G protein-coupled receptor 156 -1.98 0.409  -13.33 0.000  3.16 0.071 
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NM_000581 GPX1 Glutathione peroxidase 1 -1.07 0.998  1.32 0.909  1.38 0.868 
NM_002083 GPX2 Glutathione peroxidase 2 (gastrointestinal) 1.01 1.000  1.87 0.483  1.72 0.589 
NM_002084 GPX3 Glutathione peroxidase 3 (plasma) -1.39 0.861  -1.29 0.931  -1.23 0.959 
NM_002085 GPX4 Glutathione peroxidase 4 (phospholipid hydroperoxidase) -1.66 0.642  -1.20 0.972  -1.21 0.968 
NM_001509 GPX5 Glutathione peroxidase 5 (epididymal androgen-related   protein) 1.32 0.913  1.79 0.537  3.78 0.029 
NM_182701 GPX6 Glutathione peroxidase 6 (olfactory) -1.20 0.970  -1.22 0.962  -1.03 1.000 
NM_015696 GPX7 Glutathione peroxidase 7 -1.05 1.000  15.94 0.000  25.05 0.000 
NM_000637 GSR Glutathione reductase -1.60 0.690  -1.27 0.942  -1.33 0.903 
NM_000178 GSS Glutathione synthetase -1.54 0.742  -1.33 0.901  -1.27 0.940 
NM_001518 GTF2I General transcription factor IIi -1.35 0.893  -1.81 0.527  -1.80 0.534 
NM_015553 IPCEF1 Interaction protein for cytohesin exchange factors 1 3.39 0.050  2.03 0.380  4.56 0.010 
NM_006121 KRT1 Keratin 1 1.98 0.414  1.60 0.691  2.03 0.384 
NM_006151 LPO Lactoperoxidase -1.24 0.953  7.25 0.000  6.88 0.001 
NM_000242 MBL2 Mannose-binding lectin (protein C) 2, soluble -7.23 0.001  -1.70 0.607  -2.04 0.377 
NM_004528 MGST3 Microsomal glutathione S-transferase 3 -1.07 0.998  -1.07 0.998  1.01 1.000 
NM_000250 MPO Myeloperoxidase 4.25 0.015  46.29 0.000  81.61 0.000 
NM_002437 MPV17 MpV17 mitochondrial inner membrane protein -1.04 1.000  1.02 1.000  1.20 0.971 
NM_012331 MSRA Methionine sulfoxide reductase A 1.04 1.000  -1.26 0.944  -1.33 0.902 
NM_005954 MT3 Metallothionein 3 1.20 0.970  1.48 0.794  1.33 0.901 
NM_004923 MTL5 Metallothionein-like 5, testis-specific (tesmin) -1.11 0.994  -1.27 0.938  -1.34 0.900 
NM_000265 NCF1 Neutrophil cytosolic factor 1 -2.10 0.345  -1.43 0.828  -1.29 0.931 
NM_000433 NCF2 Neutrophil cytosolic factor 2 -1.33 0.904  1.00 1.000  -1.26 0.943 
NM_003551 NME5 Non-metastatic cells 5, protein expressed in (nucleoside- diphosphate kinase) -1.03 1.000  1.12 0.993  1.13 0.991 
NM_000625 NOS2 Nitric oxide synthase 2, inducible -1.45 0.815  6.41 0.001  5.40 0.004 
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Symbol Description Fold Change P-value  Fold Change P-value  Fold Change P-value 
NM_024505 NOX5 NADPH oxidase, EF-hand calcium binding domain 5 -1.10 0.996  -1.21 0.968  -1.35 0.892 
NM_002452 NUDT1 Nudix (nucleoside diphosphate linked moiety X)-type motif 1 -1.48 0.793  -1.86 0.490  -1.66 0.643 
NM_005109 OXR1 Oxidation resistance 1 -1.25 0.948  -1.23 0.961  -1.37 0.875 
NM_005109 OXSR1 Oxidative-stress responsive 1 -1.32 0.909  -1.28 0.935  -1.48 0.791 
NM_020992 PDLM1 PDZ and LIM domain 1 -1.25 0.949  1.12 0.993  1.08 0.997 
NM_007254 PNKP Polynucleotide kinase 3'-phosphatase -1.13 0.992  -1.90 0.460  -2.03 0.384 
NM_002574 PRDX1 Peroxiredoxin 1 -1.06 0.999  -1.11 0.994  1.06 0.999 
NM_005809 PRDX2 Peroxiredoxin 2 1.11 0.995  -1.15 0.987  -1.19 0.977 
NM_006793 PRDX3 Peroxiredoxin 3 1.08 0.998  -1.23 0.959  -1.14 0.989 
NM_006406 PRDX4 Peroxiredoxin 4 -1.12 0.992  -1.35 0.889  -1.27 0.937 
NM_181652 PRDX5 Peroxiredoxin 5 -1.23 0.961  1.02 1.000  1.03 1.000 
NM_004905 PDRX6 Peroxiredoxin 6 -1.14 0.989  -1.04 1.000  -1.04 1.000 
NM_020820 PREX1 Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 2.00 0.399  1.34 0.899  2.20 0.296 
NM_006093 PRG3 Proteoglycan 3 -1.39 0.861  -1.44 0.827  -1.01 1.000 
NM_183079 PRNP Prion protein 1.20 0.971  1.83 0.509  1.77 0.554 
NM_000962 PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) -2.66 0.147  1.96 0.421  7.47 0.000 
NM_000963 PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) -1.06 0.999  -1.11 0.995  1.04 1.000 
NM_012293 PXDN Peroxidasin homolog (Drosophila) -1.05 0.999  -1.93 0.444  -1.57 0.714 
NM_144651 PXDNL Peroxidasin homolog (Drosophila)-like -2.14 0.324  -2.17 0.309  -1.89 0.469 
NM_014245 RNF7 Ring finger protein 7 -1.12 0.993  1.01 1.000  -1.02 1.000 
NM_182826 SCARA3 Scavenger receptor class A, member 3 -1.53 0.745  -2.15 0.318  -3.03 0.086 
NM_203472 SELS Selenoprotein S -1.16 0.983  1.18 0.979  1.13 0.991 
NM_005410 SEPP1 Selenoprotein P, plasma, 1 1.19 0.975  -1.03 1.000  -1.10 0.995 
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NM_003019 SFTPD Surfactant protein D -4.63 0.009  -1.82 0.515  -2.07 0.358 
NM_016276 SGK2 Serum/glucocorticoid regulated kinase 2 1.28 0.936  1.14 0.990  2.22 0.287 
NM_012237 SIRT2 Sirtuin 2 1.15 0.988  -1.15 0.987  -1.13 0.990 
NM_000454 SOD1 Superoxide dismutase 1, soluble -1.11 0.994  -1.08 0.998  1.04 1.000 
NM_000636 SOD2 Superoxide dismutase 2, mitochondrial 1.03 1.000  -1.09 0.997  -1.12 0.993 
NM_003102 SOD3 Superoxide dismutase 3, extracellular -1.75 0.567  -1.31 0.917  -1.32 0.909 
NM_080725 SRXN1 Sulfiredoxin 1 -1.56 0.726  2.18 0.304  1.84 0.505 
NM_006374 STK25 Serine/threonine kinase 25 1.13 0.991  -1.24 0.955  -1.22 0.965 
NM_000547 TPO Thyroid peroxidase 2.88 0.106  31.88 0.000  15.67 0.000 
NM_003319 TTN Titin 1.51 0.769  1.10 0.995  1.17 0.982 
NM_032243 TXNDC2 Thioredoxin domain containing 2 (spermatozoa) -1.42 0.836  1.16 0.985  -1.12 0.992 
NM_003330 TXNRD1 Thioredoxin reductase 1 1.26 0.947  1.91 0.453  1.87 0.479 
NM_006440 TXNRD2 Thioredoxin reductase 2 -1.17 0.981  -1.43 0.833  -1.27 0.939 
 
Significant results (P<0.1, compared to control) are noted in bold. 
